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1 General introduction
Background and problem statement
With an estimated 9.6 million caused deaths in 2018, cancer is one of the leading causes
of mortality worldwide (Bray et al., 2018). Moreover, absolute cancer incidence rates have
been continuously rising and with an expanding population and life expectancy these rates
are projected to increase another 62 % by 2040 (IARC, 2018). On the other hand, the five-
year survival rates for most cancer sites have been increasing, e.g. in the United States
from 50 % in 1970 to 67 % in 2018 (Roser and Ritchie, 2019). This directly reflects the
significant improvements in the diagnostics and treatment of cancerous diseases within the
last decades (Arruebo et al., 2011).
Alongside with surgery and chemotherapy, radiation therapy (RT) is one of the three main
pillars of modern cancer treatment (Rosenblatt and Zubizarreta, 2017). The aim of RT is
to damage the DNA in clonogenic tumor cells through the exposure of high-energetic pho-
tons or particles while keeping the dose to surrounding healthy tissue as low as reasonably
achievable (Baskar et al., 2012). This can be performed with a curative intent to fully sterilize
the tumor cells, in a preoperative (neoadjuvant)/postoperative (adjuvant) setting to reduce
tumor margins before/after surgery or with a palliative intent to reduce tumor growth and
relieve the pain caused by the tumor (Lutz et al., 2014). RT benefited heavily from the ad-
vances in imaging technology, improving tumor visualization in RT simulation prior to dose
delivery as well as allowing for the implementation of adaptive treatment strategies that use
image guidance to re-optimize RT plans during the course of treatment. This allowed for
escalating the radiation dose to the tumor while sparing healthy tissue to the utmost extent
(Verellen et al., 2008) and thereby increasing the therapeutic window.
Amongst the broad improvements in managing cancerous diseases, pancreatic cancer
presents one of the indications that withstands the progress in treatment and still has an
extremely poor survival prognosis with a five-year survival rate of only 7 % – 10 % (Doi et
al., 2008; Siegel et al., 2015). This is largely due to the late diagnosis, where in more
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than 80 % of the patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) tumor
progress is advanced and prohibits radical surgical resection. Surgical resection, however,
is still considered to be the sole curative treatment option for PDAC (Hartwig et al., 2011).
Although it has been indicated that neoadjuvant chemo-radiotherapy increases the rate of
secondary resectability (Combs et al., 2013) and the rate of microscopically radical primary
tumor resections (van Tienhoven et al., 2011), PDAC poses a challenge for both chemo-
and radiotherapy. On the one hand, PDAC presents a distinct resistance to existing drugs
used in chemotherapy (Kelsen, 1994; Hajatdoost et al., 2018). On the other hand, the ra-
dioresistant PDAC is surrounded by several radiosensitive organs (Goto et al., 2018), e.g.
the duodenum, the bowel or the stomach, and is affected by various sources of organ mo-
tion and deformation due to respiratory induced motion, organ filling or peristalsis (Keall
et al., 2006). Furthermore, due to the limited soft-tissue contrast of computed tomography
(CT), tumor contouring based on CT varies substantially between different radiation oncol-
ogists, leading to large uncertainties in the dose distribution applied in RT (Yamazaki et al.,
2007; Fokas et al., 2015; Versteijne et al., 2017). This makes RT for patients with PDAC
particular challenging and its use is therefore still controversial.
RT of PDAC may benefit from the use of magnetic resonance imaging (MRI). MRI pro-
vides a superior soft-tissue contrast compared to CT and has shown to reduce inter-
observer variations in tumor contouring (Gurney-Champion et al., 2017). Its functional
imaging capabilities allow for a more distinct tumor staging and control of metastatic spread
(Kartalis et al., 2015). Its real-time imaging capability makes it furthermore promising for or-
gan motion evaluation (Brix et al., 2014). Finally, in contrast to X-ray and CT imaging, MRI is
free of ionizing radiation, allowing for repetitive imaging of patients without risking radiation
induced toxicities (Bujold et al., 2012).
In order to cope with the challenge posed by surrounding organs at risk, patients with
PDAC may benefit from particle therapy (PT) instead of receiving conventional photon ther-
apy (XT) (Fuji et al., 2013; Jouglar et al., 2016). High energetic charged particles decelerate
along their beam path until they eventually stop and deposit most of their energy at the end
of their track at the so called Bragg Peak (Bragg and Kleeman, 1904). This effect is used
in PT to deposit a high radiation dose to the tumorous target volume while sparing critical
organs behind the distal end of the beam from toxic dose. However, the nature of stopping
particles leads to a strong susceptibility to density changes along the beam path. Hence,
both inter- and intrafraction organ motion and deformation are particularly critical in PT (Al-
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bertini et al., 2010) and lead to the requirement of large safety margins, which compromise
the dosimetric benefit of PT.
To mitigate interfraction motion in RT, immobilization equipment is typically used such as
vacuum mattresses as well as image guidance by in-room X-ray imaging for daily patient
setup verification (Riou et al., 2017). In the latter, volumetric cone beam CT (CBCT) or
orthogonal X-ray imaging in treatment position is matched with the CT images used for
treatment planning or from CT generated digitally reconstructed radiographs, respectively.
Since abdominal organs like the pancreas are poorly visualized under X-ray guidance,
radiopaque solid fiducial markers are often implanted in close proximity to the tumor to
facilitate co-registration of the X-ray images with the planning CT scan. These markers,
however, may deteriorate image quality in CT and MRI by causing streaking artefacts in the
former and geometric image distortions in the latter imaging modality (Gurney-Champion et
al., 2015). This may lead to errors in dose calculation or an inaccurate co-registration of CT
and MR images. Furthermore, solid markers may cause significant local dose perturbations
in PT (Giebeler et al., 2009). Injectable liquid fiducial markers are therefore currently being
developed that offer multiple advantages over solid markers such as good visibility in CT
at less image degradation, low dose perturbation in PT and higher flexibility in injection
(Bair et al., 2015; Scherman Rydhög et al., 2015). Their MRI performance for the use in
pancreas tissue, however, has yet to be assessed.
Intrafraction motion of highly mobile organs like the pancreas, on the other hand, is com-
monly being coped with by the use of internal target volume (ITV) margins based on respi-
ratory correlated CT (4D-CT) (Karava et al., 2017). With these margins the aim is to achieve
full dose coverage of the tumor in all respiratory states, including geometric errors due to
positioning uncertainties, while simultaneously accepting a high dose in the included sur-
rounding healthy tissue. For pancreas tumor motion, however, it has been shown that treat-
ment planning based on 4D-CT is unable to accurately predict motion during the course
of therapy due to inter- and intrafraction irregularities (Minn et al., 2009; Ge et al., 2013).
This is why a mitigation of intrafraction motion during RT is often recommended to allow a
reduction of ITV margins and reduce uncertainties in dose delivery. Respiratory motion is
commonly mitigated through abdominal compression. Due to the strong susceptibility of PT
to density changes along the beam path and since for PDAC the equipment for abdominal
compression is positioned on the same axis than the target volume, care has to be taken
that this equipment does not increase dose delivery uncertainties by a non-reproducible
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impact on the range of the traversing beam.
The need for improved soft-tissue contrast in abdominal imaging and the susceptibility of
PT to motion leads to an increased interest in the integration of MRI into the treatment plan-
ning and dose delivery workflow (Oborn et al., 2017). In a technically simple approach, the
integration can be approached by MRI simulation, where MRI is utilized for the delineation
of relevant tumor and organ structures (Gurney-Champion et al., 2017), tumor motion as-
sessment for the definition of personalized treatment margins (Stemkens et al., 2016), or
is used for RT planning based on synthetic CT images generated from MRI (Hsu et al.,
2019). In a technically more challenging approach, MR guidance of PT can be performed,
in which the treatment setup and dose delivery is adapted based on MRI. MRI is, how-
ever, particularly susceptible to geometric distortions and image artefacts, which is why the
quantification of physiological properties by the use of MRI has to be thoroughly validated
with ground truth measurements, which can be provided by MRI phantoms.
While a variety of concepts have been developed for the management of inter- and in-
trafraction pancreas tumor motion in conventional X-ray guided RT, the translation to MR
guided PT is not generally feasible or is often connected with severe drawbacks (Bolsi et
al., 2018). Hence new concepts have to be developed and tested which correspond with
the safety regulations and technical demands of MR guided PT.
Aims and hypotheses
The aim of this thesis is therefore threefold. Firstly, for interfraction motion management, a
novel liquid fiducial marker, which has been shown both to be visible in X-ray imaging and
not to significantly perturb the local dose distribution applied by PT, is tested regarding its
applicability in MR guidance for PT of PDAC. It is hypothesized that this marker is detectable
in MRI when injected in pancreas tissue and reduces the amount of MR image degradation
relative to solid fiducial markers.
Secondly, for intrafraction motion mitigation the concept of applying abdominal pressure
through the use of an MR compatible patient-specific corset, previously presented for use
in XT, is adapted for the use in PT. For this, initially three different types of abdominal
corsets are tested regarding their suitability for PT. Subsequently, with the corset consid-
ered most suitable, a clinical study is conducted to analyze the reduction of respiratory
induced pancreas motion by use of time-resolved 2D-cine and respiratory correlated 4D-
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MRI on a diagnostic 3.0 T MRI scanner. It is hypothesized that an abdominal corset can be
implemented into the PT workflow, reduces the respiratory induced pancreas motion and
is tolerated by patients with abdominal tumors.
Thirdly, to assess the accuracy that the diagnostic 3.0 T MRI scanner provides for mo-
tion characterization purposes, it’s motion tracking performance had to be first evaluated
with ground truth measurements. Hence, a 4D-MRI motion phantom is commissioned and
implemented for quality assurance (QA) of motion depicting MRI pulse sequences and ge-
ometric fidelity. It is hypothesized that this motion phantom, originally designed for a hybrid
MR-Linac system, can be implemented on a diagnostic 3.0 T MRI scanner and used therein
for QA of motion depicting MRI pulse sequences and scan protocols.
Structure of the thesis
To motivate the experimental approaches and establish a theoretical foundation regarding
the research aims, the clinical rational for- and state of the art of image- and especially MR
guided PT of PDAC is introduced in chapter 2. The theoretical background of quantitative
MRI will be discussed in detail to establish a foundation for quantitatively evaluating the MRI
characteristics of the novel liquid fiducial marker for its use in MR guidance. In chapter 3
these characteristics are analyzed and compared to two clinically used solid fiducial mark-
ers in a quantitatively manner in the framework of a phantom study. Furthermore, the liquid
marker is tested for the first time in ex vivo tumorous pancreas tissue to examine its MRI vis-
ibility in human pancreas tissue. In chapter 4, the commissioning of the MR-Linac motion
phantom on the 3.0 T diagnostic MR scanner will be described. Furthermore, a software
tool will be developed for an automatic assessment of the geometrical fidelity and motion
tracking accuracy of the scanner by use of this phantom for QA purposes. In chapter 5
three different MR compatible abdominal corsets are tested regarding their applicability in
PT. Subsequently, the MR pulse sequences previously tested with the motion phantom are
used for analyzing the reduction of respiratory pancreas motion by application of an MR-
and PT compatible abdominal corset within a patient study. The clinical implementation will
be described, the patient’s tolerance towards such a corset presented and the achieved
reduction of pancreas motion assessed. Finally, the advances in knowledge and future per-
spectives of the reasearch conducted for this thesis are discussed in chapter 6. A summary
can be found in chapter 7 and chapter 8 in English and German, respectively.
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2 State of the art: MRI for image guided PT of
pancreatic cancer
This chapter is a short theoretical introduction to the subjects relevant for this thesis and
is not raising claim for completeness. Reference is made to comprehensive literature for
a thorough study of the clinical rational for PT of PDAC (Robin and Goodman, 2017), the
physical background of PT (Dosanjh and Bernier, 2018), the principles of MRI (Brown and
Semelka, 2003) and practical applications of MR guidance in RT (Liney and van der Heide,
2019).
2.1 Clinical rationale for particle therapy of pancreatic cancer
Although pancreatic cancer is currently only the twelfth most common malignancy world-
wide, its burden on society is increasing, particularly in countries with a high human devel-
opment index (Wong et al., 2017), e.g. in North America and Western Europe, where it is
projected to be the second and third most common cause of cancer related death by 2030,
respectively (Roser and Ritchie, 2019). This trend is influenced both by rising incidence
rates as well as the poor treatment outcome with a five-year survival rate of only 7 % – 10 %
(Doi et al., 2008; Siegel et al., 2015). Radical surgery is thereby still considered the only cu-
rative treatment option. However, due to the typically late diagnosis and the consequentially
high rate of tumor progression, surgical resection is only an option for approximately 20 %
of patients (Hartwig et al., 2011). This can either be due to distant metastatic spread or due
to local infiltration of crucial blood vessels (portal vein, mesentric artery, mesentric vein)
located directly adjacent to the pancreatic head and body, as can be seen in Figure 2.1.
Patients that undergo surgical resection, however, still frequently develop systemic (> 70 %)
or local (> 20 %) disease recurrence (Vincent et al., 2011).
It has been indicated that a combined neoadjuvant chemo-RT increases the rate of mi-
croscopically radical primary tumor resections (van Tienhoven et al., 2011). For patients
7
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Figure 2.1: Transverse T1 weighted MR image showing the pancreas (red arrow) in close proximity
to several organs (yellow arrows), which limit the possible dose to a target volume in PDAC.
with unresectable PDAC, it has been shown that it increases the median survival (Moertel
et al., 1981) and furthermore yields a 30 % – 40 % rate of secondary resectability (Combs
et al., 2013) which improves median survival up to 21 months, comparable to patients with
primarily resectable PDAC (Gillen et al., 2010). Using stereotactic radiosurgery local dis-
ease control was shown to be improved relative to conventional chemo-RT (Didolkar et al.,
2010). In the study by Didolkar et al. (2010) it was also shown that gastrointestinal toxi-
city rates were reduced when tumor tracking was performed and consequently the dose
to the healthy tissue was reduced. Since the pancreas is in close proximity to several or-
gans at risk (see Figure 2.1), the dose that can be deposited to PDAC without inducing
severe gastrointestinal toxicities is limited. Considering the substantial rate of secondary
resectability after radiotherapy and the favorable normal-tissue dose sparing capabilities
over XT, patients with resectable, unresectable or borderline PDAC might benefit from PT.
Furthermore, due to the superb soft-tissue contrast and real-time imaging capability of MRI,
PT of PDAC might benefit from image guidance by MRI.
2.2 Particle therapy
PT using protons or heavier ions like helium or carbon is increasingly being investigated
as alternative for XT in thoracic and abdominal tumors. This is mainly motivated by the
beneficial dose distribution achievable in PT (Wilson, 1946) due to the inverse depth-dose
profile found in charged particles (Bragg and Kleeman, 1904). This inverse depth-dose
8
2.2 Particle therapy
Figure 2.2: (a) Depth-dose profile of a 15 MeV photon beam (green), a mono-energetic 135 MeV
proton beam (purple) and a multi-energy proton spread-out Bragg peak in water to homogeneously
cover a hypothetical tumor (red) with the prescribed dose. (b) Dose variations in a proton spread-
out Bragg peak due to change in anatomy due to an air or bone insert (yellow) in the beam path.
The under-dosage of the tumor and the over-dosage of the surrounding healthy tissue (light blue) is
visualized in the two scenarios (brown, orange). (Image courtesy: Dr. Wohlfahrt.)
profile allows for minimizing the dose to organs at risk beyond the distal end of the beam
(Durante and Loeffler, 2009) as visualized in Figure 2.2 (a). Moreover, PT provides a higher
relative biological effectiveness than XT (Lühr et al., 2018).
Charged particles with clinically relevant energies per nucleon of up to ∼ 400 MeV/u
transfer their energy primarily through the mechanism of inelastic Coulomb scattering with
the shell electrons of the target tissue. The energy transfer dE within a path length dx can
hence be approximated by the Bethe-Bloch formula (Bethe, 1930; Bloch, 1933)
−
dE
dx
≈ k0
z2
β2
Z
A
ρ

ln
(
2mec
2 β
2
1 − β2
)
− β2 − lnI

 , (2.1)
where k0 is a constant scaling factor, z is the nuclear charge and β the velocity of the
projectile and Z is the atomic number and A the atomic mass of the target nuclei, as well as
ρ the target’s density and I its ionization potential. From equation 2.1 it follows that charged
particles deposit most of their energy at the end of their track, after having been slowed
down continuously, and stop at the so-called Bragg peak. This is contrary to the dose
deposition by high-energetic photons, where after an initial dose build-up, the deposited
dose decays exponentially with the traversed path length. In state-of-the-art RT, termed
intensity-modulated RT (IMRT), implemented both for XT and PT, multiple treatment beams
of varying intensities are applied from different beam directions to deliver the prescribed
dose to the tumor while limiting the volume of healthy tissue exposed to high dose. The
steep gradient dose fall-off of PT at the Bragg peak leads to a high sensitivity to density
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changes along the beam path, as visualized in 2.2 (b). PT is therefore especially susceptible
to inter- and intrafraction motion due to patient mis-positioning, respiratory induced motion,
stomach and bowel filling or peristalsis.
2.3 Magnetic resonance imaging
2.3.1 Physical background
The fundamental basis of MRI is the quantum-mechanical energy separation ∆E observed
in a system of nuclei with a non-zero spin exposed to a static magnetic field B0, termed
nuclear Zeeman effect (Zeeman, 1896; Preston, 1898). Hydrogen nuclei, most commonly
used in clinical MRI due to their high abundance in living organisms, are thereby separated
into two energy states with the energy difference
∆E = ~ω0 = ~γB0, (2.2)
where ~ is the Planck constant and γ/2π = 42.6 MHz·T−1 the gyromagnetic ratio of
the proton. The energy separation can be classically understood as orientation of the z
component of the nuclei’s magnetic momentum parallel (N+) and anti-parallel (N−) relative
to the static magnetic field. The two energy states are thereby unequally occupied towards
the lower energy state N+ given by the ratio
N+
N−
= e
∆E
kBT , (2.3)
with the Boltzmann constant kB and the temperature T . The excess spins in the lower
energy state lead to a net magnetization M0 of the tissue parallel to the static magnetic
field. The net magnetization can be manipulated by excitation through a radiofrequency
(RF) pulse (B1) with the resonance frequency ω0 and an orientation perpendicular to B0.
This excites the protons from the N+ state to the N− state and vise versa stimulates the
release of energy from the protons in the N− state which will then occupy the N+ state.
This effectively describes a rotation of the net magnetization M0 to a higher energy state.
The rotation of M0 is thereby perpendicular to both B0 and B1 and thereby creates a new
longitudinal magnetization Mz and a transverse magnetization component Mxy, precess-
ing around B0. The respective magnitude of Mz and Mxy after excitation depends on the
10
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Figure 2.3: Schematic visualization of net magnetization flip towards the transverse plane in a
rotating frame after RF excitation with a 90° pulse. After the time t the net magnetization shows
partial longitudinal and transverse relaxation towards it’s equilibrium state.
length and magnitude of the B1 pulse, described by the flip angle α. The excitation of M0 is
schematically shown in Figure 2.3 in a rotating frame for an excitation pulse of α = 90°.
After excitation, the system will de-excite into the equilibrium while emitting an RF signal
with the frequency ω0 (Bloch, 1946). The de-excitation of the net magnetization towards
equilibrium, termed relaxation, is a statistical process and is defined by the macroscopic
relaxation times T1 and T2. The longitudinal relaxation time T1, or spin-lattice relaxation
time, is the time required for Mz to return to 63 % of M0, i.e.
Mz(t) = M0 − M0 · e
−t/T1 · (1 − cosα). (2.4)
The transverse relaxation time T2, or spin-spin relaxation time, on the other hand, is the
time required for Mxy to decay to 37 %, i.e.
Mxy(t) = M0 · e
−t/T2 · sinα. (2.5)
These relaxation times are material specific parameters, since they describe the rate of
energy transfer from excited protons to their molecular environment (spin-lattice relaxation)
and the energy transfer and dephasing within the spin system (spin-spin relaxation). The
material specific properties M0 (which is directly proportional to the tissues spin or proton
density ρ(H)), T1 and T2 are the basis for the superb soft-tissue contrast of MRI.
In a classical spin-echo (SE) sequence the MR signal is sampled after an echo time
(TE) where at t = TE/2 the magnetization is flipped with α= 180° to create an echo of the
dephasing spins during signal sampling at t = TE. In a more sophisticated gradient-recalled
echo (GRE) sequence this echo is induced by fast switching of the frequency gradient coils,
11
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which leads to an accelerated decay of the transverse coherence with the relaxation time
T∗2, for which
1/T∗2 = 1/T2 + γ∆B0 (2.6)
depending on the inhomogeneity of the local static magnetic field ∆B0.
From this magnetic resonance, in an idealistic scenario one would only retrieve a single
RF signal with a frequency ω0 and an amplitude proportional to ρ(H). In order to create a 3D
image, sophisticated spatial encoding is performed by the use of magnetic gradient fields.
The gradient fields alter the static magnetic field in all three directions, thereby allowing
for slice selected excitation (slice-encoding direction), frequency encoded signal sampling
(frequency-encoding direction) and phase encoded signal sampling (phase-encoding di-
rection) through repeated excitations at different phase gradient strengths. The excitation
is therefore repeated after the repetition time (TR).
The combination of the tissue specific properties ρ(H), T1 and T2 with the variability
of pulse sequence parameters TE, TR and α yields the potential for numerous different
contrasts of identical tissue. This versatility of MRI allows, on the one hand, for superb
soft-tissue contrast of different body regions but also leads to the preferred use of MRI as
qualitative imaging modality.
2.3.2 Quantitative MRI
A possible method for quantitative imaging with MRI is to directly deduce the tissue specific
parameters (ρ(H), T1, T2) by relaxometry instead of creating a qualitative signal contrast.
By performing relaxometry, quantitative information correlated to pathophysiology can be
retrieved. However, since relaxometry in vivo is highly non-trivial, lacks robustness and
typically requires long acquisition times, it is not standard of care in clinical routine. In this
chapter, different methods for quantification of ρ(H), T1, T2 and T∗2 will be shortly discussed,
as they will be used primarily in chapter 3 of this thesis.
T1 mapping
IR SE method The gold standard of measuring longitudinal relaxation times T1 in MRI
is based on an inversion recovery (IR) spin echo (SE) method (Kingsley et al., 1998). Here
12
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the signal intensity of the tissue is measured after the application of an inversion pulse
(α= 180°) at different inversion times (TI) with a subsequent SE acquisition. Under as-
sumption of perfect 180° and 90° RF pulses the signal intensity is given by
SI(TI)IRSE = M0
(
1 − 2e
−
TI
T1 + e
−
TR
T1
)
. (2.7)
This acquisition effectively samples the longitudinal magnetization during longitudinal re-
laxation. When TR is hold constant during the different TI acquisitions, T1 can be retrieved
directly from the exponential fit.
VFA method A faster approach to quantify T1 in MRI is by utilizing a spoiled gradient
recalled echo (SPGR) sequence with multiple low flip angles, where transverse coherence
is actively disrupted after every sampling (Haase et al., 1986). The signal intensity of a
SPGR sequence with a flip angle α is a function of T1 and given by (Cheng and Wright,
2006)
SISP GR(T1) = M0 · sinα ·
1 − e
−TR
T1
1 − e
−TR
T1 · cosα
. (2.8)
When equation 2.8 is linearized with E = e
−TR
T1 , it follows that
SISP GR(T1)
sinα
= E ·
SISP GR(T1)
tanα
+ M0(1 − E), (2.9)
where T1 can be extracted from the slope E of the linear function
T1 = −TR/ln(E). (2.10)
Since this approach is sensitive on the effective flip angle α applied, one has to consider
the spatial dependence of α given by the RF transmit profile B+1
α(x, y) = α · B+1 (x, y). (2.11)
B+1 map Based on the principle of reciprocity (Hoult, 2000) the RF transmit profile B
+
1 is
correlated to the RF receive profile B−1 . When B
−
1 is approximated to be equal to B
+
1 , it can
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be determined utilizing a dual-repetition time GRE sequence (Yarnykh, 2007)
B1 = acos



S(TR2)
S(TR1)
·
TR2
TR1
− 1
TR2
TR1
−
S(TR2)
S(TR1)



, (2.12)
where S(TR1,2) is the signal intensity of the GRE sequence with the repetition time TR1,2,
respectively.
T2 mapping The gold standard for mapping the transverse relaxation time T2 is measur-
ing the exponential signal decay in a SE sequence at different TE. In a SE sequence the
signal intensity is given by
SISE = k · ρ(H) · B
−
1 (1 − e
−
TR
T1 ) · e
−
TE
T2 , (2.13)
with the proton density ρ(H), the receiver coil profile B−1 and a scaling factor k, including
amongst others the receiver coil sensitivity (Muir and J Balcom, 2013).
T2* mapping The transverse relaxation time T2* manifests in an accelerated decay of
transverse magnetization under the application of a gradient echo acquisition. In a GRE
sequence the signal intensity is given by
SIGRE = k · ρ(H) · B
−
1 · sin(B
+
1 · α) ·
1 − e
−
TR
T1
1 − cos(B+1 · α) · e
−
TR
T1
· e
−
TE
T∗
2 (2.14)
and can hence be simply retrieved by fitting the exponential signal decay in a multi-echo
gradient recalled echo (GRE) sequence (Sabati and Maudsley, 2013).
∆ B0 mapping The amount of transverse spin dephasing in between two GRE acquisi-
tions at two different TE directly correlates with the homogeneity of the static magnetic field
∆B0. This allows to map ∆B0 when the phase information φ1,2 at different TE1,2 is acquired
(Windischberger et al., 2004) by
∆B0 =
φ2 − φ1
2π · γ · (TE2 − TE1)
. (2.15)
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2.3.3 MRI simulation and guidance for PT
MRI can be integrated in the RT workflow in various ways and can therein be used in both
simulation and image guidance (Devic, 2012; Pollard et al., 2017). The level of integration
of MRI in PT lags behind that already found in XT (Paganelli et al., 2018) but shall be shortly
discussed with already achieved and yet to be developed applications.
MR simulation The superb soft-tissue contrast of MRI seemingly makes it an ideal modal-
ity for tumor- and organs at risk contouring in RT planning. However, in contrast to CT, MRI
does not inherently provide information about the electron density of the tissue. The elec-
tron density information is, however, mandatory for dose calculation since the attenuation
of radiation directly relates to this tissue property. In combination with its high geometrical
fidelity, this characteristic made CT the backbone of treatment simulation in RT. The utiliza-
tion of MRI in RT planning for target volume delineation was yet still suggested early on
(Fraass et al., 1987). In the first approach, which is still most common to date, MRI was
used solely for the delineation of the tumor and potentially also for the organs at risk. The
delineation of e.g. pancreas or prostate tumors based on MRI has thereby shown to reduce
inter-observer variability (Villeirs et al., 2005; Gurney-Champion et al., 2017). The tumor
and organ contours delineated are subsequently transferred from MRI to CT, after non-rigid
coregistration of the MRI dataset with a CT dataset, which is later used for dose calcula-
tion and optimization. In this approach patient position verification in treatment position is
still commonly performed by X-ray based image guidance. The poor soft-tissue contrast of
orthogonal X-ray or CBCT, however, requires the use of fiducial markers to facilitate accu-
rate interfraction positioning of mobile tumors like PDAC (Varadarajulu et al., 2010; Van der
Horst et al., 2013). Hence, the MR simulation workflow would benefit from fiducial markers
visible in both X-ray and MR based image modalities.
A method that is recently getting more attraction, particularly through the implementation
of machine learning techniques, is the MR-only treatment planning workflow. Here, MR im-
ages are both used for delineation and dose calculation after planning by converting MR
images to synthetic CT images. This conversion can be performed by an atlas-based ap-
proach (Demol et al., 2016), based on non-rigid registration of the patients MRI data to a
CT atlas. Furthermore, a signal intensity-based approach can be used (Tyagi et al., 2017),
where voxels within certain signal thresholds are overwritten with a pre-defined bulk elec-
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tron density value (Hsu et al., 2019), or alternatively by a sophisticated machine learning
approach (Maspero et al., 2018). MR-only treatment planning has shown high accuracy for
both XT (Edmund and Nyholm, 2017) as well as PT (Koivula et al., 2016; Maspero et al.,
2018) for indications like brain or prostate tumors but has yet to prove itself for the treatment
planning of PDAC.
For treatment planning of tumors that show high intrafraction mobility, e.g. for abdominal
tumors, simulation can include a tumor motion assessment. This allows for intrafraction mo-
tion management by addition of treatment margins to the target volume (van Herk, 2004).
These margins aim to cover the tumor in all respiratory states during dose delivery, while
simultaneously accepting higher dose to the included surrounding healthy tissue, and are
commonly retrieved from respiratory gated 4D-CT images. Motion assessment based on
4D-CT, however, has shown to be susceptible to measurement errors by both under- and
overestimating motion of abdominal and thoracic tumors (Dou et al., 2015). The real-time
imaging capability and high soft-tissue contrast of MRI makes it an ideal imaging modality
for soft-tissue motion characterization. During treatment simulation, respiratory gated 4D-
MRI has shown to provide accurate motion information (Bernatowicz et al., 2016), where
the respiratory states reconstructed from MRI are registered to a static CT image for 4D-CT
dose calculations.
MR guidance After simulation for treatment planning, MRI can furthermore be utilized in
different levels of technical integration for guidance of RT. In an off-line guidance approach,
MRI can be used for an adaption of the treatment in case of changing tumor size or patho-
logical response to treatment (Chandarana et al., 2018). For off-line guidance, the patient
is not required to be positioned at the treatment machine.
In the near-room approach, the designated MRI scanner is installed close to the treat-
ment room to facilitate a shuttle-based transport in between the two. This is performed to
benefit from the soft-tissue contrast provided by MRI while minimize anatomical changes
in between off-line imaging and treatment. For a final position verification, however, X-ray
imaging in at the treatment machine is still often necessary. The feasibility of this approach
has been shown for MR guided XT (Bostel et al., 2018).
With the in-room approach, the patient is scanned in treatment position while the scanner
or the treatment couch are moved to furthermore reduce changing of anatomy in between
imaging and treatment. While this method has been implemented clinically for neurosurgery
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with a movable 1.5 T MR scanner (Chicoine et al., 2011) and for MR guided XT (Jaffray et
al., 2014), the clinical integration of a movable in-room MR scanner in a PT facility has yet
to be performed.
The highest possible level of integration is achieved with an in-beam approach in which
the MRI scanner is physically integrated with the treatment machine. This allows for an
imaging of the patient in the iso-center of the treatment beam and hence an off-line or on-
line image based adaption without the requirement of patient repositioning. Moreover, an
MR integrated system allows for the possibility of a real-time adaption of the treatment beam
if the MR scanner and treatment machine are synchronized, fully exploiting the real-time
imaging capability and high soft-tissue contrast of MRI. This level of integration has already
been clinically introduced for XT in hybrid MR-Linac devices (Mutic and Dempsey, 2014;
Raaymakers et al., 2017). For PT a simultaneous proton beam irradiation and in-beam MR
imaging has been shown technically feasible but the development of an integrated MR-PT
system is still in its infancy (Oborn et al., 2015; Schellhammer et al., 2018).
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For several primary tumors, solid gold fiducial markers have replaced bony anatomy based
X-ray position verification in RT as standard of care and thereby reduced residual setup er-
rors (Varadarajulu et al., 2010; Van der Horst et al., 2013). Fiducial markers are implanted
into the pancreas using endoscopic ultrasonography (EUS), a procedure that is well estab-
lished and generally well tolerated (Park et al., 2010). However, solid markers deteriorate
image quality in CT (Scherman Rydhög et al., 2017) and MRI (Gurney-Champion et al.,
2015), thereby hampering target volume delineation and image co-registration. Moreover,
due to their high Z-elemental composition these markers have shown to significantly perturb
the local dose distribution in particle therapy up to 80% (Newhauser et al., 2007; Giebeler
et al., 2008; Habermehl et al., 2013). Increased effort is therefore being put into the devel-
opment of injectable liquid fiducial markers that may offer multiple advantages over solid
markers such as: 1) good visibility in CT at less image degradation and 2) low dose pertur-
bation in PT as well as 3) higher flexibility in injection (Bair et al., 2015; Scherman Rydhög
et al., 2015). Their performance in MRI, however, has yet to be assessed.
The aim of this work is therefore to test a novel liquid fiducial marker (BioXmark® , Nanovi
Radiotherapy A/S, Lyngby, Denmark) regarding its applicability for MR guidance in particle
therapy. The marker has already been shown to be adequately visible in kilovolt (kV) X-ray,
CT, CBCT and ultrasound (US) imaging and did not significantly perturb proton beam dose
distributions (Scherman Rydhög et al., 2017). Moreover, the marker has been shown to stay
chemically stable after normo-fractionated and high-dose single-fraction proton irradiation
schemes (Troost et al., 2017) and has recently been validated in its long-term positional and
structural stability in lung cancer patients 36 months after initial XT irradiation (De Blanck
et al., 2018).
At the time this study was initiated, the MRI properties of this liquid marker had not been
investigated and a CE certification for its use in abdominal cancer patients was pending.
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In order to compare the visibility and induced artefacts of the liquid fiducial marker in MRI
with two clinically used solid gold fiducial markers, an MRI phantom was designed to mimic
the relaxation properties of pancreatic tissue at a magnetic field strength of 3.0 T. Since
visibility and artefacts of markers in MRI are heavily dependent on pulse sequence pa-
rameters (Rouvière et al., 2006; Jonsson et al., 2011; Rylander et al., 2011), relaxometry
was performed to evaluate visibility and the induced artefacts in a quantitative, sequence
independent manner based on the methods proposed by Gurney-Champion et al. (2015).
Finally, due to the pending CE certification for the liquid marker to be used in abdominal
cancer patients, an ex-vivo study was conducted in which the liquid marker was injected
into freshly resected tumorous pancreas tissue and qualitatively evaluated regarding its
visibility in CT and MR imaging.
The results of these studies have been published by Schneider et al. (2018) and Schnei-
der et al. (2019b), respectively. The design and manufacturing of the phantom described in
this section was performed in cooperation with Nanovi Radiotherapy A/S. Gold Anchor™
and VisiCoil™ fiducial markers were kindly provided by Naslund Medical AB and IBA
Dosimetry GmbH, respectively. BioXmark® was provided by Nanovi Radiotherapy A/S.
3.1 Phantom for quantification of MRI properties of fiducial
markers
3.1.1 Composition of pancreas tissue equivalent gel phantom
A gel matrix was prepared mimicking the relaxation behavior of pancreatic tissue at 3.0 T
(T1 = 725 ms ± 71 ms, T2 = 43 ms ± 7 ms) as reported in literature (De Bazelaire et al., 2004).
The gel composition was based on the evaluation and empirical model by Hattori et al.
(2013) describing the dependency of T1 and T2 relaxation times to the concentrations of
agarose, gadolinium chloride and sodium chloride in a carrageenan-based gel. Result-
ing from this model, a composition of 1.0 w/w % carrageenan, 0.03 w/w % sodium azide,
0.291 w/w % sodium chloride, 97.6µmol/kg gadolinium chloride and 1.22 w/w % agarose
dissolved in Milli-Q water is proposed to achieve the pancreas tissue equivalent relaxation
properties at 3.0 T. For validation and to allow for a final adjustment of the relaxation be-
havior, a set of four gel samples were initially prepared with varying agarose concentrations
from 1.0 w/w – 2.0 w/w % while the other parameters remained constant. A fifth sample filled
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Figure 3.1: (a) Image of tested samples positioned in 8-channel head coil showing (from left to right)
the sample filled with water and the four samples filled with gel of different agarose concentrations
(1.0 w/w % – 2.0 w/w %). (b) T1 map calculated based on dual-echo gradient echo sequence with
varying flip angles. (c) T2 map calculated based on 8-echo spin echo sequence with increasing echo
time. To visualize the differences in T2 found in the samples, the calibration window was chosen to
be [0 – 100] ms, leading to the saturation of the water sample, which revealed a T2 relaxation time
of 1448 ms ± 101 ms.
with pure water was dedicated as control tube with known relaxation behavior (T1 = 2.9 s,
T2 = 1.4 s) (Coletta, 2001) to assure the used sequences and fitting procedures performed
accurately. The four samples along with a reference tube filled with water were scanned
with a 3.0 T Philips Ingenuity TF PET / MR scanner using an 8-channel head coil (Philips
Ingenuity TF PET/MR scanner, Philips Healthcare, Eindhoven, The Netherlands).
Determination of the T1 relaxation time was based on the variable flip angle method
(Haase et al., 1986) utilizing a spoiled gradient echo (SPGR) sequence with two flip angles
as described in 2.3.2. For correction of spatial inhomogeneities in the RF transmit-field
(B+1 ), a B
+
1 -map was additionally calculated based on a gradient echo sequence with two
repetition times as described in 2.3.2. The T1-map was corrected according to equation
2.11. T2 mapping was performed based on a spin echo sequence with eight echo times,
where T2 was deduced as the exponential fit parameter of the observed voxel-wise signal
Table 3.1: Measured mean and standard deviation of T1 and T2 relaxation times of gel samples with
varying agarose concentration (1.0 w/w – 2.0 w/w %) and a sample with Milli-Q water as reference
sample.
Sample MQ-H2O 1.0 w/w % 1.22 w/w % 1.5 w/w % 2.0 w/w %
T1 / ms 2630 ± 82 793 ± 12 769 ± 12 721 ± 11 721 ± 10
T2 / ms 1448 ± 101 64.7 ± 0.7 56.0 ± 0.5 47.9 ± 0.6 38.9 ± 0.5
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decay. Both mapping procedures included a masking of the background noise. The relevant
MRI sequence parameters can be found in the supplementary Table A.1. The resulting T1
and T2 maps (see Figure 3.1) were manually segmented to measure the mean relaxation
time of the respective sample. Based on the results shown in Table 3.1, the gel composition
leading to an optimal pancreas tissue equivalency was therefore projected at an agarose
concentration of 1.8 w/w %. It should be noted, however, that the measured T1 value of
all four gel samples as well as the T2 value of two out of four gel samples (1.22 w/w –
2.0 w/w %) coincided with the literature values (T1 = 725 ms ± 71 ms, T2 = 43 ms ± 7 ms (De
Bazelaire et al., 2004)) of pancreas tissue at 3.0 T.
3.1.2 Phantom design
Following the results of section 3.1.1 a gel matrix (725 g) was prepared with an agarose
concentration of 1.80 w/w %. The gel components (carrageenan (7.25 g, 1.0 w/w %), sodium
azide (217.5 mg, 0.03 w/w %), sodium chloride (2.11 g, 0.291 w/w %), gadolinium chloride
(26.4 mg, 97.6µmol/kg) and agarose (13.05 g, 1.8 w/w %)) were dissolved in Milli-Q water
(702.7 g) in a boiling water bath for 2 h with constant stirring. Air bubbles were removed
using sonication, to reduce susceptibility inhomogeneities and consequently potential static
magnetic field inhomogeneities in the phantom material. The gel matrix was enclosed by
Figure 3.2: (a) Schematic illustration of the coronal plane of the spherical phantom containing the
fiducial markers. The solid markers Gold Anchor™ and VisiCoil™ were differently oriented in re-
spect to the static magnetic field B0 in order to account for directional dependencies. One Gold
Anchor™ was additionally placed in a ball-shaped form as often applied in clinical practice. The
liquid marker BioXmark® was injected as spheres in four different volumes (10µL, 25µL, 50µL and
100µL). (b) Schematic illustration of the transverse view of the spherical phantom with the water
sphere placed in the lower hemisphere. During MRI the phantom was aligned so the B0 was in
parallel with the marker plane and perpendicular to the transverse plane.
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Figure 3.3: (a) Spherical gel phantom positioned on a cork stand for stability in the 8-channel head
coil used for MRI. (b) Exemplary CT slice and (c) kV X-ray image of phantom showing all eleven
implanted fiducial markers clearly visible in these two imaging modalities. The different orthogonal
orientation of the solid markers can be appreciated.
a non-signal producing urethane phantom (Magpham SMR 140 phantom, The Phantom
Laboratory, Salem, USA) composed of two hemispherical shells with an inner diameter of
10 cm. The spherical geometry was chosen in accordance to the recommendation by the
AAPM Nuclear Magnetic Resonance Task Group No. 6 (Och et al., 1992) to reduce the
effects of the phantom on the static magnetic field homogeneity of the MRI scanner.
In the lower hemisphere of the phantom a polyethylene sphere with a diameter of 35 mm
filled with Milli-Q water was placed. The water sphere acted as reference value for quan-
tification of relative proton density, since no literature value of the relative proton density of
pancreas tissue was available. The lower hemisphere was then fully filled with the prepared
gel. The upper hemisphere was initially only filled to 75 %. Furthermore, a petri dish with a
diameter of 10 cm was filled with the gel matrix up to a height of 1 cm which was allowed to
set at 5°C for 1 h. In the petri dish the fiducial markers were subsequently placed into the
intended locations and orientations, as shown in Figure 3.2 (a). Thereafter, gel was added
to the petri dish to cover all markers. Once fully solidified, the insert containing the fiducial
markers were removed from the petri dish using a scalpel and transferred to the 75 % filled
upper hemisphere, where additional gel was added to fully fill the hemisphere. Finally, the
two hemispheres were tightly closed and the phantom was stored at 5°C until use. Before
any measurement, the phantom was allowed to set at room temperature for at least 10 h.
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3.1.3 Investigated liquid and solid fiducial markers
The phantom was equipped with the liquid fiducial marker BioXmark® as well as two clini-
cally used types of solid gold fiducial markers, Gold Anchor™ (Naslund Medical AB, Hud-
dinge, Sweden) and VisiCoil™ (IBA Dosimetry, Schwarzenbruck, Germany). BioXmark®
is a three-component biocompatible liquid fiducial marker, consisting of sucrose acetate
isobutyrate (SAIB), organo-iodinated SAIB and ethanol. After injection in soft tissue, ethanol
diffuses out of the marker, leading to an increase in viscosity. The marker comes enclosed
in vials of 1 mL volume, allowing in principle for an adaption of marker size up to 1 mL
depending on the injection site and the proposed imaging protocol. Due to the low initial
viscosity, the marker is suitable for minimal invasive EUS guided injection using thin nee-
dles (≤ 25 G). Four approximately spherical volumes of BioXmark® (10µL, 25µL, 50µL
and 100µL) were positioned in the mid-plane of the phantom (see Figure 3.2 (a)). The
gelatinization of the markers was induced by injection into water filled glass vials using a
thin 25 G needle and a high-precision Hamilton syringe (precision ± 1 %, Hamilton Labora-
tory Products, Reno, USA) prior to their placement in the phantom.
For comparison, differently sized rigid gold (> 99.9% Au, VisiCoil™) and composite metal
(99.5 % Au + 0.5 % Fe, Gold Anchor™) markers were placed in the same plane as the
liquid markers in three different orthogonal orientations relative to the static magnetic field
to cover directional dependencies. The requirement for the rigid markers was a diameter
d < 0.686 mm, so that they would fit in a 19 G needle, typically used for EUS-guided fine
needle aspiration of the pancreas. Four Gold Anchor™ (three d = 0.28 mm and l = 10 mm;
Figure 3.4: (a) Image of the tested liquid fiducial marker BioXmark® as is received in 1 mL vials
(courtesy of Nanovi Radiotherapy A/S, Lyngby, Denmark). (b) Schematic illustration the solid Gold
Anchor™ fiducial marker in linear and folded shape, which is facilitated by its segmented struc-
ture (courtesy of Naslund Medical AB, Huddinge, Sweden). (c) Schematic illustration the solid
VisiCoil™ fiducial marker which is flexible through its helical design (courtesy of IBA Dosimetry,
Schwarzenbruck, Germany).
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one d = 0.28 mm and l = 20 mm) were placed in the bottom half of the mid-plane in horizon-
tal, perpendicular and vertical orientation in respect to the static magnetic field as well as
one marker in a folded ball shape, as clinically performed. Three VisiCoil™ (two d = 0.35 mm
and l = 5 mm; one d = 0.35 mm and l = 10 mm) were placed in the upper half of the mid-plane
in horizontal, perpendicular and vertical orientation.
3.2 Visibility and artefacts of fiducial markers in phantom at 3T
MRI
Since in MRI a vast amount of contrasts can be created by the adaption of multiple se-
quence parameters, the typical visibility scoring found in literature is a subjective analysis
by a limited amount of observers and is only valid for comparable MRI sequences. In the
following chapter the aim was to provide a quantitative, pulse sequence-independent as-
sessment of the visibility and artefacts by the tested markers in MRI. This approach was
based on the method proposed by Gurney-Champion et al. (2015), which was extended for
the purpose of including the liquid marker. In this approach the idea was to investigate the
source of the markers visibility and artefact in MRI instead of their final effect in a specific
sequence. For the solid markers this is mainly due to differences in magnetic susceptibil-
ity relative to their vicinity which reduces the local T∗2 relaxation time. This describes an
enhanced spin dephasing, which in GRE sequences leads to pronounced signal voids in
tissue caused by the marker. Therefore, in this work visibility of solid markers was analyzed
by their induced reduction of surrounding T∗2 relaxation time. At the same time field pertur-
bations can lead to geometric distortions in the images, where voxels affected are shifted
relative to their actual position in the object. Artefacts caused by both solid and liquid mark-
ers will therefore be analyzed by the increase in static magnetic field inhomogeneity (∆B0).
In case of the liquid marker BioXmark®, based on its anhydrous and ferromagnetic-free
composition, low signal intensity was expected in MRI independent on the effect on the lo-
cal T∗2 relaxation time. Hence the visibility of the liquid marker was analyzed by its reduction
of relative water proton density ρ(H). Since visibility of an object in any imaging modality
ultimately is a combination of its magnitude in contrast to the surrounding tissue and its
visualized size, both visibility and artefact were separately evaluated in terms of size and
magnitude, based on the approach proposed by Gurney-Champion et al. (2015).
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3.2.1 Quantitative evaluation of marker visibility and artefacts
MRI acquisition
As described in section 3.1.1 the phantom was scanned with a 3.0 T Philips Ingenuity TF
PET / MR scanner using an 8-channel head coil where special care was taken that the
phantom orientation was correctly aligned with the magnetic field, as shown in Figure 3.2.
All acquired data was processed with MATLAB® in order to create quantitative field maps.
To facilitate a quantitative evaluation of marker visibility and artefacts based on T∗2-, ∆B0-
and ρ(H) mapping, relaxometry was performed similarly to section 3.1.1. For T∗2- and ∆B0
mapping a multi-echo Spoiled gradient recalled echo (SPGR) sequence was acquired at
eight echo times with equidistant intervals ∆TE = 4.6 ms. From the phase image, a ∆B0 map
was calculated according to equation 2.15. To correct for phase wraps in the area of high-
field inhomogeneity, phase unwrapping was performed based on the algorithms by (Ghiglia
and Pritt, 1989).
For evaluating the visibility of the liquid marker a ρ(H) map was created based on a multi-
echo gradient and spin echo (GRaSE) sequence (Meyers et al., 2015) acquired at eight
echo times with equidistant intervals ∆TE = 16 ms. Based on equation 2.13, ρ(H) can be
deduced for every voxel by interpolation of the exponential signal decay curve to TE = 0 ms.
For this approach the T1 decay and the inhomogeneities in B
−
1 have to be considered.
Therefore, a T1 map was additionally calculated with the gold standard Inversion recov-
ery (IR) Spin echo (SE) method acquired at six different inversion times Inversion time (TI).
The complex data was then fitted to a five-parameter model (Barral et al., 2010) to calcu-
late a T1-map. Furthermore, a B
−
1 map was calculated based on a dual Repetition time (TR)
Gradient recalled echo (GRE) sequence. Finally, the retrieved scaling constant was normal-
ized to the sphere containing MQ-water to gain proton density information relative to water
ρ(H).
All relevant parameters of the acquired sequences can be appreciated in the supplemen-
tary Table A.2.
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Analysis
The semi-manual segmentation of markers was performed with the ImageJ software tool
(ImageJ 1.41n, National Institute of Health, Bethesda, Maryland, USA). Since the visibil-
ity of the investigated markers arises from their induced signal void, the potentially visible
size of the solid markers was defined as the volume of short relaxation time V(T∗2 < T
∗
2,low).
The threshold value was set three standard deviations (i.e. 3σ= 12.3 ms) lower than the
mean T∗2 value of the phantom material T
∗
2,phan, measured in a homogeneous slice outside
the marker plane. The threshold value of 3σ was chosen in order to ensure that under
the assumption of a Gaussian distribution, with 99.7 % confidence the phantom material is
not falsely contributing to the segmented marker volume. A region of interest was defined
around the respective marker and visually inspected for potential air inclusions. In the oc-
currence of the latter the segmented volume was manually corrected, which was necessary
for five markers (vertical VisiCoil™, 25µL BioXmark® , 100µL BioXmark® , perpendicular
GoldAnchor™ , ball shaped GoldAnchor™). The potential magnitude of visibility was de-
fined as the maximum relative reduction of T∗2 in the volume affected by the marker
MT∗
2
=
T∗2,phan − T
∗
2,min
T∗2,phan
, (3.1)
where T∗2,min is the lowest measured value within the inner fence of the segmented T
∗
2
dataset
T∗2,min = min
[
Q1 − 1.5 · (Q3 − Q1); Q3 + 1.5 · (Q3 − Q1)
]
, (3.2)
to account for possible outliers. Here, Q1 and Q3 denote the first and third quartile of the
ranked data. In correspondence to this approach the visibility analysis of the liquid marker
based on ρ(H) was performed. First, a volume of low ρ(H) was determined with a threshold
value lower than 3σ from the mean proton density value of the phantom material ρ(H)phan
(i.e. 6 %) as a measure of potentially visible size, of which finally the relative reduction in
ρ(H) was evaluated according to
Mρ(H) =
ρ(H)phan − ρ(H)min
ρ(H)phan
. (3.3)
Here again ρ(H)min represents the lowest measured value within the inner fence of the
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segmented ρ(H) dataset
ρ(H)min = min
[
Q1 − 1.5 · (Q3 − Q1); Q3 + 1.5 · (Q3 − Q1)
]
, (3.4)
to account for outliers.
Since artefacts can arise from field inhomogeneities, the size of potential artefacts was
defined as the volume of high field inhomogeneity V(|∆B0,marker| >∆B0,high). The absolute
value of ∆B0,marker had to be considered since both the increase as well as the decrease
in B0 contributes to artefacts. In order to eliminate marker unrelated low-frequency shifts,
the ∆B0 map was subtracted by a Gaussian-filtered map (with a radius of 8 pixels). The
threshold value ∆B0,high was again defined as a 3σ deviation from the phantom material (i.e.
4 Hz). As a measure of magnitude of artefacts, the maximum difference in local magnetic
field ∆maxB0 = ∆B0,max−∆B0,min within the volume of the respective marker was evaluated.
Results
The quantitative maps, resulting from the performed relaxometry, are depicted in Figure 3.5.
For quantification of visibility of the solid and liquid markers, the T∗2 map (Fig. 3.5 (a)) and
the ρ(H) map (Fig. 3.5 (b)) were used, respectively. The ∆B0 map (Fig. 3.5 (c)) was used
for quantification of artefacts, where the segmentation of all markers is shown in Figure 3.5
(d). The relationship between the potentially visible size and the potential size of artefact
Figure 3.5: Coronal plane of the phantom including the fiducial markers showing (a) the T∗
2
map,
(b) the ρ(H) map in percent units [pu] relative to ρ(H) of water, (c) the Gaussian-filter subtracted
∆B0-map and (d) the Gaussian-filter subtracted ∆B0-map overlaid with the segmentation (green)
resulting from a threshold of 4 Hz. The segmentation was corrected in the presence of artefacts due
to air inclusions.
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Figure 3.6: Trade-off between the volume with low transverse relaxation time T∗
2
(left axis) and low
relative proton density ρ(H) (right axis) as a measure of potentially visible size and the volume with
high ∆B0 as a measure of potential size of artefact.
Abbreviation: Verti. = Vertical; Hor. = Horizontal; Perp. = Perpendicular
for all markers included in the study is illustrated in Figure 3.6. Gold Anchor™ markers
were found to have the largest volume of potential visibility due to the included ferric com-
ponent (0.5 %). Simultaneously, Gold Anchor™ markers induced the largest volume of field
inhomogeneity. As can be seen in Figure 3.6, a difference in affected volume (factor 2.8)
was observed between identical Gold Anchor™ when oriented horizontally with respect to
the static magnetic field or perpendicular, respectively. A similar behavior was observed for
VisiCoil™ , however, with a smaller absolute size of affected volume in both visibility and
artefact due to the absence of iron. For the solid markers a linear dependency between
potentially visible size and field inhomogeneity was observed (coefficient of determination:
R² = 0.996, Spearmann correlation coefficient: RS = 0.99).
The liquid marker showed only a weak correlation between potentially visible size and
volume of field inhomogeneity (RS = 0.4). The introduced volume of high ∆B0 did not in-
crease directly proportional to the potentially visible size. In the ∆B0-map (Figure 3.5 (c)),
voxels affected by high ∆B0 were found heterogeneously spread in the direct interface be-
tween marker and phantom gel matrix. BioXmark® marker with a volume of 50µL showed
a visible size comparable to the 1 cm long solid marker VisiCoil™ in perpendicular orien-
tation, while only showing 20 % of the affected volume in ∆B0. The largest liquid marker
(100µL) induced a signal void comparable to the potential size of the horizontally-oriented
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Figure 3.7: Trade-off between maximum reduction of T∗
2
(left axis) and ρ(H) (right axis) in percent
units [pu] as a measure of potential magnitude of visibility and the maximum magnetic field inhomo-
geneity introduced by the marker as a measure of magnitude of potential artefacts.
Abbreviation: Verti. = Vertical; Hor. = Horizontal; Perp. = Perpendicular
1 cm long Gold Anchor™ marker at only 19 % of the respective volume affected by arte-
facts. The potential magnitude of visibility and artefact (Figure 3.7) showed a non-linear
correlation (R² = 0.992, RS = 0.964) for the solid markers. Within the group of solid markers,
Gold Anchor™ marker were found to produce the largest magnitude of visibility as well as
overall the most pronounced tendency towards artefacts (91 Hz). BioXmark® marker did not
show a correlation between magnitude in visibility and artefact (RS = 0.0). The liquid marker
with a volume of 50µL showed to induce a high magnitude of visibility, with a relative signal
reduction factor of 0.98, at the smallest potential artefact (5.0 Hz).
3.2.2 Qualitative evaluation of marker visibility
The interpretation of a low ρ(H) as the source of visibility of the liquid marker led to the
expectation that the liquid marker should be similarly visible in all MRI sequences if res-
olution is constant, since ρ(H) affects all MRI sequences as a scaling factor in the same
way. In order to validate this hypothesis, the phantom was first scanned with sequences
typically used in our institution for patients with PDAC (see supplementary Table A.3 (a-
d)). Additionally, in order to visualize the visibility characteristics of the fiducial markers, a
SPGR sequence at two TE (e, f) was acquired as well as a SE sequence at two TE (g,
h). The apparent size of the fiducial marker was then determined in sequences (e-h) to
30
3.2 Visibility and artefacts of fiducial markers in phantom at 3T MRI
Figure 3.8: Qualitative assessment of the fiducial marker in different MRI sequences. (a) T1-
weighted spoiled GRE, (b) T2-weighted SE, (c) Diffusion-weighted SE, (d) Apparent diffusion co-
effcient map in M-gradient direction calculated from DWI image in (c) , (e-f) GRE with TE = 2.3 ms
(e) and TE = 29 ms (f) , (g-h) SE with TE = 18 ms (g) and TE = 109 ms (h)
validate the hypothesis of the different sources of visibility for the solid and liquid markers.
The size of markers was evaluated by setting a threshold value of 3σ from the mean sig-
nal of the phantom material in the respective sequence. Signal values below this threshold
were considered as affected by the markers. Segmentation was manually corrected in the
occurrence of air inclusions close to markers. Finally, for every type of marker, the relative
standard deviation (RSD) of the visible size in the GRE sequences (e, f) was determined
as a measure of change in visibility at different TE.
All markers caused signal voids in the utilized sequences. An evaluation of their respec-
tive visible size in GRE and SE sequences at different TE is shown in Fig. 3.9. Gold An-
chor™ markers were especially visible in sequences that are affected by field inhomo-
geneity effects (i.e. GRE and DWI), in which VisiCoil™ markers were also best detectable.
There, at long TE (Fig. 3.8) the solid markers appeared larger (RSDGoldAnchor = 70.5 %,
RSDVisiCoil = 74.0 %). In SE sequences the visibility of the solid markers was smaller and
relatively constant in between different TE. In particular VisiCoil™ markers were hard to
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Figure 3.9: Evaluation of visible size for all 11 markers in the 4 sequences (e-h) shown in Figure
3.8 used for qualitative assessment.
Abbreviation: Vert. = Vertical; Hor. = Horizontal; Perp. = Perpendicular.
detect and Gold Anchor™ marker were much less pronounced. BioXmark® caused signal
voids with comparable size at different TE (RSDBioXmark = 16.7 %). This is in agreement
with the understanding that the solid markers are primarily visible due to their effect on T∗2
of their surrounding tissue, while BioXmark® causes signal voids due to the lack of water
protons, equally affecting all MRI sequences.
3.2.3 Discussion
In accordance with literature, the solid fiducial markers were found to cause variations in
the surrounding static magnetic field due to their magnetic susceptibility difference relative
to the phantom material. This was most prominent in pulse sequences that are strongly
affected by inhomogeneities in the static magnetic field (e.g. GRE or DWI). On the contrary,
the liquid marker did not substantially affect the surrounding tissue through an increase in
field inhomogeneity, but primarily caused signal voids through the lack of water protons. The
analysis based on the reduction of T∗2 relaxation time, as proposed by Gurney-Champion et
al. (2015), led to an underestimation of the potential visibility of BioXmark®. The approach
of quantifying visibility through a reduction of ρ(H) on the other hand did not cope with the
potential visibility of the solid markers. This was due to their effect on the T∗2 relaxation
of the surrounding tissue, leading especially in GRE sequences to a visibility larger than
their physical size. Hence, for comparison the visibility of the fiducial liquid and solid mark-
ers were analyzed in their respective nature (ρ(H) for the liquid markers, T∗2 for the solid
markers).
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Based on the results presented, the two factors that affected the visibility of the BioXmark®
marker were the resolution of the MRI acquisition and sufficient signal from the surround-
ing tissue as contrast to the signal void induced by the markers. When the resolution was
higher than the size of the injected marker, the resulting signal voids were found to be in-
dependent of the pulse sequence parameters and were easily distinguished with a signal
reduction factor of up to 0.98 (see supplementary section A.1 for evaluation of visibility in
respect to resolution). Marker visibility in different pulse sequences would facilitate a co-
registration of a multi-parametric MRI acquisition with CT (Fernandes et al., 2017). Due
to the fact that the source of visibility in BioXmark® lies in the reduction of ρ(H), which is
a property directly affecting all MR sequences, no tuning of MR parameters is necessary
to optimize the marker’s visible contrast. However, in a more heterogeneous structure like
pancreatic tissue, the size of BioXmark® of at least twice the image resolution is advised
to achieve an appropriate visibility that is not hampered by partial volume effects.
Furthermore, the size of high ∆B0, as a measure of size of artefacts, was found to be 81 %
smaller around BioXmark® than the size of high ∆B0 around the implanted Gold Anchor™
and smaller or comparable than the non-ferromagnetic VisiCoil™. The inhomogeneities
were heterogeneously spread at the interface between marker and gel. In case of the 25µL
and 100µL BioXmark®, artefacts due to small air inclusions could not be fully corrected.
This indicates that the marker itself does not induce the measured field inhomogeneities,
but rather small remaining air gaps from the manufacturing process of the phantom.
As found in Gurney-Champion et al. (2015) for the solid markers, the potential to be visi-
ble and cause artefacts strongly correlated (RS = 1.0), i.e. better visibility comes at the cost
of a stronger tendency towards artefacts. Both solid markers showed a linear dependency
(R² = 0.996) between visible size and size of artefacts. This differs slightly from the results
found in Gurney-Champion et al. (2015) where a non-linear dependency was reported.
This difference could potentially result from differently defined thresholds in the analysis, a
different acquired resolution or the smaller number of samples of solid markers in our study.
The orientation of the solid markers with respect to the static magnetic field affected their
potential visibility and artefacts, in agreement with the findings in Gurney-Champion et al.
(2015). Markers implanted horizontally showed both smaller visibility and artefacts. The per-
pendicular and vertical orientation induced effects of similar size. Since in the clinical case
the orientation is random, we expect an average of the investigated scenarios. Gold An-
chor™ markers are typically implanted in a folded ball-shaped form. The 2 cm long marker
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implanted in a ball-shaped form had an effect of approximately twice (factor 1.88) the size
of the mean of the horizontally and vertical orientated 1 cm long markers. In an ideal case,
BioXmark® forms a spherical shape after injection, which makes the orientation relative to
the static magnetic field arbitrary.
In this study, the potential magnitude of visibility was defined as the maximum relative
reduction in T∗2 or ρ(H) to describe the signal voids of the markers in their respective nature.
The analysis showed a result for the solid markers comparable to Gurney-Champion et al.
(2015). We found a non-linear correlation (R² = 0.992, RS = 0.964) between the potential
magnitude of visibility and artefact, approaching a maximum reduction factor in T∗2 of 0.87
at increasing magnetic field inhomogeneities up to 91 Hz, where Gold Anchors™ induced
the strongest field inhomogeneity. With exception of the 25µL BioXmark® marker and the
horizontally aligned VisiCoil™, BioXmark® markers induced the lowest field inhomogeneity.
Again, BioXmark® showed a different dependency where the magnitude of visibility was not
correlated (RS = 0.0) to the magnitude in field inhomogeneity. At a high ρ(H) reduction factor
of 0.98, the 50µL liquid marker only induced low field inhomogeneities of maximum 5 Hz.
The fact that the magnitude in artefact is not correlated to the size of the liquid marker
indicates that the measured field inhomogeneity (especially from the 25µL and 100µL
sized marker) is due to remaining air in the interface between marker and phantom material.
One should note that both the measured T∗2- as well as ρ(H) reduction are dependent
on the acquired voxel size. Due to a stronger partial volume effect at a lower resolution the
magnitude of the reduction would be underestimated, while the size of the affected volume
is overestimated. This holds true up to a minimum resolution, where the marker cannot be
identified anymore and both size and magnitude would be underestimated (as shown in the
supplementary A.1). On the other hand the T∗2-reduction is also potentially overestimated
at a lower resolution due to stronger dephasing within lager voxel.
One should also note that the threshold values chosen for differentiation of markers and
phantom material affect the outcome of the analysis. In this study a 3σ threshold was con-
sistently used for segmentation. In the case of the ∆B0-map this led to a threshold of 4 Hz.
It has to be noted that when e.g. using a commonly implemented DWI sequence with an
in-plane resolution of 3×3 mm² at a pixel bandwidth of 30 Hz, field inhomogeneities of 4 Hz
would only led to a voxel shift of approximately 0.4 mm. For most clinically used sequences
this level of field inhomogeneity would have a negligible effect. Possible signal alterations
due to eddy currents induced in the solid markers were not considered. Given the size and
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composition of fiducial markers tested, this effect is expected to be secondary relative to the
susceptibility induced T∗2-reduction effect (Graf et al., 2006; Vashaee et al., 2014; Gurney-
Champion et al., 2016). Eddy currents resulting from changing RF-field or image gradients
are, however, very likely the main source of the Gold Anchor™ signal voids observed in
SE sequences (as seen in Figure 3.8). This also applies to the ρ(H)-map (Figure 3.5 (b)),
where Gold Anchor™ markers appear larger than their physical size.
The markers were selected as they can be implanted using a 19 – 22 G needle, typically
used for EUS-guided fine needle aspiration of the pancreas. All three included markers
have been originally designed for X-ray based image guidance, but possess visibility in
MRI due to their physicochemical properties and their effect on the magnetic field in the sur-
rounding tissue. Several other commercially available solid markers such as FusionCoil™
and PolyMark™ have been developed for enhanced MRI-compatibility. Since these markers
require 18-gauge needles for implantation, their suitability for use in pancreatic adenocar-
cinoma is compromised by the fact that they need to be inserted via the EUS-guided fine
needle aspiration technique, requiring at least 19 G needles. Consequently, FusionCoil™
and PolyMark™ were not included in this study. The use of other liquid fiducial markers for
CT and MR imaging has been reported in the literature. TraceIT® (Augmenix Inc, Waltham,
MA), a hydrogel-based marker has been reported for use in gynaecological (Bair et al.,
2015), bladder (Chamie et al., 2014) and oesophageal cancer (Machiels et al., 2015) with
sufficient visibility in both imaging modalities. In T2-w MRI this marker was in fact visible as
hyperintensity. However, due to their low X-ray attenuation, their visibility in CBCT was poor
with only 22 % markers visible 13.5 days after initial injection (Machiels et al., 2015). Con-
sequently rather large volumes > 400µL had to be injected for sufficient visibility, preventing
the formation of small discrete markers. Furthermore, long-term stability, which is crucial
for fractionated radiotherapy of several weeks, has been reported to be limited with only
11 % of the injected markers remaining visible in CBCT during the course of RT(Machiels
et al., 2015). Terry et al. (2014) reported the in vitro use of aqueous solutions of iopamidol
for CT and MR imaging and concluded that a 10 % aqueous solution proved to be optimal
with respect to visibility and low degree of artefacts. However, in vivo use of such a sys-
tem for tissue injection is limited due to biological washout following injection, resulting in
unspecific tissue marking.
It should be noted that due to the design of the phantom, our study only analyzed the
MRI characteristics of the markers in pancreatic-like tissue at 3 T. Based on our correlation
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analysis between the potential to be visible and cause artefacts, and given that suscepti-
bility induced B0 inhomogeneities decrease at lower magnetic field strengths (Soher et al.,
2007), we expect that solid markers would induce both smaller artefacts and visibility at
1.5 T and even more so at 0.35 T, commonly used for MR-Linac systems. BioXmark® how-
ever, should give similar results based on its proton density effect. Furthermore, the results
based on the reduction of ρ(H) can only be limitedly transferred to the clinical case. The
constructed gel phantom was designed to mimic the relaxation properties of pancreatic
tissue, not to accurately resemble its ρ(H) value. No literature was found that accurately
describes ρ(H) of pancreatic tissue in vivo relative to water. An investigation of the markers
behavior in real pancreatic tissue is therefore mandatory.
3.3 Detectability of liquid fiducial marker in ex vivo tumorous
pancreas tissue
Concluding section 3.2 the visibility of the liquid marker is induced by the low water proton
density in the volume the marker is occupying. This volume effect makes the visibility of the
marker strongly depending on its injection behavior. In section 3.2, the liquid markers were
injected into water to facilitate gelatinization prior to placement into the phantom, leading
to sphere like shapes. In vivo, however, a spherical injection is not ensured and will likely
depended on its cellular structure. Shortly after concluding the prior presented phantom
study, De Roover et al. (2018) found the liquid marker to be hypointense in T1-weighted
but iso-intense and consequently non-visible in prostatic tissue in T2-weighted images at
1.5 T. This finding is in part contradictory to those of our study. Since in MR-guided RT
and organ at risk delineation is often performed on or supported by T2-weighted images,
the detectability of fiducial markers in these sequences is of particular interest. Since a CE
certification for the use of BioXmark® in abdominal patients was at the time of this study
still pending, an ex vivo investigation of the markers behavior in tumorous pancreas tissue
was the closest achievable to a clinical scenario. This study is described in the following
chapter.
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3.3.1 Material and methods
Three patients (two males, age 69 and 72; one female, age 68), suspected to have an
adenocarcinoma of the pancreatic head and scheduled for primary pancreaticoduodenec-
tomy, provided informed written consent for injection of the liquid fiducial marker into the
resection specimen and for subsequent X-ray, CT and MR imaging thereof. Immediately
after resection, the resection specimen was transported to the Department of Pathology of
the University Hospital Carl Gustav Carus for immediate biopsy selection for frozen section
analysis. During transport the specimen was stored in a container with ice to prevent en-
zymatic degradation. Thereafter, the injection of the markers and imaging of the resection
specimen were performed within the next 2 hours, while still being on ice. In order to test
the stability of the marker after fixation in formaldehyde, the complete scan protocol was re-
peated for one of the three resection specimens after fixation in formaldehyde for 24 hours.
Surgical clips or sutures placed into the resection specimen during the surgical resection
were not removed and remained present during marker injection and subsequent imaging.
The study was approved by the local Ethics Committee of the Faculty of Medicine and Uni-
versity Hospital Carl Gustav Carus of the Technische Universität Dresden (EK-534122015).
In each specimen several liquid markers (5 – 6) of various volumes (20/25µL, 50/60µL,
100µL) were injected at a depth of 1 cm – 2 cm directly adjacent to the tumour boundaries
approximately 30 min after surgical resection. Moreover, three different needle sizes (18 G,
22 G, 25 G) were used during the injection into the three specimens, respectively, to test
the injection behavior depending on needle size. For this, the needles were attached to
a unit dose injector (MicroDose™, Vlow Medical B.V., Eindhoven, The Netherlands) for
accurate and reproducible injection. The injection was performed under kV X-ray guidance
to facilitate the subsequent differentiation of injected markers and surgical clips or sutures.
While in two resection specimens (specimen volume 191.0 cm³ and 334.3 cm³) six mark-
ers were injected, in one specimen only five markers were injected due to a relatively small
size of the specimen (specimen volume 154.2 cm³). Furthermore, for two specimens a unit
dose injector was used which allowed smallest injection volumes in steps of 25µL, while
for the other specimen only a unit dose injector was available which allowed smallest injec-
tion volumes in steps of 20µL. This led to a slightly different size and number of injected
markers throughout the used resection specimens.
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3.3.2 Image acquisition
Marker injection was performed under kV X-ray guidance. This enabled an injection with
sufficient distance to surgical clips or sutures as well as facilitated the discrimination of
markers and clips in subsequently acquired CT images (Siemens SOMATOM Definition
AS, Siemens Healthineers, Erlangen, Germany). In order to test the MRI visibility of the
marker ex vivo, pulse sequences were utilized which are also commonly used in our clinic
for patients with pancreatic adenorcarcinoma. Coronal MR images were acquired with a
32-channel SENSE Torso/Cardiac coil (3.0 T Philips Ingenuity TF PET/MR scanner, Philips
Healthcare, Eindhoven, The Netherlands) acquiring a T1-weighted spoiled gradient echo
sequence (GRE) and a T2-weighted turbo spin echo (TSE) sequence. Both CT and MRI
scans were performed with the specimen still placed on ice.
3.3.3 Analysis
The CT images were first rigidly registered onto the MR images taking into account the
specimen contour. The markers were then segmented on the CT images as hyperintense
structures with the open source software 3D Slicer (Pieper et al., 2004) by threshold seg-
mentation such that the lower threshold (i.e. 129.3 HU) was 3σ higher than the mean signal
intensity of the pancreatic tissue (see Figure 3.10 (c)). In order to correctly assign the re-
spective marker and to prevent erroneously segmenting surgical clips or sutures instead of
Figure 3.10: (a) kV X-ray of a resection specimen during marker injection in which the needle is
visible on the right half of the image, as well as several surgical clips close to the marker injec-
tions of which a 100µL marker is marked with a red arrow. (b-e) Coronal slice where the in (a)
marked 100µL marker is visible on CT (b) and T2-weighted turbo spin echo (TSE) MRI superim-
posed with the threshold based orange-yellow CT segmentation (c), native T2-weighted TSE MRI
(d) and T1-weighted gradient echo (GRE) MRI (e). The injected 100µL fiducial marker is depicted
as hyperintensity on CT and as signal void on T2- (d) and T1-weighted (e) MRI
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liquid fiducial markers, the X-ray images taken during injection were used as a visual aid.
MRI visibility of the liquid marker was approved if a hypointense structure was visible on
MRI enclosed by the registered CT segmentation, following the results in section 3.2.1.
In order to assess the geometrical stability of the fiducial marker after fixation of the re-
section specimen in formaldehyde, for one resection specimen the segmentation procedure
was repeated on the CT scan obtained after fixation for 24 hours. The segmented volumes
of the respective markers on CT before and after fixation were compared to deduce a pos-
sible volume decrease.
3.3.4 Results
Figure 3.11 shows (from left to right) exemplary slices of the resection specimens on CT, T1-
and T2-weighted MRI from all three patients included in this study (top to down). As can be
Figure 3.11: Exemplary coronal slice of all three resection specimens on CT [left], T1-weighted
gradient echo (GRE) MRI [middle] and T2-weighted turbo spin echo (TSE) MRI [right]. In each
of the three specimens one marker of different size (25µL, 50µL, 100µL) was highlighted with a
yellow square in the respective imaging modality. Markers are visible as hyperintensity on CT and
as hypointensity on both T1- and T2-weighted MRI. On the top right of each segment a close-up
view of the yellow squared region of interest is shown for clear visualization of the marker
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appreciated, the liquid fiducial marker is detectable on CT as hyperintense structure and as
hypointense structure on both T1- and T2-weighted MRI, respectively. Markers of all sizes
(20µL – 100µL) tested in this study could be detected with the clinically used sequences.
Noteworthy, CT revealed that injection generally resulted in a non-spherical marker, making
MR detectability dependent on slice orientation and voxel size. Moreover, a diffuse injection
or injection too close to the surface hampered MR detectability, leading to 4 of 17 markers
being non-detectable on MRI. CT and MR images of all 17 marker injection sites can be
found in the supplemental material Fig. A.4.
After 24 h fixation in formaldehyde all six markers in the investigated resection spec-
imen were still visible on CT (see Figure 3.12 for a coronal maximum intensity projec-
tion) and MRI (Figure 3.13), and geometrically stable. Overall, the volume decrease was
6.6 % ± 13.0 %, which was expected due to the efflux of ethanol within the first 2 h after in-
jection, as described in literature (Scherman Rydhög et al., 2016). Only one 60µL marker
was partially washed out of the specimen. As was detected on the CT images, this marker
was initially injected too close to the specimen surface, leading to its partial protrusion out
of the specimen.
Figure 3.12: Maximum intensity projection of the resection specimen scanned with CT before (a)
and after (b) fixation in formaldehyde. All six injected markers were stable in their size and position.
It can be appreciated that after fixation an additional hyperintense structure was found in the top
right corner of the container filled with formaldehyde. This corresponds to a partially washed out
60µL marker (marked with an asterix).
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Figure 3.13: Four representative T1-weighted MRI slices of a pancreatic cancer resection specimen
fixated in formaldehyde showing all six injected markers. Remaining hypointensities caused by a
surgical suture and air cavities are also visible.
3.3.5 Discussion
While marker detectability on CT imaging was found to be satisfactory with markers clearly
depicted as hyperintense structures, on MRI the fiducial marker was difficult to identify due
to signal voids from tissue heterogeneity, air cavities, surgical clips or sutures resembling
fiducial markers in MRI. To distinguish fiducial marker induced signal voids from the latter,
a prior registration with the CT images was necessary. Moreover, visible marker backflow
was reduced using smaller needle diameters, and the marker was found geometrically
stable after 24 h fixation in formaldehyde.
The marker detectability on MRI may improve using a composition with gadolinium lead-
ing to a hyperintense marker, which would facilitate its differentiation in heterogeneous
tissue. This would however impair the markers transparency for proton beam irradiation
due to the consequently higher Znumber. On the other hand, for the in-vivo situation, the
marker detectability is expected to improve since less or no hypointensities caused by air
cavities and/or surgical clips are present. Conversely, since fiducial marker injection in case
of PDAC is often performed into the adipose tissue in direct proximity of the tumour, marker
detectability on fat-saturated MRI sequences will be hampered, as was also found in clini-
cal practice with fiducial gold markers in our institute. After registration with the CT images
of the specimen, many markers were still only poorly visible or even not visible at all on
MRI. When investigating these markers on the CT images, it appeared that in these cases
the injection was not spherical. Hence detectability was strongly dependent on the injected
shape and the distance to the specimen surface. Nevertheless, in particular larger markers
≥ 50µL, which formed sphere-like volumes, were visible as strong signal void on both T1-
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and T2-weighted MRI. This is concordant to the results found in chapter 3.2.1, where the
BioXmark® marker was found to be causing signal voids at 3 T independent of the con-
trast mechanism due to an apparent lack of water protons. In De Roover et al. (2018) the
same marker was found to be isointense to prostatic tissue on T2-weighted MR images at
1.5 T. These different findings may result from the lower field strength used in their study.
It is more likely, however, that this effect resulted from a signal contamination caused by
the phantom material in which the marker was injected. Since the ellipsoid shaped 300µL
marker analysed in the study by De Roover et al. (2018) showed a size in slice encoding di-
rection that was close to the slice thickness acquired (4 mm), a partial volume effect cannot
be ruled out.
When introduced into clinical practice, it is expected that the in vivo use of the BioXmark®
will lead to more spherical and hence better detectable markers on MRI. This is due to
the persisting metabolism and fast efflux of ethanol after injection. This effect is expected
to be magnified by faster efflux and consequential faster gelation in warm in vivo tissue
in comparison to the ∼ 4 C° realized in this study due to the transport of the specimens
on ice. Alongside, motion blurring will impede on the MR quality and will most likely re-
quire larger marker volumes of 50µL – 100µL to still be visible on MRI. These volumes
should preferably be injected with a needle of at least 22 G preventing marker backflow.
The marker’s detectability on different anatomical imaging modalities is of great value to
the field of radiation oncology. In addition, its minimal proton dose perturbations (Jølck et
al., 2014; Scherman Rydhög et al., 2017), the chemical stability during a prolonged course
of fractionated radiotherapy (Troost et al., 2017) and also after fixation in formaldehyde
makes the marker promising for neoadjuvant and definitive treatment concepts involving
photon or proton beam therapy.
3.4 Summary
In this study, the MRI properties of the novel liquid fiducial marker BioXmark® have been
investigated for the first time. A method for quantitative evaluation of MRI visibility and arte-
fact, as proposed by Gurney-Champion et al. (2015), was used and extended to compare
the liquid marker against the two commonly used solid markers Gold Anchor™ and Visi-
Coil™. In our approach, visibility of solid markers was determined based on their reduction
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on local T∗2 relaxation time, while the visibility of the liquid marker was quantified as reduc-
tion of ρ(H) relative to water. The quantification of artefacts induced by both solid and liquid
markers was based on the locally increased static field inhomogeneity by the markers. All
fiducial markers were implanted within a gel phantom, mimicking the relaxation properties
of pancreatic tissue at 3.0 T and were visible in this phantom as hypointense structures.
While a strong correlation was found between visibility and artefacts of solid markers, in
the case of the liquid marker no such correlation was found. The interpretation of visibility
due to low ρ(H) in the liquid marker was validated by comparing the size of visibility in differ-
ent sequences (SE and GRE) at different TE. The liquid marker was found to induce strong
hypointensities at a level of background noise and showed a constant size in all tested
sequences. This led to the conclusion, that the liquid marker’s visibility is depending only
on the combination of marker size and sequence resolution, when injected in MRI signal
generating tissue.
Furthermore, BioXmark® was tested for the first time ex vivo in freshly resected pancre-
atic cancer specimen. While visibility in CT and kV X-ray was found to be satisfactory where
all markers with a size between 20µL – 100µL was easily detectable, visibility in MRI was
relatively poor due to the large amount of similar hypointensities due to tissue heterogeneity
as well as surgical clips and sutures still present in the specimen. In vivo the visibility of the
liquid marker is expected to increase due to the absence of air inclusions and surgical clips
resembling the marker as well as due to the more spherical gelation in an environment with
persisting metabolism. Conversely, marker visibility will suffer due to persisting motion in
vivo. Considering both effects we expect a marker size of > 50µL to be necessary in order
to allow MRI visibility of the liquid marker in vivo.
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4 Geometric fidelity and accuracy of phantom target
tracking with MRI
To increase the accuracy of RT for patients with moving tumors, it is of paramount im-
portance to take intrafractional motion into account during pre-treatment image acquisition,
treatment planning and dose delivery (Keall et al., 2006). Respiratory motion is the predom-
inant cause of intrafractional motion affecting all tumor sites in the thorax and abdomen (De
Ruysscher et al., 2015). The quantification and management of respiratory motion is there-
fore an essential component to improve treatment outcome through IGRT. Motion charac-
terization through MRI, however, has to be approached with care due to the susceptibility
of MRI towards geometrical distortion. Therefore, the accuracy and precision of dedicated
MRI pulse sequences for motion tracking initially need to be assessed in a quality assur-
ance (QA) procedure. For this purpose, MRI motion phantoms should be utilized to simulate
reproducible motion patterns with known ground-truth trajectories, which are generally not
available for patients due to day-to-day variations in patient anatomy, breathing patterns
and uncertainties in patient positioning.
Historically QA in MRI has been radiology-oriented. Hence both QA protocols as well as
commercially available MRI phantoms have largely been designed to evaluate the image
quality of static objects (Jackson et al., 2010). With the recent development and increased
clinical interest in MR integrated RT systems, however, the evaluation of MR image quality
of moving objects is becoming increasingly important, especially when used for organ mo-
tion characterization studies and gating or tracking purposes in RT. Consequently, several
MRI motion phantoms are now commercially available.
In the following chapter, the aim is to develop a commissioning protocol for an MRI-Linac
motion phantom on a diagnostic 3.0 T MR scanner, that is used for RT simulation purposes
including organ motion characterization studies, and to assess the scanners 3D geometric
fidelity and accuracy in dynamic target tracking. In section 4.1 the phantom is presented.
Since the phantom was designed for use on an MR-Linac scanner with a lower magnetic
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field, a positioning setup was designed, which considers safety regulations at higher mag-
netic fields and allows for a fast reproducible positioning at the 3 T MR scanner, which had
previously been modified for radiotherapy compatibility (see section 4.2). Subsequently, a
method was developed for an automatic quantification of 3D geometric distortion. With this
tool a 3D GRE sequence, used for abdominal patients, was analyzed regarding its geo-
metric fidelity (section 4.3). Preparatory to the motion analysis, relaxometry was performed
(section 4.4.2) to assess the relaxation properties of the phantom’s moving cylinder and
the included target, for contrast optimization of the pulse sequences used for motion ana-
lysis. Finally, a method for automatic quantification of multi-dimensional target motion is
presented in section 4.4 for the analysis of the MR scanner’s accuracy in motion tracking.
Both the distortion analysis as well as the motion tracking analysis are in principle applica-
ble to other 4D-MRI motion phantoms and allow for repeated QA.
The results of this study have in part been published by Schneider et al. (2019a), in the
report by Engler (2017) and in the bachelor thesis by Engler (2018).
4.1 MR-Linac motion phantom
The 4D-MRI motion phantom (MRI-LINAC Dynamic Phantom, Computerized Imaging Ref-
erence Systems Inc., Norfolk, USA) (CIRS, 2014), shown in Figure 4.1, consists of a body
shell approximating a human torso in size and shape (25.5 × 29.5 × 20 cm³). The body shell
needs to be filled with an MR signal generating fluid by the user. In this study 7.6 L of mineral
oil were used (Marcol Blend 3 T, Philips Healthcare, Eindhoven, The Netherlands), result-
ing in a total phantom mass of 12.8 kg. The phantom includes a 3D distortion grid for the
assessment of geometric accuracy as well as a central fiducial aligned with exterior laser
Figure 4.1: Schematic setup of the CIRS MRI-LINAC Dynamic Phantom - Model 008M (CIRS,
2014) comprising an actuator (left), modular extension shafts (middle), and movable cylinder with
simulated target inserted into a torso-shaped body (right). (Image courtesy: CIRS, Computerized
Imaging Reference Systems Inc., Norfolk, USA)
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marks on the outer shell surface to facilitate a laser-to-isocenter coincidence analysis. A
cylindrical thru-hole is incorporated in the phantom body to accommodate a cylinder with a
decentralized hyper-intense target to perform rotational and translational movements. The
3D target motion, resulting from the combination of rotation and translation, is software-
controlled by an MR-conditional actuator, positioned at a distance of up to 2.655 m from
the phantom and connected with modular extendable rigid shafts. The target can optionally
host MR-compatible dosimeters for verification of the dose applied by an MR-Linac device.
4.2 Positioning setup for 3.0 T MR scanner modified for RT
compatibility
Setup design
The phantom was commissioned on a 3 T MRI scanner (Philips Ingenuity TF PET/MR
scanner, Philips Healthcare, Eindhoven, The Netherlands) using a 32-channel SENSE
Torso/Cardiac coil. The posterior coil was positioned underneath a glass-fiber flat tabletop
overlay in a coil holder (Medibord Ltd, Nottingham, UK), which enabled a stable positioning
of the phantom on the patient couch. Likewise, the anterior coil was positioned on a coil
bridge. The combination of coil holder and coil bridge facilitated a reproducible positioning
of the receiver coils relative to the phantom. In case of a patient scan this setup prevents
Figure 4.2: Left: setup of 4D-MRI phantom on flat tabletop overlay positioned on the patient couch.
Top right: close-up view of phantom positioned on base plate. Bottom right: close-up view of actuator
positioned on base plate for couch extension
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body deformations due to pressure of the coil, simulating the conditions during RT dose
delivery.
The maximum distance of 2.655 m between the actuator and magnetic isocenter of the
MRI scanner bore, as advised by the phantom manufacturer, could not be realized on
the patient couch, which only allowed for a maximum distance of 1.65 m relative to the
magnetic isocenter. This provided a safety margin of only 15 cm to the 0.2 T field isoline
of the MRI scanner, which was stated to be the minimum distance for safe operation by
the phantom manufacturer. Hence, a fixation base plate for the actuator made of polyvinyl
chloride (PVC) and polyurethane (PU) was constructed to both extend the couch by 30 cm
as well as to mechanically fix the actuator to the couch in order to avoid any projectile
hazard in case the 0.2 T field contour is exceeded by a user-related positioning error. Due
to the extended positioning of the actuator on the fixation base plate, the phantom body was
initially not in-line with the height of the actuator. Hence, new feet made out of polymethyl
methacrylate (PMMA) were designed for the phantom to lift it by 17 mm to the necessary
height. Incorporating the custom made feed, a positioning base plate made out of PMMA
was constructed to allow fast and accurate positioning of the phantom body onto the patient
couch (Figure 4.2). The positioning system was constructed with manufacturing tolerances
of < 1 mm.
Positional reproducibility
Positional reproducibility was evaluated based on the distance of the central fiducial in
the phantom relative to the magnetic isocenter. For such an analysis, the central fiducial
is aligned with laser marks on the surface of the phantom shell. The MRI pulse sequence
used for evaluation of reproducibility was a 3D GRE sequence with an isotropic voxel size of
1.5 mm and a bandwidth of 721 Hz/pixel (details of the pulse sequence can be found in the
supplementary Table B.5). The same sequence was later on used for the distortion analysis.
The position of the central fiducial (shown in Figure 4.3) was determined in 3D based on
its center-of-mass, which was analyzed using the open source software ImageJ (ImageJ
1.41n, National Institute of Health, Bethesda, Maryland, USA). Since the central fiducial is
hypointense in MRI, the images were first inverted and then threshold segmented with a
threshold set 3σ higher than the background signal of the mineral oil. Within a time frame
of eight months, eight measurements were performed to increase statistical significance.
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Figure 4.3: (a) Transverse and (b) coronal view of CIRS motion phantom with the central fiducial
used for assessment of positional reproducibility marked with red arrow. (c) Distance of central
fiducial to magnetic iso-center plotted as boxplot for three directions left-right (LR), inferior-superior
(IS) and anterior-posterior (AP). ∗The distance in AP was corrected for an offset of 77.7 mm.
The results can be found in Figure 4.3 (c), where the distance of the central fiducial to the
magnetic isocenter is plotted as boxplot for three directions left-right (LR), inferior-superior
(IS) and anterior-posterior (AP). The distance in AP includes an offset of 77.7 mm which
was corrected for better illustration. The maximum deviation found were 0.4 mm, 2.4 mm
and 0.2 mm in LR, IS and AP, respectively.
Discussion
Before routine usage of the phantom on the 3.0 T MRI scanner, several setup challenges
had to be overcome. The flat tabletop overlay, which enables to scan patients in radiation
treatment position on the scanner’s default concave shaped patient couch, allowed the
usage of a coil holder to position a posterior torso/cardiac coil underneath the tabletop
overlay. The coil holder setup ensures a stable positioning of the phantom directly on the
flat tabletop.
Furthermore, reproducible positioning of the phantom body based on the laser marks
showed to be laborious due to the large mass (12.8 kg) of the filled phantom. Therefore,
an easily mountable base plate for the phantom was constructed to facilitate a fast and
reproducible positioning without affecting MR image quality. While positional reproducibility
49
4 Geometric fidelity and accuracy of phantom target tracking with MRI
was analyzed for three directions, only the measurement in LR direction is truly assess-
ing the reproducibility of the positioning plate, which was measured to be 0.4 mm. This is
due to the fact that, firstly, the positioning in AP direction is purely affected by the patient
couch. The height of the patient couch is not adjustable with the used scanner and hence
showed the smallest deviation of maximum 0.2 mm. Secondly, the positioning in IS direction
is mainly limited by the laser alignment, combining both user error as well as inaccuracy of
the patient couch mechanics. This increased the deviation in IS direction to 2.4 mm.
MRI acquisitions with and without the actuator showed no noticeable effect on the image
quality when positioning the actuator close to the 0.2 T field contour, stated as the mini-
mum distance for safe operations by the phantom manufacturer. However, at this position
magnetic forces acting on the partially ferromagnetic actuator had to be considered. The
limited length of the MR scanner’s patient couch allowed a positioning of the actuator with
a distance of maximum 1.65 m to the magnetic isocenter, i.e. at a safety margin of only
15 cm to the 0.2 T field iso-line. An in-house developed fixation base plate increased the
safety margin by 30 cm and fixed the actuator on the couch to avoid any projectile haz-
ard in case of accidental mis-positioning of the phantom by the user. However, due to the
thereby elevated position of the actuator, the phantom feed had to be redesigned to stay
aligned with the actuator which lifted the phantom by an additional 17 mm. In combination
with the distance due to the flat tabletop overlay, this led to a distance of the posterior
coil to the phantom of ∼ 4 cm. Albeit a consequential reduction of the signal to noise level,
image quality was sufficient to proceed with the QA assessment of clinically used pulse
sequences.
4.3 Image distortion analysis
Methods
A computed tomography (CT) scan of the phantom was acquired (Somatom Definition AS,
Siemens Healthineers, Erlangen, Germany) as the ground truth for assessment of the 3D
geometric distortion in MRI. A 3D GRE pulse sequence (THRIVE) was used which is typi-
cally acquired for abdominal patients in our clinic. The MR images were acquired in trans-
verse orientation with phase encoding in anterior-posterior direction. The scan parameters
used for CT and MR imaging of the 3D grid are summarized in the supplementary Table
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Figure 4.4: (a) Transverse MR image (3D T1 GRE) and (b) CT image of the 3D distortion grid. (c)
The threshold segmented grid structure (yellow) of the CT scan was rigidly registered with the MR
scan based on the grid point closest to the magnetic isocenter (blue target).
B.5.
Since the used 3.0 T MR scanner only allowed for a laser alignment along the longitudinal
axis, the phantom was positioned differently along the sagittal axis relative to the isocenter
of the CT and MR scanner, respectively. Furthermore, since the custom-made positioning
setup could only be applied on the flat tabletop of the MR scanner, positioning errors (both
in translational and rotational direction) were likely introduced during the CT scan. In order
to analyze the 3D image distortion in the MR images, first these positioning differences
were corrected by rigid image registration. Image distortion in MRI was then determined by
non-rigid image registration. Registration was performed using the open source software
elastix (Klein et al., 2009; Shamonin et al., 2014).
Results
Figure 4.4 shows a transverse MR image (3D T1 GRE sequence), a reference CT image
of the 3D distortion grid at the same slice position and the rigid registration of both af-
ter threshold segmentation (threshold = 155 HU) of the grid in the CT scan. The magnetic
isocenter in the MR images is marked with a blue target symbol, which was due to the
flat tabletop overlay and the elevating phantom feet positioned at the posterior end of the
phantom. In Figure 4.5, the in-plane geometric distortion is shown for four transverse slices
of the grid. As expected, the MR images showed an increasing 3D distortion with increas-
ing distance to the magnetic isocenter with a maximum distortion of ∆max = 1.31 mm at a
distance of 160 mm, as plotted in Figure 4.6. The mean absolute 3D Euclidean distance
between the grid points on MR and CT images measured over the whole grid volume was
∆mean = 0.58 mm ± 0.30 mm. In Figure 4.7 the 2D components of the geometrical distor-
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Figure 4.5: Left: coronal MR image of the phantom with four transverse slices (color coded) at
longitudinal distances to the central fiducial of z= [+30, +10, -10, -30] mm used for the geometric
distortion analysis. Right: measured in-plane geometric distortion between transverse CT and MR
images. Arrows were elongated by 10× for better visibility.
tion is shown separately for all three orthogonal planes, where the distortion in the coronal
plane is shown to be the smallest with a mean 2D distortion of δ= 0.35 mm.
Discussion
In Fatemi-Ardekani et al. (2015) an analysis of the 3D grid distortion on an identical MR
scanner by means of different MR sequences (2D T1w FFE, 2D T1w TSE and 3D T1w TFE)
has shown similar maximum deviations of 1.0 mm, 0.7 mm and 1.8 mm, respectively. In the
referenced study, however, distortion was considered only separately in lateral, anterior-
posterior and cranio-caudal direction. In contrast, in the present study the 3D image dis-
tortion was analyzed over an elliptic cylindrical volume of 15 × 23 × 6 cm³ using a 3D GRE
(THRIVE) sequence. With a maximum 3D distortion of < 1.31 mm this sequence fulfills
the criteria for stereotactic radiotherapy of targets with a diameter > 25 mm (Pappas et al.,
2017). It is, however, important to note that the investigated geometric distortion mainly
arises from system related sources due to imperfections in the homogeneity of the scan-
ner’s static magnetic field and non-linearities in the gradient magnetic fields. Patient related
sources due to magnetic susceptibility differences or chemical shift artefacts were not in-
cluded in the analysis. Furthermore, the geometric distortion was only analyzed for one
clinically relevant sequence having a fixed receiver bandwidth of 721 Hz/pixel. Since ge-
ometric distortion inversely correlates with bandwidth, the distortion analysis should be
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Figure 4.6: 3D geometric deformation ∆, measured by non-rigid registration of the 3D GRE MR
image onto the reference CT images.
repeated when other sequences are used.
The phantom’s 3D grid covers a range of 6 cm in IS direction, which is sufficient for
covering the maximum possible target motion of this phantom. The 3D grid is however not
an adequate replacement of a large field homogeneity phantom in order to fully describe
the magnetic field homogeneity. For this purpose, different 2D/3D grid-based MR phantoms
like the ACR phantom (Chen et al., 2005) or large FOV field homogeneity phantoms (Wang
et al., 2004; Baldwin et al., 2007) are available and have proven to be suitable for analysis
of geometric distortions.
4.4 Target tracking accuracy
4.4.1 Static displacement in CT
In order to verify the accuracy of the target motion performed by the phantom, CT scans
were acquired at different pre-set target positions. The static target displacement was set to
the maximum motion amplitude used for this study, with ± 20 mm in IS, ± 5 mm in AP and
± 5 mm in LR direction, respectively. The maximum amplitude was limited by the phantom
design to be ± 25 mm / ± 5 mm / ± 5 mm in IS / AP / LR direction, respectively. However the
largest amplitude of ± 25 mm in IS direction could not be achieved with desired frequencies
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Figure 4.7: Three components of 2D (in-plane) geometric deformation δ of the 3D GRE MR image
in transverse, sagittal and coronal orientation, respectively.
of 0.2 Hz, which led to the maximum ± 20 mm used in this work. The pre-set values were
then compared to the displacement of the target’s center-of-mass found in the CT scan,
which where analyzed with the open source software ImageJ. The CT scan parameters are
listed in the supplementary Table B.7.
An exemplary transverse and coronal slice of the CT scan of the phantom is shown in
Figure 4.8, where the static 3D target displacement is visible for maximum and minimum
target positions. The pre-set and the measured displacement are summarized in Table 4.1.
While in IS direction no deviation from the pre-set displacement could be measured, the
target showed a smaller displacement in AP/LR direction than defined in the controlling
software, likely due to a small mis-placement of the target relative to the center of the
movable cylinder. Consequently, this intrinsic error has to be considered in the assessment
of target tracking accuracy with MRI.
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Figure 4.8: Transverse (top) and reconstructed coronal (bottom) CT image of the phantom for
maximum exhale and inhale target positions: -20/-5/-5 mm in IS/AP/LR (left) and +20/+5/+5 mm
in IS/AP/LR (right) .
Table 4.1: Comparison of pre-set target displacement to CT measurement between two different
target positions.
Direction of displacement Pre-set displacement / mm Measured displacement / mm
IS 40.0 40.0
AP 10.0 9.6
LR 10.0 8.9
4.4.2 Relaxometry for MRI sequence optimization
For balanced steady-state free precession (bSSFP) pulse sequences, as used in our clinic
for MRI based motion analysis, the signal intensity is given by
MSS = ρ(H)
√
E2 · (1 − E1) · sinα
1 − (E1 − E2) · cosα − E1 · E2
, (4.1)
with E1,2 = eTR/T1,2 and ρ(H) is the proton density. Under the assumption that TR ≪ T1 and
TR ≪ T2, which is typically the case for TR ≈ 3 ms, as used for cine acquisitions, equation
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Figure 4.9: T1-(top left) and T2 (bottom left) relaxation times at 3T clearly show the decentralized
target in the top right of the movable cylinder. (right) Signal of the target and background cylinder
of the motion phantom as a function of flip angle in bTFE sequences, as used for motion depicting
cine MRI sequences.
4.1 can be simplified to
MSS = ρ(H)
sinα
1 + cosα + (1 − cosα) · (T1/T2)
. (4.2)
The contrast between two structures can therefore be modified based on the flip angle
(Scheffler and Lehnhardt, 2003), if their relaxation properties are known.
Hence, MR relaxometry of the movable target and its background gel was performed, as
described in section 2.3.2. For T1 determination an inversion recovery spin-echo (IR SE)
method with six different inversion times was acquired. A T1-map was then calculated by
fitting the complex data to a five-parameter model (Barral et al., 2010). A T2-map was cal-
culated based on a gradient-and-spin-echo (GraSE) sequence (Fernández-Jiménez et al.,
2015) sampled at nine echo times by fitting the magnitude data to a mono-exponential func-
tion. To minimize the influence of B1 inhomogeneities found in multi-echo SE sequences,
a correction was performed by discarding the first echo signal (Lebel and Wilman, 2010;
Milford et al., 2015). The scan parameters used for MR relaxometry are summarized in the
supplementary Table B.6.
Relaxometry yielded the quantitative T1- and T2-maps shown in Figure 4.9, from which
it can be appreciated that the target and background gel in the movable cylinder show a
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different relaxation behavior at 3 T. In Table 4.4.2 the measured relaxation behavior of target
and background gel of the cylinder are shown. Based on the found relaxation properties
of the cylinder, the flip angle for the theoretically optimum contrast in bSSFP sequences
was found to be α= 47.8°, as can be appreciated from the function of contrast in Figure
4.9. For bSSFP sequences this relatively large flip angle increased the acquisition time
to an unacceptable level. Hence, the flip angle was finally reduced to 30°, to achieve a
satisfactory temporal resolution of > 2 Hz.
Table 4.2: Measured (mean ± standard deviation) T1 and T2 relaxation times at 3.0 T of the target
and background gel in the movable cylinder as determined by MR relaxometry.
Phantom target Cylinder background
T1 / ms 208.1 ± 2.8 871 ± 36
T2 / ms 30.5 ± 0.7 13.4 ± 1.3
4.4.3 Phantom target motion in MRI
Methods
A bSSFP sequence was used for the evaluation of 1D- and 2D-motion trajectories in single-
slice coronal and transverse 2D-cine MRI. For the analysis of 3D-motion trajectories, an or-
thogonal 2D-cine MRI scan was acquired interleaved in transverse and sagittal orientation.
Additionally, based on the method by Von Siebenthal et al. (2007), a 4D-MRI dataset was
reconstructed for 3D motion assessment using MATLAB (MATLAB R2016a, The Mathworks
Inc., Natick, USA) by retrospectively binning a multi-slice 2D-cine MRI acquisition with no
slice gap combining classical phase and amplitude binning methods. The continuously ac-
quired 2D images of a 3D volume with 40 dynamics were resorted into a maximum inhale
and exhale phase as well as three phases in between with directional dependency, which
were sorted based on the trajectories amplitude, to obtain eight trajectory phases in total. In
order to be less affected by the binning algorithm performance the phantom’s set trajectory
was used as surrogate of a respiratory curve instead of a 1D MR navigator or image nav-
igator. Moreover, a 1D MR navigator signal following the target could not be successfully
extracted from the scanner. An examplary image of the phantom in two respiratory states
depicted by 4D-MRI can be seen in Figure 4.10. All cine MR images were acquired with a
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Figure 4.10: CIRS phantom performing sinussoidal 3D target motion with amplitudes of ± 7.5/5/2.5
mm in IS/AP/LR direction was scanned by means of retrospectively resorted 4D-MRI with 8 respi-
ratory phases. The maximum exhale(top) and maximum inhale (bottom) positions are shown in all
three orthogonal planes (from left to right: coronal, transverse, sagittal). The coronal and sagittal
images were reconstructed from the volumetric dataset that was acquried in transverse orientation.
temporal resolution of > 2 Hz.
Sinusoidal 1D-, 2D- and 3D-motion trajectories were programmed in the graphical user
interface of the phantom’s control software. In addition, a realistic motion pattern was im-
ported from a 1D MR navigator scan of a healthy volunteer with a mean frequency of
0.17 Hz and motion amplitudes < 20 mm. The pre-set frequencies (0.1 Hz – 0.2 Hz) and am-
plitudes (maximum ± 20 mm in IS, ± 5 mm in AP and ± 5 mm in LR direction) were based
on breathing patterns observed in patients (Keall et al., 2006). All set motion trajectories
can be found in the supplementary Table B.8. For motion analysis the phantom target was
aligned longitudinally to be in plane with the magnetic isocenter.
The motion analysis was performed using an in-house developed automated tracking
algorithm based on functions provided by the Image Processing Toolbox of MATLAB (MAT-
LAB R2016a, The Mathworks Inc., Natick, USA). The 2D-cine MR images were first pre-
processed by applying a Gaussian filter to reduce the influence of noise and artifacts.
Objects with connected structures were identified by threshold detection. From these ob-
jects, the target was identified based on its known geometric properties. Subsequently, the
center-of-mass of the target was determined as a surrogate for its position at each time
step. The measured positions were fit with a sinusoidal function by minimizing squared er-
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Figure 4.11: Left: programmed and measured 3D sinusoidal target motion patterns using pre-set
amplitudes of ± 7.5/5/2.5 mm in IS/AP/LR direction. Right: 1D navigator-based volunteer breathing
pattern with pre-set and measured target positions.
rors using the simplex search method (Lagarias et al., 1998), from which the amplitude and
frequency were estimated. For analysis of the 3D motion in the reconstructed 4D-MRI, the
target was manually segmented in each trajectory phase over the whole volume to deter-
mine the center-of-mass in every state of motion. The maximum displacement was then
determined as the distance of the target’s center-of-mass between the reconstructed max-
imum inhale and exhale state. The MR scan parameters are listed in supplementary Table
B.7.
Results
The motion trajectories programmed in the target motion control software and the motion
patterns measured from 2D-cine and reconstructed 4D-MRI are listed in Table B.8. An
exemplary sinusoidal 3D target trajectory and real volunteer navigator data is shown in Fig-
ure 4.11 with the respective measured target position overlayed. For the sinusoidal motion
patterns, the estimated frequencies agreed within 0.5 % to the pre-set frequencies. When
considering the intrinsic error in AP/LR direction found in section 4.4.1, the measured am-
plitudes showed a mean deviation < 0.2 mm in all three directions. For the 1D navigator
motion pattern extracted from a volunteers breathing pattern, the estimated motion pa-
rameters showed a maximum deviation in amplitude of 1.0 mm and a mean deviation of
0.3 mm in IS direction (Figure 4.11). The motion amplitudes extracted from the transversely
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acquired retrospectively binned 4D-MRI showed a deviation of < 0.3 mm in all directions.
Due to the rotation of the target cylinder to induce motion in the transverse plane (AP/LR)
it is obvious that it is not possible to set a pure 1D motion in AP/LR direction. Therefore,
when a sole AP motion was set an additional displacement of 0.4 mm in LR direction was
measured, whereas a pure LR motion trajectory resulted in an additional displacement of
0.5 mm in AP direction. This deviation from a set zero motion was hence treated separately
and was not included in the measured deviation listed above.
Discussion
MR relaxometry was performed to facilitate sequence optimization, i.e. adaption of the flip
angle for contrast enhancement of the target. However, since for motion depicting MR se-
quences the temporal resolution is one of the most critical sequence parameters, the flip
angle was finally adjusted to achieve a sufficiently short temporal resolution of ≈ 2 Hz. For
different magnetic field strengths than 3T the image quality would need to be reassessed
and MR sequence parameters may need to be adjusted based on the T1/T2 values of the
target and the background material to obtain high contrast images. The relaxation param-
eters should also be considered for an elaborated choice of signal generating medium for
the phantom body.
The reference CT measurement of the extreme target displacement revealed a good
agreement with the pre-set parameters, however not within the accuracy of < 0.1 mm as
stated by the vendor. While in IS direction no measurable deviation from the set ampli-
tude was found, in AP/LR direction the target displacement was 0.2 mm and 0.5 mm, re-
spectively. This deviation has to be considered when analyzing the accuracy of MR based
motion tracking sequences.
The measured motion parameters found by single slice 2D-cine MRI as well as orthog-
onal 2D-cine MRI agreed well with the pre-set values. The measured deviations in IS di-
rection were < 0.2 mm, and in consideration of the intrinsic error found in section 4.4.1 the
same deviation of < 0.2 mm were found in AP/LR direction. The 3D motion analysis based
on the retrospectively resorted 4D-MRI sequence also agreed well with the set trajectory
but with slightly higher deviations in IS direction of 0.3 mm. In this sequence a larger de-
viation in IS direction was expected, since slice orientation was transverse and therefore
resolution in IS direction was the lowest (5 mm). Considering the relatively low resolution in
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IS direction given by the slice thickness, the found deviation in IS direction is still remarkably
small. MR motion analysis measurements with different MR motion phantoms have shown
similar results with motion amplitude errors of 0.1 mm – 0.4 mm (Lagendijk et al., 2008) and
have reported on good agreement between measured and reference positions (Soliman
et al., 2016).
With respect to motion extraction in MRgRT, the 4D-MR phantom used in this study
shows some limitations. Firstly, the phantom motion is purely rigid, which is usually not
the case for moving tumors or organs at risk. Secondly, for patient cases, image artifacts
caused by different magnetic susceptibility may occur, leading to additional magnetic field
distortions of the resulting MR images (Czervionke et al., 1988). Future studies should
take these effects into account by combination of measurements with both rigid phantoms
having highly reproducible motion behaviors and dynamic non-rigid anthropomorphic phan-
toms (Ehrbar et al., 2016; Mann et al., 2017).
4.5 Summary
A 4D-MRI dynamic phantom was successfully commissioned on a diagnostic 3.0 T MRI
scanner used for MR simulation in RT. A fixation and positioning aid was designed and
constructed to overcome several compatibility issues that appeared when using the MRI-
Linac motion phantom on this MR scanner. The setup facilitates repeated QA, for which it
allows for a highly reproducible phantom positioning.
For a fast analysis of geometric fidelity within a QA procedure, a method for automatic
distortion analysis was developed based on a previously acquired reference CT scan. The
analysis of a clinically used 3D GRE sequence showed that it fulfills the criteria for stereo-
tactic radiotherapy of targets with a diameter of > 25 mm with a measured maximum 3D
distortion of 1.3 mm.
Furthermore, the accuracy of the 3.0 T MR scanner in tracking of motion was assessed
based on single-slice 2D-cine, orthogonal 2D-cine and retrospectively resorted 4D-MRI.
High-contrast and geometrically reliable 2D-cine MR images of the phantom’s moving tar-
get could be obtained. The accuracy of the used sequences was found to be < 0.2 mm in
single-slice and orthogonal 2D-cine acquisitions, and < 0.3 mm in 4D-MRI when the found
intrinsic error of the target motion in AP/LR direction is considered. The high accuracy found
61
4 Geometric fidelity and accuracy of phantom target tracking with MRI
in the phantom measurements gave us confidence in using these sequences for organ mo-
tion assessment in patients. For the analysis of continuously acquired cine acquisitions a
Matlab based tool was developed for automatic quantification of multi-dimensional target
motion. The two developed tools can be used for automatic evaluation in repeating QA of
spatio-temporally resolved MR sequences used for MRgRT.
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an abdominal corset
Appropriate immobilization of the target volume is a key component in the treatment pro-
cess for precise dose delivery. This is of particular importance for PT due to its relative
to XT higher sensitivity to density variations caused by inter- and intrafraction changes in
patient anatomy. Morphological changes along the beam path due to organ motion, defor-
mation and filling can influence the position of the Bragg peak relative to the target volume.
Furthermore, the use of active dose delivery techniques that employ scanned beams to
volumetrically scan a mono-energetic Bragg peak over the target volume in combination
with intrafraction organ motion may further degrade the precision of dose delivery due to
the interplay effect (Phillips et al., 1992; Bert et al., 2008a). This may result in over- or
underdosage of the target volume and unwanted dose deposition in adjacent organs at
risk.
For thoracic and abdominal organs, the main source of intrafraction motion is respiration.
To reduce respiration-induced uncertainties in PT, breathing motion can be accounted for
by 4D treatment planning and optimizations (Bert and Durante, 2011; Graeff, 2014; Dolde
et al., 2018a), rescanning (Knopf et al., 2011), tumor tracking (Bert et al., 2008b) or gat-
ing (Mori et al., 2009). However, their individual application has shown to not completely
mitigate motion effects (Kraus et al., 2011; Zhang et al., 2018) and particularly when no
active tumor motion control options are available, physically reducing respiratory induced
motion by abdominal compression techniques (Fontana et al., 2016; Heerkens et al., 2017;
Dolde et al., 2018b) becomes critical in order to prevent extensive margin expansion of the
planning target volume.
For PT of targets in the upper gastro-intestinal tract, motion mitigation by means of ab-
dominal compression bands or pressure plates can exacerbate the range uncertainties
when the devices extend into the treatment fields due to a limited setup reproducibility and
consequential edge effects (Wroe et al., 2014). In particular, pressure plates incorporated
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in a frame system for reproducibility only allow for limited usability in MR guided PT due to
their bulky setup. Since in PT the proton beam nozzle should be positioned close to the pa-
tient’s surface in order to reduce lateral beam spread in air (Newhauser and Zhang, 2015),
the risk of a collision of the immobilization device with the nozzle arises by using such
frame based pressure plates. Moreover, compression bands are known to be the source
of a high level of patient discomfort (Mampuya et al., 2014; Van Gelder et al., 2018) which
can increase the tumor motion variability (Bissonnette et al., 2009).
As a solution to reduce respiratory induced tumor motion in patients with pancreatic can-
cer, polyurethane-based customized abdominal corsets have recently been used in stereo-
tactic XT (Heerkens et al., 2017). Moreover, studies using MRI in orthogonal 2D-cine or 4D
mode have shown the ability of abdominal corsets to reduce pancreatic motion mainly in
inferior-superior direction (Fontana et al., 2016; Heerkens et al., 2017; Dolde et al., 2019b).
However, corsets used in XT may not be applicable for PT, since for the latter a high re-
producibility of the setup for immobilization devices placed in the beam path is critical and
higher standards of material properties (i.e. thickness and homogeneity) have to be met
in order to be able to correctly calculate the beam penumbra and range in the patient.
Therefore, in this work three types of abdominal corsets that differ in terms of material
composition, size, and degree of patient customization were compared regarding their suit-
ability for PT. In PT, the water equivalent ratio (WER) of any material placed in the beam
path needs to be known precisely to ensure that the treatment planning system is able to
accurately take the materials effect on beam penumbra and range into account. Hence, in
section 5.1, the WER of the three tested corsets was determined and their material was
analyzed to assess the degree of material homogeneity and variance in thickness. Fur-
thermore, their effect on respiratory motion reduction was tested for one healthy volunteer
based on orthogonal 2D-cine MRI and 4D-MRI.
With one corset, which was considered to be suitable for PT, a patient study was con-
ducted. In this study, for patients with an abdominal tumor (pancreas, liver, gallbladder)
scheduled for PT, an individual corset was constructed before the treatment planning was
performed. In section 5.2 the implementation of the corset in the PT workflow and treat-
ment planning is presented. The design of the corset considers several challenges which
the clinical implementation brought to light (section 5.2.1). The effect of the corset on the
respiratory pancreas motion was analyzed based on orthogonal 2D-cine and 4D-MRI (sec-
tion 5.2.2). Finally, the patient’s acceptance toward the corset was evaluated (section 5.2.3).
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The results of this work have in part been published by Dolde et al. (2019). The measure-
ments and analysis for the determination of the WER values of the corsets were performed
with the friendly support of Nils Peters.
5.1 Comparison of three different abdominal corsets for use in
particle therapy
In this study, three different abdominal corsets were investigated: a foam-based polyurethane
corset (PU), a polyethylene corset (PE) and a 3D-scan based polyethylene corset (3DPE).
All three corsets applied onto the healthy volunteer in this study, are shown in Figure 5.1.
Polyurethane corset (PU)
The patient-individualized PU corset (OKMSystem®, OKM Química Ortopédica, Girona,
Spain) is a custom-made (Orthopädie und Rehatechnik Dresden GmbH, Dresden, Ger-
many) solid foam-based corset enclosed in a cotton fabric, which is molded in soft condition
directly around the lumbar spine, where it hardens within 20 min after mixing its initial liquid
components isocyanate and polyol. The corset is fastened using hook-and-pile fasteners,
which were positioned ventrally, 5 cm left of the mid-sagittal plane. In inferior-superior di-
rection, the corset ranged from the ileum to the xiphoid process, compressing the stomach
and lower four ribs. Its manufacturing and solidifying require approximately 30 min in total.
This type of corset has been shown to reduce respiratory pancreas motion in the frame of
stereotactic XT (Heerkens et al., 2017).
Polyethylene corset (PE)
This Boston Overlap Brace (BOB)-hull orthoses (Basko Healthcare, Hamburg, Germany)
corset was fitted in cooperation with the Prosthetics and Orthotics Department of the Hei-
delberg University Hospital, Germany. It consists of a polyethylene (PE) prefabricated sym-
metrically formed module that enables individual adaptation based on size and gender.
Three different lordosis angles (0°/ 15°/ 30°) are available. The trim lines are adjusted to
the patient’s individual anatomy to avoid uncomfortable pressure to the greater trochanter
and the axilla. The corset is ventrally closed by four hook-and-pile fasteners, such that no
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Figure 5.1: Healthy subject with three different corsets, which were used in this study: (a) A patient-
specific polyurethane corset (PU), (b) a semi-specific polyethylene corset (PE) and (c) an optical
3D-scan based polyethylene corset (3DPE).
fastener material or buckles are present at the side and back of the subject. This type of
corset allows for an adequate stabilization of the lumbosacral spinal segments from the
sacral spine (S1) up to the thoracic spine (Th8). Corset adjustment lasts for approximately
30 min.
3D-scan based polyethylene corset (3DPE)
The patient-individualized 3DPE corset (Orthopädie- und Rehatechnik Dresden GmbH,
Dresden, Germany) is custom-made based on an optical 3D-surface scan (Artec Eva®,
Artec3D, Luxembourg, Luxemburg) of the patient. The 3D-surface scan is performed in
treatment position using a vacuum cushion (TapMed Medizintechnik Handels GmbH, Ha-
bichtswald, Germany) for modeling the dorsum from its imprint. The surface model is finally
replicated as a milled wooden model onto which a 5 mm PE plate (Streifylast®/Trolen) is
thermoformed in an industrial oven at 150°C. The individually shaped corset is finally ad-
justed and equipped with hook-and-pile fasteners, which were positioned on the anterior
and posterior left side of the corset, approximately 5 cm and 12 cm away from the mid-
sagittal plane, respectively. In inferior-superior direction, the corset ranged from the xiphoid
process to the ilium, compressing the stomach and the lower five ribs. The modeling and
manufacturing requires two outpatient clinic appointments of 20 min duration each and a
total manufacturing time of at least 3 days between the two appointments.
5.1.1 Homogeneity and thickness of the corsets
Material and methods
CT scans of all corsets were acquired (Somatom Definition AS, Siemens Healthineers,
Erlangen, Germany) to assess material homogeneity and regularity of thickness (pixel
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size = 0.8 mm², slice thickness = 2 mm, tube voltage = 140 kVp, tube current time product =
80 mAs). Material homogeneity was assessed based on the standard deviation of the mea-
sured CT numbers of the respective corset, measured at 10 different slice positions. Fur-
thermore, the size and distribution of air inclusions in the PU corset was analyzed due to
its heterogeneity. To quantify the size and number of air inclusions, the air inclusions were
automatically threshold-based delineated in the CT image and analyzed by means of a
connected-components analysis using MATLAB (MATLAB R2017b, The Mathworks Inc.,
Natick, USA) and analyzed thereby. The corset thickness was measured as the full width at
half maximum (FWHM) of the corset’s intensity profile at five different positions in five dif-
ferent slices in the CT images, using the open-source software ImageJ. Due to the varying
thickness of the PU corset, the maximum and minimum thickness were stated instead of
a mean thickness value. The thickness was measured in treatment-relevant regions of the
corset around the longitudinal center and at beam angles between 140°– 270°. The angles
were chosen based on the fact that pancreatic cancer patients are typically treated with two
or three posterior oblique beams at our PT facilities in Dresden and Heidelberg.
Results
All measured material properties are listed in Table 5.1. The acquired CT images confirmed
a homogeneous material in the PE / 3DPE corsets with CT values of - 130 HU ± 31 HU
/ - 107 HU ± 32 HU and no visible hyper- or hypointense structures. Moreover, a constant
thickness of 2.8 mm ± 0.2 mm / 3.8 mm ± 0.2 mm was found for the PE and 3DPE corset, re-
spectively. The PU corset material was inhomogeneously comprising air inclusions through-
out the whole corset with sizes of up to 7.6 mm in diameter and a mean volume of 12.9 mm³
(range 1.2 mm³ – 263.7 mm³). 95 % of the air inclusions were smaller than 50 mm³, and 5 %
had larger volumes of up to 263.7 mm³ (see Fig. 5.2). Moreover, smaller hyperintensities
were observed in the CT images. The HU density of these small hyperintense volumes
did not correspond to components in the list of materials received from the manufacturer
and the origin of these hyperintensities was not identified. For the PU corset, the average
CT value was - 677 HU ± 113 HU with values from - 1024 HU (air inclusions) to + 990 HU
(hyperintensities). Furthermore, its thickness varied between 4.2 mm – 27.7 mm.
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Figure 5.2: In the CT-Scan of the PU-Corset, air inclusions with different sizes are visible as shown
in three exemplary slices (a) and with superimposed threshold-segmented volumes in green (b).
The distribution of the air inclusions (c) shows 95 % to have a volume of < 50 mm³ with maximum
volumes of up to 264 mm³.
5.1.2 Analysis of water equivalent ratios of the corsets
Material and methods
The WER is defined as the ratio of the mass thickness of water and the given material (in
g/cm²) that leads to the same beam energy loss (De Vera et al., 2013). WER measure-
ments were performed at the University Porotn Therapy Dresden with two different proton
energies (150 MeV, 200 MeV) using a multi-layer ionization chamber (Giraffe, IBA Dosime-
try, Schwarzenbruck, Germany) that measured the shift of the single Bragg peak along the
central beam axis after penetrating the respective corset samples. The corset samples,
approximately 10 × 10 cm² in size, were positioned directly in front of the entrance window
of the ionization chamber at a distance of 50 cm to the proton beam nozzle. Each sam-
ple was measured twice for both proton beam energies, respectively, with and without the
PMMA cover of the ionization chamber. This increased the number of data points for each
depth-dose curve, which was then fitted with a Bortfeld-fit (Bortfeld and Schlegel, 1996).
The proton range was determined by the depth of the 80 % dose level at the distal dose
fall-off of the Bragg peak (R80). The two samples of the PU (PU1 and PU2, respectively)
and PE corsets were cut out of an already manufactured corset, while the 3DPE sample
was provided from raw material prior to its thermoforming. The thickness of the samples
was measured with a caliper five times at three different spots around the center of the
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Figure 5.3: (a) Sample of the polyurethane corset (yellow arrow) positioned in front of the multi-
layer ionization chamber at a distance of 50 cm to the proton beam nozzle for measurement of
water equivalent ratio. (b) Depth dose curve of 150 MeV proton beam with PU corset sample in
beam path and without sample as reference.
respective sample. The center of the sample was aligned with the proton beam axis.
Results
The setup for measuring the WER of the corset samples as well as an exemplary data-
set showing the shifted Bragg peak for the PU sample is illustrated in Figure 5.3. Due to
the inconsistent thickness of the PU corset, two samples were analyzed which were cut
out from a region with the most constant thickness found in the corset. The average thick-
ness of the PE, 3DPE and the two PU samples used for the WER measurements was
2.53 mm ± 0.07 mm, 4.87 mm ± 0.03 mm and 11.42 mm ± 0.34 mm / 10.10 mm ± 0.29 mm,
respectively. The difference in thickness between the 3DPE corset and the 3DPE sample
of 1 mm resulted from the thermo-forming of the base material during the corset manufac-
turing process, which reduces the thickness of the base material. The WER of the PE and
the 3DPE corset averaged over the two used proton energies was almost water-equivalent
with 0.9556 ± 0.0001 and 0.9900 ± 0.0030, while for the PU corset the WER was substan-
tially smaller with 0.2980 ± 0.0010.
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Table 5.1: Material analysis of the three tested corsets. The measured thickness of corsets and
samples, material homogeneity as well as the average measured water equivalent ratio (WER)
for protons at energies of 150 MeV (a) and 200 MeV (b), respectively, are listed. Two samples of
the PU corset (PU1, PU2) were analyzed due to the heterogeneity of the corset. For the corset
thickness, sample thickness and material homogeneity, the indicated uncertainties represent the
standard deviation of the measured value from multiple measurements (N ≥ 15). The uncertainties
of the WER measurement resulted from the uncertainty of the underlying Bortfeld-Fit of the depth-
dose curve.
Corset Corset Sample Material WER
thickness / mm thickness / mm homogeneity / HU
PE 2.8 ± 0.2 2.53 ± 0.07 -130 ± 31 0.956 ± 0.002
(a)
0.956 ± 0.002(b)
3DPE 3.8 ± 0.2 4.87 ± 0.03 -107 ± 32 0.988 ± 0.002
(a)
0.993 ± 0.002(b)
PU1 4.2 – 27.7 11.42 ± 0.34 -677 ± 113 0.297 ± 0.002
(a)
0.297 ± 0.002(b)
PU2 4.2 – 27.7 10.10 ± 0.29 -677 ± 113 0.298 ± 0.002
(a)
0.298 ± 0.002(b)
5.1.3 Respiratory motion reduction
Material and methods
To quantify respiration-induced pancreatic motion, a healthy volunteer (male, age 29 years)
was scanned in treatment position with the arms positioned superior to the head (Wing-
STEP, Innovative Technologie Völp, Innsbruck, Austria) on a custom-made wooden flat-
table top overlay inside a 1.5 T MR scanner (Magnetom Aera, Siemens Healthineers) using
a combination of a 14-channel phased array spine coil, which was positioned inside the
patient couch, and an 18-channel phased array torso coil, which was placed directly on the
corset/volunteer.
The volunteer underwent respiratory phase-resolved volumetric 4D-MRI and fast orthog-
onal single-slice 2D-cine MR imaging in coronal and sagittal orientation while subsequently
wearing one of the three corsets and without corset for reference. The scans were per-
formed twice on two consecutive days to investigate reproducibility of the pancreatic motion
reduction. The 4D-MRI data hence provides information about the interfraction motion vari-
ability. No specific breathing instructions were given to the volunteer, aiming to acquire
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Figure 5.4: Orthogonal single-slice 2D cine (coronal and sagittal) (top) and 4D MRI (bottom) of
healthy volunteer in free breathing (left) and wearing the 3DPE corset (right) showing the state of
maximum expiration and inspiration. The pancreas is segmented and lines are added at the caudal
and cranial edge of the pancreas to visualize the amount of pancreatic motion.
free-breathing patterns. For the 4D-MRI measurements, a T1-weighted GRE sequence
with radial golden angle stack-of-stars sampling was used to acquire 3D images under
free breathing of the subject (field of view = 384 × 384 mm², pixel spacing = 1.5 × 1.5 mm²,
slice thickness = 3 mm, spokes per partition = 2100, bandwidth = 610 Hz/pixel, echo time
(TE) = 1.5 ms, repetition time (TR) = 3.3 ms, flip angle = 12°, acquisition time = 8 min, re-
constructed phases per respiration = 20). The raw data were reconstructed offline, using
a motion-compensated iterative reconstruction algorithm, based on a k-space-center self-
gating signal, which provides up to 20 overlapping breathing phases (Rank et al., 2016). On
each 4D-MRI data set, the pancreas was manually delineated on the end-inhale and end-
exhale images using the open-source software MITK (German Cancer Research Center,
Heidelberg, Germany). All contours were validated by an experienced radiation oncologist.
The center-of-mass of these delineations was determined to estimate the pancreatic motion
in IS, AP and LR directions.
To allow an analysis of pancreas motion during individual breathing cycles and thereby
assess the intrafraction motion variability, orthogonal single-slice 2D-cine MRI were ac-
quired using a TrueFISP sequence in coronal and sagittal orientation at a frame rate of
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approximately 4 Hz (field of view = 384 × 384 mm², pixel spacing 1.5 × 1.5 mm², slice thick-
ness = 4 mm, bandwidth = 1030 Hz/pixel, TE = 1.26 ms, TR = 222.3 ms, flip angle = 55°, ac-
quisition time = 50 s). The pancreas was manually segmented in the 2D images and tracked
by the position of its center-of-mass. The motion amplitude was determined as the aver-
age peak-to-peak motion amplitude between several inhale and exhale states, where the
upper and lower 2.5 % of the data were discarded (M95) to reduce the effect of outliers. For
each motion direction the standard deviation of the respective motion amplitude is given as
measure of intrafraction variability.
The 2D-cine MRI data was used to determine the real-time motion amplitudes in IS, LR
and AP direction of a selected area of the pancreas as well as the length of breathing
cycles, whereas the 4D-MRI data provides averaged information over several breathing
cycles in IS, LR and AP directions for the full pancreas volume. Exemplary images of 2D-
cine and 4D-MRI are shown in Figure 5.4 where the pancreas was segmented and lines
were added at the cranial and caudal edges for visualization of motion between maximum
inhale and maximum exhale states.
Results
Orthogonal 2D-cine MRI showed that all three corsets reduced pancreatic center-of-mass
motion mainly in IS direction. Without corset, the analysis of the 2D-cine MRI showed an
average pancreas motion in IS direction of 16.9 mm ± 1.7 mm (range 10.4 mm – 25.7 mm).
With the corsets, this motion was substantially reduced to an average of 7.5 mm ± 1.6 mm
(range 2.5 mm – 10.3 mm), 9.2 mm ± 2.6 mm (range 3.0 mm – 14.7 mm), and 8.7 mm ± 1.9
mm (range 2.9 mm – 15.0 mm) for the PU, PE and 3DPE corset, respectively. Hence, on
average, the respiratory induced motion amplitude in IS direction was reduced by 56 %,
46 % and 49 % with the PU, PE and 3DPE corset, respectively. Compared to the intrafrac-
tion motion variability in IS direction in free breathing (σ= 1.7 mm), motion variability was
similar for the PU (σ= 1.6 mm) and 3DPE (σ= 1.9 mm) corset and slightly increased for the
PE corset (σ= 2.6 mm). The motion amplitude in AP and LR direction in free breathing was
substantially smaller with 3.1 mm ± 0.8 mm in AP and 2.8 mm ± 1.1 mm in LR direction. By
application of the corset, the motion amplitude in these two directions was consequently
only slightly reduced to 2.1 mm ± 0.5 mm, 1.7 mm ± 0.6 mm and 1.1 mm ± 0.7 mm in AP
direction and 1.1 mm ± 0.7 mm, 2.1 mm ± 1.0 mm and 1.3 mm ± 0.7 mm for LR direction
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Figure 5.5: Pancreas motion amplitudes on two consecutive days extracted from coronal / sagittal
2D-cine MRI (4 images/s) of a volunteer wearing three different corsets and the reference measure-
ment without corset. Motion amplitudes are given as averaged peak-to-peak M95 amplitudes, where
the upper and lower 2.5 % of data was discarded to reduce the effect of outliers.
Abbreviations: 3DPE = three-dimensional-scanned polyethylene, PU = polyurethane, PE = polyethy-
lene.
Figure 5.6: Average center-of-mass motion of the pancreas in inferior–superior (IS), ante-
rior–posterior (AP) and left–right (LR) direction with the PU, PE and 3DPE corsets and without
corset extracted from 4D-MRI. The error bars represent the range of motion on the two consecutive
days on which the measurements were performed.
Abbreviations: 3DPE = three-dimensional-scanned polyethylene, PU = polyurethane, PE = polyethy-
lene.
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for the PU, PE and 3DPE corset, respectively. When wearing either of the corsets, the
breathing frequency increased, leading to a mean length of breathing cycles of 3.2 s ± 0.4 s,
3.3 s ± 0.6 s, and 4.6 s ± 1.1 s for the PU, PE and 3DPE corset, respectively, instead of
7.1 s ± 0.7 s without corset. The summarized results of the motion as measured in orthog-
onal 2D-cine MRI is shown in Figure 5.5.
4D-MRI was in accordance with the results found in 2D-cine MRI in that all three corsets
reduced pancreatic center-of-mass motion mainly in IS direction but also reduced motion
in AP direction substantially as well as increased the interfraction motion variability in these
two directions. IS motion was found to be on average 3.5 mm ± 1.5 mm, 4.8 mm ± 2.2 mm
and 2.6 mm ± 0.9 mm with the PU, PE and 3DPE corset, respectively, as opposed to 13.2
mm ± 2.9 mm without corset. In AP direction, the mean amplitude was reduced from
3.8 mm ± 1.6 mm without corset to 0.7 mm ± 0.3 mm, 0.6 mm ± 0.6 mm and 0.5 mm ± 0.2
mm with the PU, PE and 3DPE corset, respectively. In LR direction, mean amplitudes with-
out corset of 1.6 mm ± 0.3 mm were observed, which were decreased by the PU and 3DPE
corset to 0.1 mm ± 0.1 mm and 0.8 mm ± 0.1 mm and increased by the PE corset to 2.9 mm
± 0.2 mm. The detailed values are illustrated in Fig. 5.6.
5.1.4 Discussion
All three corsets evaluated in this study reduced respiratory induced pancreatic motion, in
particular in IS direction. Compared to the study by Heerkens et al. (2017), investigating
the pancreatic motion reduction for 10 patients by use of a PU corset based on orthogonal
single-slice 2D cine MRI and reporting a mean IS motion reduction of 4.1 mm (36 % reduc-
tion), in this study pancreatic motion reduction based on orthogonal 2D-cine MRI yielded
a reduction of 8.4 mm (50 % reduction) in IS direction by use of three different corsets in a
single healthy subject.
In this study, pancreatic motion reduction was also analyzed based on 4D-MRI, which
revealed a motion reduction of around 9.6 mm (73 % reduction) in IS direction. While 4D-
MRI is volumetrically more reliable than orthogonal 2D-cine MRI, since it includes the full
volume of the pancreas, it can be affected by the resorting algorithm. Furthermore, the
4D-MRI acquisition requires a longer acquisition time and hence includes more respira-
tory cycles. Lastly, since image quality in 4D-MRI is degraded relative to single-slice 2D
cine MRI, segmentation is more prone to errors and could distort the results. These funda-
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mental differences between the two image modalities could explain the difference in mean
pancreas motion found between orthogonal 2D-cine and 4D-MRI.
Additionally, a noticeable AP motion reduction of 3.2 mm (84 % reduction) was observed
in 4D-MRI, as well as 1.5 mm (47 % reduction) in 2D-cine MRI, whereas in the previ-
ous study by Heerkens et al. (2017) no motion reduction was observed. As reported by
other studies analyzing respiratory induced motion reduction by abdominal compression
(Fontana et al., 2016; Heerkens et al., 2017; Dolde et al., 2019b), such results are highly
patient-specific with a large inter-patient variability. Since only one healthy subject was in-
cluded in this study, the magnitude of motion reduction found should not be generalized but
understood in the context of a feasibility study.
Moreover, as opposed to the corset design presented in this study, covering the ribs and
abdomen in order to reduce both abdominal respiratory motion and chest breathing, the
corset used by Heerkens et al. (2017) left out the ribs to promote chest breathing. It is
therefore likely that these differences in corset design may contribute to the divergence in
observed motion reduction patterns. One has to note, that for free-breathing the volunteer
was scanned with the anterior coil positioned directly on his chest since no coil holder
setup was available for this scanner. This could have influenced the amount of respiratory
motion in the reference scan. On the other hand, care has been taken that the already light
weighted coil was not compressing the volunteers chest to minimize its affect on respiration.
While 2017 (2017) aimed for a utilization of the corset in stereotactic XT, the focus in this
study was on its applicability for PT, for which constant and reproducible corset thickness
and homogeneity are more critical than for XT. With regard to the material properties, both
the PE and the 3DPE corset showed potential to be used in PT since they have a constant
thickness and are made of a homogeneous material with WER values similar to adipose
tissue (Möhler et al., 2018). From a manufacturing point of view, the 3DPE corset is more
time-consuming and hence also more costly as a consequence of the additional necessary
working hours by a trained technical orthopedic staff. This, on the other hand, allows for
flexibility in the design and hence a positioning of corset opening and buckles that does
not collide with intended treatment beam directions, in order to avoid beam edge effects
where imperfect reproducibility of positioning leads to under- or over-shoot of the proton
beam. Although the treatment planning system will take the resulting range shifts into ac-
count and robust treatment planning can partially compensate for imperfect reproducibility
in positioning, shifts in patient position relative to the edges will impact the range of the
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traversing beam and should be avoided if possible. The design of the 3DPE corset con-
sidered that beam angles between 40°– 100° were a priori not intended for pencil beam
scanned PT planning since the presence of the stomach and the large intestine prevents
the usage of left lateral (oblique) beam angles for pancreatic patients in our institutes due
to the otherwise strong density changes the beam path (Batista et al., 2017; Stefanowicz
et al., 2018). Hence, the left lateral part was chosen as an opening. The PE corset, on the
other hand, shows partially overlapping material layers at the anterior side, where the four
hook-and-pile fasteners are placed (see Figure 5.1). Since for this corset the opening is
fixed by design, it compromises the use of anterior beams, since edge effects may occur
due to the fact that the beam will pass across edges of the corset layers or the closing
buckles. In order to minimize the impact of air gaps on beam penumbra, the corset should
closely match the patients’ skin surface. However, since no CT scan of the healthy volun-
teer wearing the corset could be acquired, the fitting accuracy of the corset to the body
surface could not be investigated.
The WER measurements show that both PE corsets with their WER of 0.956 – 0.991 as
well as the PU corset with a WER of 0.298 would have an impact on the range shifts in PT,
and hence need to be included in the treatment planning. The measured WER showed to be
constant for the two proton beam energies used, which is in good agreement with literature
(Palmans and Verhaegen, 1997; Akbari et al., 2014). The PU corset showed pronounced
wrinkles, air cavities and a variable thickness throughout the whole corset. In collabora-
tion with two experienced orthopedic technicians the manufacturing of the PU corset was
slightly varied with different volunteer positioning to thereby produce a corset with a more
constant thickness and reduce air inclusions. Since after three attempts no improvements
were observed, the idea of creating a homogeneous PU corset was discarded. Depend-
ing on the size of air cavity in the beam path, this heterogeneity could lead to range shifts
from 1.3 mm – 7.6 mm for varying corset thicknesses of 4.2 mm – 25.6 mm. For XT, these
drawbacks would have no detrimental effect on dose deposition, besides an increased skin
dose by the corset that needs to be considered (Heerkens et al., 2017). For XT purposes,
the use of the PU corset would hence allow for a patient-individualized solution, which has
low manufacturing costs and lead time. For PT, the air inclusions in the PU corset make it
unsuitable, since the resulting range shifts lead to increased range uncertainties (Paganetti,
2012).
The difference in measured thickness between the PE-based sample used for WER de-
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termination and the corsets themselves is partially influenced by the different measurement
procedures. While the thickness of the samples was measured 15 times around their center
with a caliper, it was determined as full width at half maximum (FWHM) values in the re-
spective CT scans for the corset at 15 different positions. Due to the pixel width of 0.8 mm
in the CT scans, the determination of the small corset thicknesses might be distorted.
Furthermore, the discrepancy of the measured thickness of the 3DPE corset and the sam-
ples used for WER measurements results from the thermoforming process underlying the
corsets manufacturing. This leads to a decreased thickness of the thermoformed corset
relative to its base material used as sample.
For fractionated radiation treatment of patients with pancreatic carcinoma, it is well-
known that intra-abdominal anatomy changes occur from day to day, depending on the
filling of the stomach and bowel (Van der Horst et al., 2013). Moreover, substantial weight
loss has been observed in these patients during the course of treatment (Naumann et al.,
2013). These factors compromise the setup reproducibility and may require the corset pres-
sure to be adjusted between treatment fractions in order to secure adequate immobilization.
This study has shown that pancreatic motion reduction obtained with patient-individualized
corsets is similar to that of the semi-specific corset. Therefore, semi-individualized corsets
may be sufficient, which would have the advantages of re-usability and shorter manufac-
turing time. Still, substantial inter-patient variability has to be expected. This variability may
depend on natural breathing patterns (i.e. chest or abdominal breathing), the size and lo-
cation of the primary tumor, and its infiltration into surrounding tissues. Therefore, a com-
parative study with a large patient cohort is mandatory to get good statistics and analyze
subgroups.
From a logistic point of view, the construction and adjustment of the PE and 3DPE corsets
requires the cooperation with an orthopedic institution and the technical infrastructure. On
the other hand, the PU corset can be produced by the clinical staff, after an initial training.
While the PU and non-individualized PE corsets required only 30 min of adjustment time,
for the 3DPE-corset a manufacturing time of 3 days were needed, which also scales with
the costs of these corsets.
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Figure 5.7: (a-b) Patient positioned in a vacuum mattress for acquisition of a 4D planning CT wear-
ing the 3DPE corset. A recess (white arrow in (a)) is incorporated into the corset for positioning
of a respiratory sensor (white arrow in (b)) for 4D CT reconstruction. (c) Example of a delivered
proton therapy plan (robustly optimized scanned pencil beam) of a patient with a carcinoma of the
pancreatic head wearing the 3DPE corset. Three beam angles were applied (140°, 170°, 208°) to
accumulate a dose of 50.4 Gy within 28 fractions in the internal clinical target volume (red contour).
The buckle of the corsets hook-and-pile fasteners and the corset opening are marked (red arrow in
(c)). Beam angles penetrating these structures (40°– 100°) were avoided.
5.2 3DPE corset for patients with abdominal cancer
5.2.1 Clinical implementation of 3DPE corset
For the implementation of the 3DPE corset in the existing clinical workflow for PT of ab-
dominal cancer patients, several requirements had to be considered in the design of the
corset. In our clinic, the treatment planning of moving tumors is based on 4D CT, where
for its retrospective reconstruction the respiratory signal is extracted by use of a pressure
sensor using the Anzai respiratory gating system (Anzai Medical Co., Ltd., Tokyo, Japan).
The initially tested strategy in which the sensor was positioned above the corset on the
patients upper right chest led to a poor performance of the sensor. Hence, a recess of
10 × 6 cm² was incorporated into the corset at the lower right abdomen caudally of the um-
bilicus (see Figure 5.7 (a)), which facilitated the use of the pressure sensor as typically
performed without a corset by the medical technical assistance staff.
The cranial end of the corset was positioned at the height of the xiphoid process in order
to omit the breasts of the patient from the corset, due to their tendency towards variability,
which can hamper reproducible tightening of the corset but still include the lower four ribs
to reduce of both chest and diaphragmatic breathing. As discussed in section 5.1.4 and
illustrated in Figure 5.7, the corset was designed such as that both the buckles of the hook-
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and-pile fasteners as well as the corset opening were placed laterally left of the patient to
not interfere with the applied PT beams. With this design, a potential positional variability
of the buckles and opening would have no disturbing effect on the dose distribution during
PT. In order to allow for reproducible tightening of the corset, marks were drawn on the
fastener when the corset was first applied during acquisition of the planning CT scan. To
avoid covering of the fastener by the vacuum mattress, the buckles had to be positioned
anterior of the patient’s mid-plane without colliding with a potential anterior-posterior proton
beam (0°).
Based on the results of the material analysis in section 5.1.1, it was shown to be suffi-
cient to directly transform the measured CT values of the planning CT scan to WER values
with the clinically used Hounsfield look-up table. This was due to the adipose tissue equiva-
lency (Möhler et al., 2018) of both CT values (- 107 HU ± 32 HU) and WER values in proton
irradiation (0.991 ± 0.002) in combination with the small and constant corset thickness of
3.8 mm ± 0.2 mm. An already conservatively estimated error of 10 % in the translation of
HU to the stopping power would consequently only lead to a maximum error of 0.38 mm in
the proton range prediction. In Figure 5.7, a clinically applied PT dose distribution is shown,
where a patient with a carcinoma of the pancreatic head was irradiated with three proton
beams with angles between 140°– 208° to deposit a dose of 50.4 Gy within 28 fractions to
the internal clinical target volume (iCTV).
5.2.2 Pancreas motion reduction by use of an abdominal corset
Methods
To assess the reduction of respiratory induced pancreas motion, a clinical study was con-
ducted including patients with abdominal cancer (pancreas, gallbladder, liver). The study,
which was initially designed to solely include pancreas cancer patients, was extended to
other abdominal cancer patients due to an otherwise insufficient acquisition rate. Still, the
motion of the pancreas was still analyzed for patients with all three tumor sides and the
consequential heterogeneity of the patient cohort was accepted. The study was approved
by the local Ethics Committee of the Faculty of Medicine and University Hospital Carl Gus-
tav Carus of the Technische Universität Dresden (EK-398092016). 16 patients provided
informed written consent for the manufacturing of a patient-individualized abdominal corset
and for performing an MRI scan with a protocol combining diagnostic pulse sequences with
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Figure 5.8: Orthogonal (coronal and sagittal) single-slice 2D-cine MRI (top) and 4D-MRI (bottom)
of patient in free breathing (left) and wearing the 3DPE corset (right) showing the state of maximum
expiration and inspiration. The pancreas is segmented and lines are added at the caudal and cranial
edge of the pancreas to visualize the amount of pancreatic motion.
pulse sequences for motion characterization.
Out of the 16 patients included in the study, 1 patient dropped out of the study due to
cancer related death before a CT or MRI scan could be acquired and for 2 patients it was
decided to not perform an MRI scan due to their hip implants. Although the presence of
MR-compatible hip implants was no exclusion criteria per se, in one case no technical data
of the implant could be provided in time while in the second case the implant set a limit on
the product of specific absorption rate (SAR) times acquisition time that could not be met
with our combined diagnostic and study related MR protocol without risking an unaccept-
able temperature increase. Of the resulting 13 patients scheduled for MRI, 1 MRI scan had
to be aborted due to severe claustrophobia of the patient. Furthermore, 3 patients did not
fit in the MR scanner, as it was modified for RT compatibility. These patients were scanned
in the MR scanner without coil holder, as a consequence of which the anterior MRI coil was
positioned directly on the patient. Their MRI data was not included in the motion analysis
since effectively no reference scan during free breathing was acquired. Consequently, in
the motion analysis 9 patients were included (3 male and 6 female; average age 72.9 ± 9.6
years). Out of these 9 patient datasets, for 2 patients the reconstruction of the 4D-MRI
dataset (initially based on radial k-space sampling) did not result in images with a suffi-
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cient quality for analysis. During the transition towards the multi-slice based 4D-MR pulse
sequence used in this study, the MR protocol was adapted which lead to erroneously not
acquiring the orthogonal 2D-cine MRI dataset for one patient. Hence, while 8 patients were
evaluated by use of 2D-cine MRI only 7 patients were evaluated by use of 4D-MRI.
To quantify the reduction of respiration-induced pancreatic motion by use of the 3DPE
corset the included patients were scanned on a flat-table top overlay (Medibord Ltd, Notting-
ham, UK) with a 3.0 T MR scanner (Philips Ingenuity TF PET/MR scanner, Philips Health-
care, Eindhoven, The Netherlands) using a 32-channel SENSE Torso/Cardiac coil. The MRI
pulse sequences for motion analysis were acquired first with the patient wearing the corset.
Directly afterwards, the corset was removed and the patient was scanned in free breathing
to acquire a reference dataset. Subsequently, diagnostic MRI sequences (T2-TSE, DWI,
T1-GRE with contrast agent) of approximately 20 min scan time were acquired to aid the
contouring by the radiation oncologists and check for a potential metastatic spread of the
tumor. The anterior and posterior parts of the coil were positioned around the patient with a
coil holder system. Unlike in RT, the patients arms were positioned next to the body, since a
positioning of the arms superior to the head could not be realized due to the limited space
in the 60 cm diameter bore of the MRI scanner.
The patients underwent orthogonal single-slice 2D cine MRI in coronal and sagittal ori-
entation at a frame rate of approximately 2 Hz (field of view = 375 × 375 mm², resolution
= 1.0 × 1.0 mm², slice thickness = 7 mm, bandwidth = 1929 Hz/pixel, TE = 1.1 ms, TR = 2.2
ms, flip angle = 27°, acquisition time = 1 min) for the assessment of the mean pancreas
motion as well as its intrafraction motion variability. As measure of intrafraction motion
variability, the standard deviation of the peak-to-peak pancreas motion amplitude was de-
termined by manual segmentation of the pancreas over several respiratory cycles and
determination of its center-of-mass motion. Furthermore, a 4D-MRI dataset was recon-
structed for an averaged 3D motion assessment of the full pancreas volume over sev-
eral breathing cycles by retrospectively binning a multi-slice 2D-cine MRI acquisition (field
of view = 375 × 375 ×120 mm³, resolution = 1.0 × 1.0 mm², slice thickness = 5 mm, band-
width = 1929 Hz/pixel, TE = 1.1 ms, TR = 2.2 ms, flip angle = 27°, acquisition time = 9 min) to
10 respiratory phases with differentiation between mid-inhale and mid-exhale phases. The
resorting algorithm was based on the method described by Von Siebenthal et al. (2007).
However, instead of acquiring a navigator slice in between every two image slices, the
reconstruction in this study was performed with an image-based navigation method. There-
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fore, the continuously acquired parallel coronal 2D images of a 3D volume with 50 dynamics
were resorted based on the position of the dome of the liver in each MR image. This posi-
tion was retrieved from a non-rigid registration of the respective dynamics using the open
source software ANTs (Avants et al., 2008; Avants et al., 2014). This provided the informa-
tion about the respiratory state, necessary for the 4D-MRI reconstruction. On each 4D-MRI
data set, the pancreas was manually delineated on the end-inhale and end-exhale images
using the open-source software MITK. The center-of-mass of these delineations was de-
termined to estimate pancreatic motion in IS, AP and LR directions. No specific breathing
instructions were given to the patients. The MRI scan was only performed once before the
start of treatment. An assessment of the interfraction motion variability was therefore not
performed.
Exemplary images of 2D-cine and 4D-MRI are shown in Figure 5.8 where the pancreas
is segmented in maximum exhale and maximum inhale.
Results
Figure 5.9: Mean center-of-mass motion amplitude M95 of the pancreas in inferior–superior (IS),
anterior–posterior (AP) and left–right (LR) direction in free breathing and with the 3DPE corset for 8
patients as determined by orthogonal single-slice 2D-cine MRI.
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Figure 5.10: Center-of-mass motion of the pancreas in inferior–superior (IS), anterior–posterior
(AP) and left–right (LR) direction with the 3DPE corsets and without corset for 7 patients as de-
termined by 4D-MRI. For Patient 9 no orthogonal single-slice 2D-cine MRI was acquired and for
Patient 7 & 8 no 4D-MRI dataset was acquired.
Motion assessment based on orthogonal 2D-cine MRI revealed that pancreas motion
was mainly found in IS direction and was reduced in IS direction by 2.8 mm (42 % reduc-
tion, p < 0.05) when the abdominal corset was applied from in average 6.5 mm ± 3.7 mm
in free breathing to 3.8 mm ± 1.1 mm with the corset. Here, the stated standard deviation
combines both the measured inter-patient motion variability as well as intra-patient mo-
tion variability. The patients intrafraction motion variability decreased from 1.5 mm in free
breathing to 0.9 mm (p < 0.01) when the corset was applied. Pancreas motion in AP and
LR direction was small in free breathing with 1.5 mm ± 0.2 mm in AP and 1.8 mm ± 0.7 mm
in LR direction and consequently not substantially influenced by the use of the corset with
1.0 mm ± 0.1 mm (31 % reduction, p < 0.05) in AP and 1.4 mm ± 0.3 mm (20 % reduction,
p > 0.05)in LR direction. Combining all directions, the corset reduced motion in 3D from
7.1 mm ± 4.4 mm to 4.4 mm ± 1.5 mm (39 % reduction).
Motion assessment based on 4D-MRI showed a generally higher pancreas motion in
IS direction relative to the motion amplitude found in 2D-cine MRI. Motion in IS direction
was reduced by 3.6 mm (42 % reduction, p < 0.05) when the abdominal corset was ap-
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plied from in average 8.6 mm ± 3.7 mm during free breathing to 5.0 mm ± 2.4 mm with the
corset. Pancreas motion in AP and LR direction was again small during free breathing with
1.3 mm ± 1.6 mm in AP and 2.3 mm ± 0.8 mm in LR direction and consequently not sig-
nificantly influenced (p > 0.05) by the use of the corset with 1.3 mm ± 0.6 mm in AP and
2.4 mm ± 1.4 mm in LR direction. Combining all directions, the corset reduced motion in 3D
from 9.1 mm ± 3.5 mm to 5.9 mm ± 2.1 mm (35 % reduction).
5.2.3 Patient acceptance of abdominal corset
After manufacturing of the 3DPE corset and the acquisition of both the planning CT scan
and the MRI scan the patients were asked to fill out a questionnaire assessing the level of
discomfort in six questions. At this point in time, the patients wore the corset for approx-
imately 5 minutes during manufacturing, 30 minutes during CT scanning and 20 minutes
during MRI scanning. 13 patients were asked to fill out the survey, which includes four
patients who wore the corset during MRI but were not included in the motion analysis in
section 5.2.2. The results can be seen in Figure 5.11. The corset was generally well toler-
ated with on average no complaints or no pain in all categories. In only one patient slight
discomfort during the manufacturing was found and in one patient slight discomfort was
found regarding breathing ability and the general feeling of pressure during CT and MRI
Figure 5.11: Results of survey analyzing the patient acceptance of abdominal corset after manu-
facturing and wearing the abdominal corset during planning CT and MRI, including 13 patients.
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scanning, respectively. Two patients mentioned light or strong back pain. However, both
patients already complained about back pain before application of the corset, indicating
that the pain was probably not related to the corset.
5.2.4 Discussion
While the 3DPE corset was successfully implemented in the PT workflow of 13 patients
with abdominal cancer several challenges and limitations should be noted. Due to the rela-
tively high thickness of the 3DPE corset material (∼4 mm) and its consequential inflexibility,
its use for patients who’s weight significantly changes in between treatment planning and
dose delivery has been shown to be laborious and led to one case (male patient with hep-
atocellular carcinoma) where re-planning without corset was necessary. Considering the
comparable motion reduction of the 3DPE and PE corset, as found in section 5.1, with the
PE corset’s thinner material and higher flexibility, the manufacturing of the 3DPE corset with
thinner base materials seems promising but was not investigated.
The cranial end of the 3DPE corset was designed so that it would be positioned at the
height of the xiphoid process. This position was chosen in order to omit the breasts which
are heavily affected by weight gein and thereby reduce application difficulties in this sce-
nario. This position on the other hand coincides with the dome of the liver and hence for
patients with hepatocellular carcinoma may lead to a partially overlapping corset with the
proton beams, potentially increasing range uncertainties. For patients with pancreatic can-
cer this position includes the whole target volume and hence does not pose any risk.
After initially extracting the respiratory signal during 4D CT scanning with the pressure
sensor placed on the upper right chest, leading to a poor signal extraction, a recess was
incorporated in the corset in order to place the sensor on the lower right abdomen. This
facilitated the use of the sensor as performed without corset and was well perceived by the
staff of medical technical assistants. The issue of positioning a respiratory sensor could be
also resolved by a higher integration of MRI into the PT workflow, where e.g. a static CT
could be registered to motion resolved MR images (Dolde et al., 2018a) to gain the motion
information required for personalized ITV margins. This would eliminate the need for exter-
nal respiratory signal extraction, since MRI offers multiple options for respiratory signal ex-
traction (1D-MRI navigation, self-navigation through radial k-space sampling, image-based
self-navigation through body contour information). Since the MR scanner in our institute
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does not allow for a positioning of the patients with their arms above their head, as per-
formed during RT, such an integration is not feasible yet.
Hence, opposed to RT, in our study the arms of the patients were positioned next to the
body, since a positioning of the arms superior to the head could not be realized in the MR
scanner’s 60 cm diameter bore with the additional reduction of space due to the flat-table
top. This could have influenced the respiratory behavior and consequently the respiratory
induced organ motion.
The pancreas motion, as measured in the patients included in the study, was found
mainly in IS direction, in accordance to literature and the volunteer study, described in
section 5.1.3. Both orthogonal 2D-cine MRI as well as 4D-MRI revealed a reduction of pan-
creas motion in IS direction by 41 % – 42 %. Yet, the absolute motion amplitudes measured
with both image modalities differed, where 4D-MRI showed larger motion amplitudes as
well as a larger motion reduction by use of the corset with a reduction of 3.8 mm vs. 2.6 mm
in 2D-cine MRI. This divergence is affected by several factors. First, single-slice 2D-cine
MRI only captures the motion of a selected volume. Furthermore, this motion can be af-
fected by through-plane motion, which can distort the real motion. 4D-MRI includes the full
volume of the pancreas and is hence not affected by through-plane motion. On the other
hand, the reconstruction algorithm used for 4D-MRI in the patient study has the tendency
to overweight deep-inspiration states, that would potentially be discarded as outliers in the
M95 motion analysis based on 2D-cine MRI. No data is discarded in the 4D-MRI recon-
struction and for every slice the maximum state of inspiration and expiration is determined
individually based on the cranio-caudal position of the dome of the liver. This effect is par-
tially compensated by the larger volume over which the pancreas motion was determined
in 4D-MRI but could influence the results towards larger motion amplitudes. Additionally,
the limited image quality of the reconstructed 4D-MR images can influence segmentation
and hence distort the measured pancreas motion. While 2D-cine MRI only gives informa-
tion about a selected volume with potential distortion due to through-plane motion, it is a
real-time imaging modality that is not affected by resorting errors. Finally, only 6 out of the
9 patients were included in both 2D-cine and 4D-MRI evaluation, whereas 2 patients were
included in the 2D-cine MRI analysis with no 4D-MRI available and 1 patient was included
in the 4D-MRI analysis with no 2D-cine MRI available.
In general, however, the results from both image modalities conclude that pancreas mo-
tion is mainly found in IS direction and is reduced by the use of an abdominal corset by
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∼ 41 %. The free breathing pancreas motion found in the patient cohort (8.6 mm (4D MRI) /
6.6 mm (2D-cine MRI) in IS direction) was substantially smaller than the motion found in the
healthy volunteer (13.2 mm (4D-MRI) / 16.9 mm (2D-cine MRI) in IS direction). This also re-
duced the potential absolute motion reduction by use of an abdominal corset which scales
with the initial pancreas motion found in free breathing condition. In our study 4 patients
showed free breathing motion amplitudes in IS direction < 6 mm, as measured with 2D-cine
MRI. For those patients the corset only reduced motion by 1.2 mm whereas the other 4 pa-
tients showed a larger pancreas motion which was reduced by 4.6 mm. This corresponds in
4D-MRI to 3 patients with free breathing motion amplitudes in IS direction of < 6 mm which
was reduced by 1.7 mm by use of the corset and 4 patients with amplitudes in IS direction
of > 6 mm which was reduced by 5.2 mm. This underlines the significance of inter-patient
variability. A strategy for a selection of suitable patients for the manufacturing of a patient
individualized abdominal corset is therefore advised.
How to select patients eligible for wearing a corset during the course of radiation ther-
apy is an open question. A previous study with liver tumor patients furthermore reported on
dosimetric benefits of abdominal compression using a pressure belt for moderate and large
tumor motion amplitudes > 7 mm in pencil beam scanning PT (Lin et al., 2017). For patients
with initially small tumor motion of < 7 mm, however, abdominal compression was found to
be needless. In the AAPM task group 76 report (Keall et al., 2006) a slightly more conser-
vative limit of < 5 mm is stated, under which motion is considered insignificant enough that
no respiratory management is required. However, this report does not explicitly address
PT. Furthermore, the selection of suitable patients may depend on the tumor infiltration,
the patients’ condition and willingness to tolerate the abdominal pressure during repeated
imaging and irradiation fractions.
The results of the survey filled out by 13 patients included our study showed that the
corset is well tolerated with generally no complaints or no pain felt. This includes patients
who underwent EUS guided fine-needle aspiration for injection of fiducial markers within
5 days before application of the corset. Only two patients complained about back pain,
however, for both patients this back pain was present before application of the corset. At
least in one of those patients, the pain was likely cancer related due to its infiltration into
the aorta and vertebrae. It has to be noted, however, that the level of discomfort scales
with the pressure that is applied with the corset. Since the corset pressure was applied in
coordination with the patients, the level of pressure was naturally limited by the patients
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tolerance and is reflected in the results.
Lastly, the need of abdominal compression could be resolved by the implementation of
gating or tracking strategies in PT. However, while for XT a synchronized anatomical imag-
ing and radiation is available, e.g. by use of MR-Linacs, in PT gating or tracking strategies
can to date only be applied by extraction of respiratory information through external surro-
gates like pressure sensors or optical body contour scanning. The correlation of external
surrogates to target motion is, however, questionable.
Furthermore, respiratory gating techniques increase the treatment time particularly in in-
tensity modulated RT where gating can lead to a 4- to 15-fold increase in delivery time.
(Keall et al., 2006). Highly increased delivery times correlate to the likelihood of patient
movement and have been suggested to reduce tumor control due to the increased intrafrac-
tion repair of sublethally damaged tumor cells. Live target tracking, on the other hand, is
only sparcely available (e.g. CyberKnife (Snider et al., 2012)) due to an insufficient speed
of synchronizing imaging with the treatment beam.
5.3 Summary
In this study the use of a patient individualized abdominal corset for MR guided PT of pa-
tients with abdominal cancer was investigated and implemented in PT for the first time in
the frame of a clinical study. First, three different types of MR compatible abdominal corsets
were investigated regarding their applicability in PT. While the effect on respiratory induced
motion reduction was comparable for all three, their material properties and manufacturing
procedure differed substantially. The corset that requires the least additional effort in man-
ufacturing and that has already been used in XT (Heerkens et al., 2017) was found to be
not suitable for PT due to its inhomogeneous material properties. Hence, a patient individu-
alized PE corset was selected that on the one hand requires several days of manufacturing
by trained orthopedic technicians but on the other hand can be implemented in PT without
the risk of increasing inaccuracies in dose deposition.
As a second step, the abdominal corset was implemented into the clinical PT workflow in
our institute for 13 patients with abdominal cancer, where the corset was well tolerated and
did not induce strong discomfort. The MRI-based assessment of respiratory induced motion
reduction in 9 patients through the use of the corset revealed that its application reduces 3D
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pancreas motion in average by 37 % from 9.1 ± 3.5 mm to 5.9 ± 2.1 , as measured by 4D-
MRI, or 38 % from 7.1 ± 4.4 mm to 4.4 ± 1.5 mm, as measured by orthogonal 2D-cine MRI.
The main direction of motion was thereby in IS direction. The amount of motion reduction,
however, strongly correlates with the magnitude of motion in free-breathing. Consequently,
a general implementation of such individualized corsets into PT seems to be not justified
when considering the additional time and costs required, but is rather only suggested for
patients with initially large amount of respiratory induced motion. How to best select suitable
patients for wearing a corset during the course of RT was not investigated and remains an
open question.
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6 General discussion and future perspectives
The aim of this thesis was to investigate and develop methods for the management of inter-
and intrafraction motion for MR guided PT of PDAC. Three main hypotheses were therefore
tested in this thesis.
Firstly, it was hypothesized that a novel liquid fiducial marker (BioXmark®) is detectable
in MRI tumorous pancreas tissue while reducing the image distortion relative to commonly
used solid fiducial markers. A utilization of BioXmark® in vivo was, however, not possible
due to the pending CE certificate. Therefore, a gel phantom was designed that mimicked
the relaxation behavior of pancreas tissue at 3 T MRI. With 4 BioXmark® markers and 7
solid fiducial markers (Gold Anchor™, VisiCoil™) placed inside this phantom, the visibil-
ity and artefacts of the markers were quantitatively assessed and compared through MR
relaxometry. Furthermore, the MRI visibility of BioXmark® was tested for the first time in
ex vivo tumorous pancreas resection specimens to assess the marker’s gelation in human
pancreas tissue.
Secondly, for intrafraction motion mitigation an MR compatible patient-specific corset was
developed for the use in PT and implemented within the framework of a clinical study. It
was hypothesized that such a corset reduces the respiratory induced pancreas motion, is
tolerated well by patients with abdominal tumors and is suitable for a safe implementation in
PT. As a preparatory step, three different types of abdominal corsets were tested regarding
their suitability for PT. Subsequently, a clinical study in 13 was conducted with one of these
corsets patients to analyze the reduction of respiratory induced pancreas motion by use
of time-resolved 2D-cine and retrospectively resorted 4D-MRI on a diagnostic 3.0 T MRI
scanner.
Thirdly, to assess the accuracy of motion depiction provided by the diagnostic 3.0 T MRI
scanner, it’s motion tracking performance had to be first evaluated with ground truth mea-
surements. Hence, a 4D-MRI motion phantom was commissioned for QA purposes. It was
hypothesized that a 4D-MRI motion phantom designed for an hybrid MR-Linac system can
be implemented at a diagnostic MRI scanner and used therein for QA of motion estimation
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based on time-resolved 2D-MRI and retrospectively resorted 4D-MRI. For this, a position-
ing and fixation setup was designed and software tools for an automatic assessment of
phantom target tracking accuracy and 3D geometric fidelity were developed. Motion depict-
ing MR pulse sequences and a clinically used 3D sequence were assessed regarding their
motion tracking performance and geometric fidelity.
A recapitulation and reflection of the results of this thesis and future perspectives are
discussed in this chapter.
6.1 Liquid fiducial marker for interfraction motion management
in MR guided PT
Residual patient setup errors in IGRT have been shown to be reduced by the use of solid
fiducial markers in patients with PDAC (Varadarajulu et al., 2010; Van der Horst et al.,
2013). However, solid markers as utilized in image-guided XT can significantly perturb the
local dose distribution in PT (Newhauser et al., 2007; Giebeler et al., 2008; Habermehl
et al., 2013). Furthermore, they are either poorly visible in MRI or are visible due to a
large difference in magnetic susceptibility relative to the surrounding tissue. This leads to a
correlation between visibility and image distortion in MRI (Gurney-Champion et al., 2015)
and makes the MR visibility of solid markers pulse sequence dependent. Since for MR
guided PT patient position verification is still performed using X-ray imaging, the visibility of
fiducial markers in both imaging modalities is crucial for patients with abdominal tumors.
In this work, an injectable liquid fiducial marker, BioXmark®, which has been previously
shown not to locally perturb dose distributions in PT (Scherman Rydhög et al., 2017), has
been investigated regarding its MRI properties at 3 T for the first time (chapter 3). For a
quantitative analysis, MR relaxometry was performed of the marker after being implanted
inside a gel phantom that mimicked the relaxation behavior of pancreas tissue. The phan-
tom also included two types of clinically utilized solid markers (Gold Anchor™, VisiCoil™)
for direct comparison. It was found that the liquid marker is visible in MRI as strong signal
void (signal reduction factor > 60 %) independently of the used pulse sequence when the
size of the spherically gelated marker exceeds the voxel size by a factor of at least 3 times.
Furthermore, it was shown that neither the liquid marker’s size nor the magnitude of visi-
bility correlates with the degree of artefacts, as was found for the other two types of solid
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markers.
To confirm the results of the phantom study, an ex vivo study was performed. In this study
5 – 6 markers of three different size categories (20/25µL, 50/60µL, 100µL) were injected
in three tumorous pancreas resection specimens by the use of different needle sizes (18 G,
22 G, 25 G), respectively, resulting in 17 markers being implanted in total. Markers of all
three size categories could be detected as hypointensities in both T1 and T2 weighted MRI.
Only the injection with the 18 G needle was observed to cause marker backflow, increasing
non-spherical gelation and thereby potentially deteriorating visibility. The results from the
current studies and from the investigations found in literature, showed that the liquid fiducial
marker has beneficial properties for use in MR guided PT relative to solid fiducial markers
such as high visibility in CT and MRI, low image degradation and no dose perturbation
in PT. Based on the investigated MRI characteristics, the application of BioXmark® in MR
guided PT for patients with PDAC is advised using sizes of injected markers of > 50µL and
≤ 22 G needles for injection.
Before BioXmark® can be clinically used, its MRI properties needed to be tested in real
pancreatic tissue. Since CE certification for use in abdominal patients was missing at the
time of the study, an ex vivo study was performed in order to investigate the visibility of
the marker after gelation in human pancreas tissue. It has to be noted, however, that the
gelation behavior ex vivo and consequently the markers visibility is likely to differ from the in
vivo situation. An investigation of the gelation behavior in an in vivo environment is therefore
strongly advised. This is because the gelation behavior of the marker also directly affects
the possible interfraction positioning accuracy where large diffusely gelated markers would
impair the accuracy of image registration. As revealed by CT in the current presented study,
the non-spherical gelation lead to 4 of the total 17 markers, with volumes between 20µL –
60µL, being non-detectable in MRI.
Since to date X-ray based patient position verification is still a crucial step for most PT
protocols, the visibility of BioXmark® in kV X-ray imaging is of utmost importance. This
was, however, not yet systematically analyzed for injection sites in the upper abdomen. As
a first step, it is recommended to systematically analyze the marker’s X-ray visibility within
a phantom study, using a suitable phantom that mimics the X-ray attenuation of abdominal
organ behavior in patients. Such a study is currently being performed in our institute. Since
the gelation of the marker will also affect its X-ray visibility an in vivo investigation is neces-
sary before a general recommendation can be given. This should be performed as soon as
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the CE certification for the use of BioXmark® in patients with PDAC has been granted.
Despite the detectability as hypointensity in MRI, BioXmark® could potentially benefit
from the addition of an MR contrast agent (e.g. gadolinium) to the marker composition. This
would allow for a detection of the marker as hyperintensity in T1-w MR images and thereby
possibly improving the detectability of the marker in the heterogeneous environment of
pancreatic tissue. However, the addition of the high-Z element gadolinium could lead to
dose perturbation in PT and hence would have to be carefully investigated by a dosimetric
study.
With a potential future integration of MRI and PT into a hybrid in-beam MR-PT system,
fiducial markers may not be required for accurate target position verification anymore due
to the then available soft-tissue visualization in treatment position. However, the integration
of MR-PT systems to in-beam MR guided PT is still in its infancy (Schellhammer et al.,
2018). Realized near-room MR guided PT solutions by the use of a shuttle-based transport
MR systems (Bostel et al., 2018), on the other hand, still require X-ray position verification
in treatment position. This is why in the near future, fiducial markers will likely remain clin-
ically relevant for accurate target positioning of patients with abdominal cancer. For these
patients, BioXmark® could be a promising candidate for use in X-ray and MR image guided
PT.
6.2 Geometric fidelity and accuracy of target motion tracking
with MRI
Besides interfraction target motion due to positioning uncertainties and organ filling, respi-
ratory induced intrafraction target motion is a major source of uncertainty in PT. The superb
soft-tissue contrast of MRI in combination with its real-time capability makes it a promis-
ing imaging modality for motion characterization. However, the versatility of MRI comes
with various sources of image distortion, stemming from different hardware components or
scan protocols. Hence, organ motion characterization through MRI has to be approached
with care. The accuracy and precision of dedicated MRI pulse sequences for motion track-
ing has to be assessed through a QA procedure that additionally allows to detect a possible
drift in imaging performance over time.
Since the diagnostic 3.0 T MR scanner used in this thesis has not been utilized for organ
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motion quantification studies before, its target tracking performance was not known. To as-
sess the scanner’s accuracy in target tracking, in chapter 4 an 4D-MRI motion phantom
was commissioned for use on the diagnostic scanner. Prior to the phantom’s commission-
ing on the MR scanner, the performance of the phantom itself was evaluated by reference
CT measurements. For the use on MRI, an MR compatible positioning and fixation setup
was designed for reproducible positioning of the phantom on the patient couch and for the
safe use of its MR-conditional actuator. Single-slice 2D-cine MRI, orthogonal 2D-cine MRI
and retrospectively resorted 4D-MRI sequences for evaluation of target tracking accuracy
were used, based on bSSFP sequences. Relaxometry of the movable cylinder was per-
formed to facilitate contrast optimization in bSSFP sequences. Matlab based software tools
were developed for an automatic analysis of the phantom target tracking accuracy as well
as for the geometrical distortion assessment using the phantom’s 3D distortion grid in or-
der to facilitate a fast QA procedure. This is particularly recommended when new pulse
sequences for motion assessment are to be implemented. A full QA protocol was, however,
not established since the criteria for imaging performance in MR guided PT still have to be
defined.
The geometric distortion of a clinically utilized 3D GRE sequence was evaluated showing
a maximum distortion of < 1.3 mm over an elliptic cylindrical volume of 15 × 23 × 6 cm³. This
agrees with the requirements for stereotactic RT of targets with a diameter of > 25 mm (Pap-
pas et al., 2017). Furthermore, based on a reference CT scan, it was shown that the motion
phantom performs accurately in translational motion (IS direction) but contains an intrinsic
error in rotational motion, which manifests in smaller motion amplitudes in AP and LR di-
rection by 4 % – 11 % than pre-set. This is likely due to a small mis-positioning of the target
within the moving cylinder and has to be considered when evaluating the motion tracking
accuracy provided by the MRI scanner. Considering these results, the single-slice 2D-cine
and orthogonal 2D-cine sequences showed a high target tracking accuracy of < 0.2 mm in
all three directions for targets within a radius of 10 cm from the isocenter performing regular
sinusoidal motion. Similarly, the retrospectively resorted 4D-MRI sequence showed a track-
ing accuracy of < 0.3 mm. These results encouraged us to use these sequences for motion
characterization of patients with abdominal tumors without the necessity for a systematic
geometric correction.
Despite the high geometric fidelity and tracking accuracy found for the diagnostic 3.0 T
MRI scanner when using the MR-Linac motion phantom, these results cannot be fully trans-
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lated to a patient scenario. Here, susceptibility induced magnetic field inhomogeneities of
∼ 2 ppm (Lundman et al., 2017) are typically higher than for a largely homogeneous phan-
tom. This increases the geometric distortion when scanning patients. Moreover, opposed
to the phantom target, pancreas motion patterns are described by a non-rigid motion of an
asymmetric target. In single-slice 2D-cine MRI, through-plane motion of such an asymetric
target can simulate a motion which is actually not present in 3D. It is therefore recom-
mended to test the accuracy of both the scanner as well as the used motion tracking algo-
rithms with an anthropomorphic phantom, that allows for reproducible non-rigid 3D motion
patterns (Mann et al., 2017).
The 3D distortion analysis performed based on the phantom’s 3D grid yields high geo-
metric fidelity of the clinically used 3D GRE sequence in accordance with the requirements
for stereotactic RT of medium sized targets. However the integrated grid only allows for an
analysis within 6 cm depth in IS direction. Therefore, it cannot fully replace distortion ana-
lysis based on large FOV field homogeneity phantoms (Wang et al., 2004; Baldwin et al.,
2007), which are recommended to be used for full FOV distortion analysis.
6.3 Reduction of respiratory organ motion by use of an
abdominal corset
Respiration is the main cause for intrafraction target motion affecting all abdominal organs.
Although different abdominal compression techniques have been implemented in the clini-
cal routine of RT to reduce the target motion induced uncertainty in dose application, they
all come with their pro’s and con’s. Moreover, the techniques routinely used in X-ray guided
XT are often based on body frames and pressure plates positioned on the patients stom-
ach. These techniques, however, cannot safely be applied in MR guided PT of PDAC due to
incompatible materials, possible distortion of the treatment beams or relatively large setups
and hence geometrical incompatibility with the MR scanner or PT facility.
In chapter 5 the application of an abdominal corset in PT was tested for the first time.
Here, three different types of abdominal corsets (PU, PE, 3DPE) were analyzed regarding
their suitability for application in PT in terms of their motion reduction capability and their
effect on the treatment beam, combining the information about WER, material homogene-
ity and thickness. In a feasibility study with a single healthy volunteer using 2D-cine and
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4D-MRI, all three corsets have been shown to reduce respiratory induced pancreas mo-
tion to a similar degree primarily in IS direction by 46 % – 56 % (7.7 mm – 9.4 mm). The PU
corset, which had already been implemented in XT (Heerkens et al., 2017) was, however,
considered not to be suitable for PT due to its material inhomogeneity and the consequen-
tial increase in dose uncertainty. Although the material properties of the semi-individual PE
corset would allow for an implementation in PT, it was excluded due to the fixed anterior
opening of the corset. Limited reproducibility would lead to distortion of anterior beams,
which where not excluded in our clinic for patients with PDAC.
Hence, for the clinical implementation, a patient individualized PE corset was selected
that was manufactured based on an optical 3D surface scan of the patient and allowed for
a flexible design of the corsets opening, buckles and size. The 3DPE corset was adapted
considering several clinical requirements including the treatment position, the applied beam
angles and respiratory signal extraction during planning CT scan by a pressure sensor.
The corset was tested in a clinical study including 13 patients with abdominal cancer. The
corset was therein fully implemented in the PT workflow including the planning CT scan,
a combined diagnostic and motion characterizing MRI scan as well as in the fractionated
dose delivery scheme. The corset was therein well tolerated.
The intrafraction pancreas motion reduction due to the corset was determined by means
of orthogonal single-slice 2D-cine MRI and retrospectively resorted 4D-MRI. Out of the 13
successfully included patients only the MRI dataset of 9 patients was used for motion as-
sessment. For the 4 patients not included in the motion assessment the RT compatible
setup could not be used and lead to a positioning of the anterior coil directly on the pa-
tients abdomen, potentially distort their free-breathing behavior. 2D-cine MRI allowed for
the analysis of the real-time pancreas motion, limited to a selected slice. It yielded informa-
tion about intra-patient motion variability and the average motion amplitude, while excluding
outliers. 4D-MRI, on the other hand, yielded information about the average motion of the full
pancreas volume, where due to the reconstruction algorithm, no outliers where excluded,
potentially leading to a slight overestimation of the average motion amplitudes. Average
motion amplitudes were reduced in 3D by 37 % (3.2 mm), as measured by 4D-MRI, or by
38 % (2.7 mm) as measured by 2D-cine MRI. The pancreas showed a dominant motion in
IS direction, which was consequently also the direction most reduced by the application of
the corset. Furthermore, 2D-cine MRI revealed that by use of the corset, intrafraction mo-
tion variability was reduced. No dosimetric evaluation was performed to quantify the dose
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reduction to healthy tissue due to the corset. Such an analysis was beyond the scope of
this thesis but should be performed in future studies to further quantify its expected clinical
benefit.
The motion reduction capability of the 3DPE corset matches the motion reduction capa-
bility of a PU corset found by Heerkens et al. (2017) where in average a motion reduction
of 36 % (4 mm) was found. The 10 patients included in the aforementioned study showed
on average larger motion amplitudes than for the patients found in the current study. It has
to be noted, however, that other than in Heerkens et al. (2017), where solely patients with
PDAC were selected, our study was extended to include patients with cancer of the liver
and gallbladder. The decision to include these patients was made to increase the initially
very low rate of patients included in our study, but led to a heterogeneous patient cohort
and the evaluation of pancreas motion for patients with a tumor-free pancreas. Further-
more, due to the limited space of the 60 cm wide MR bore, the treatment position with the
arms positioned over the head could not be realized. This could have affected the abso-
lute values of respiratory motion. It is not appearant from Heerkens et al. (2017) if patients
were scanned with their arms above their heads or next to their body a statement about a
potential difference cannot be made.
Several studies reported about pancreas tumor motion with on average significantly
larger amplitudes of up to several centimeters (Bussels et al., 2003; Minn et al., 2009).
Considering the seemingly constant 30 % – 50 % relative motion reduction achieved through
the abdominal corset, patients with larger respiratory motion amplitudes would benefit more
from its application. The 9 patients included in the current study included 4 patients where
pancreas motion amplitudes were already noticeably small (< 6 mm) during free breath-
ing. For these patients the corset only reduced motion in average by merely ∼ 1 mm. This
shows that a decision strategy is mandatory to select patients for which the corset reduces
motion significantly enough to cover the additional time and effort required for its manu-
facturing. This could potentially be performed by external respiration analysis, but would in
an ideal case include a fast MRI scan to estimate the tumor motion characteristics. A fast
single-slice 2D-cine MRI would suffice for this purpose but would on the other hand likely
be challenging to implement due to the typically low availability of MRI scan time.
Our study also showed that although the corset only increased the patient chest diameter
by ∼ 1 cm, several patients could not be successfully scanned in the RT compatible MR
setup using the coil holder for the MR surface coils, since this setup reduces the already
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limited space in the 60 cm MRI bore. This emphasizes a drawback of MRI which is the
generally limited space in the scanner’s bore, excluding large or obese patients.
6.4 Future perspectives
Before a general recommendation for the clinical use of BioXmark® in PT of PDAC can
be made, a systematic study on its visibility in X-ray imaging (including kV-CBCT) should
be performed. As a first step, a phantom mimicking the X-ray attenuation properties of
abdominal organs should be used to test the marker’s visibility in different injection sites.
As soon as the CE certificate for clinical use in abdominal tumor patients has been granted,
an in vivo study should be conducted to validate if the marker’s gelation behavior in in vivo
pancreas leads to satisfactory visibility in X-ray and MR imaging.
A 4D-MRI motion phantom has been commissioned on the diagnostic 3.0 T MRI scanner
and its target tracking accuracy has been assessed for selected motion depicting pulse
sequences. This allows to perform QA of the scanner on a regular basis with a safe and
reproducible positioning of the phantom and its actuator as well as an automatic evaluation
of tracking accuracy. A QA protocol has, however, yet to be established including clinically
motivated criteria for imaging accuracy and a typical time frame for re-evaluating image
performance has to be set, based on the hardware dependent performance drifts. It is,
however, strongly recommended to perform the described QA tests whenever new motion
depicting sequences are used for clinical purposes. For QA on a potential future MR-Linac
system, the tested motion phantom can be utilized as well, yet the fixation setup would not
be necessary due to the lower static magnetic field. For the application on an MR-Linac the
phantom would furthermore allow for the evaluation of tracking and gating accuracy and
efficiency as well as dosimetric measurements of moving targets.
In cooperation with the ORD (Orthopädie- und Rehatechnik Dresden GmbH, Dresden,
Germany) a concept of applying abdominal compression with a patient individualized MR
guided PT compatible abdominal corset has been developed and confirmed to reduce res-
piratory induced motion. The established workflow allows for future manufacturing of the
PT compatible abdominal corset. In order to estimate the clinical benefit, a dosimetric eval-
uation has to be performed where the possible reduction of dose to healthy tissue would be
evaluated. Finally, the cost-effectiveness of the 3DPE corset should be assessed, where a
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possible gain in quality adjusted life years is compared to its production costs. This however,
would require a long-term study with more patients included for statistical significance.
Due to the high technical requirements for the manufacturing of the 3DPE corset, its clin-
ical implementation is dependent on the cooperation with a orthopedic institute. Its trans-
ferability to other PT centers can therefore not be generalized. The investigated motion
management techniques can also be translated to MR guided XT, for example for usage
within an MR-Linac, but should be re-evaluated against other existing methods considering
the complexity of the manufacturing of the presented corset. For XT the PU corset seems
sufficient and requires less costs and temporal effort than the 3DPE corset.
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Background
Patients with pancreatic cancer (PDAC) might benefit from proton therapy (PT) due to its
potential to better spare healthy tissue from toxic dose than conventional MV X-ray therapy
(XT). However, the poor soft-tissue contrast of X-ray based image guidance techniques
and inter- and intrafraction organ motion increase the uncertainties during dose application.
Hence, guidance by MR imaging might be a beneficial approach due to its high soft-tissue
contrast and real-time imaging capability. In the transition from conventional X-ray guided
XT to MR guided PT, methods for the management of inter- and intrafraction motion have
to be re-evaluated, adapted or newly developed.
Hypotheses
For interfraction motion management it was hypothesized that the novel liquid fiducial
marker BioXmark® is detectable on MRI when injected in pancreas tissue and reduces
image degradation relative to commoonly used solid fiducial markers. For intrafraction mo-
tion mitigation it was hypothesized that a patient-specific MR compatible abdominal corset
is feasible to be used in PT, reduces the respiratory induced pancreas motion and is well
tolerated by patients with abdominal tumors. To assess the accuracy that the utilized clinical
3.0 T MRI scanner provides for the motion characterization study, first ground truth mea-
surements had to be performed. Therefore, a 4D MR-Linac motion phantom was selected
It was hypothesized that this phantom can be implemented at a diagnostic MRI scanner
and used therein for QA of motion depicting pulse sequences.
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Material and methods
The BioXmark® was quantitatively analyzed regarding its MR characteristics by relaxometry
and compared to two solid fiducial markers in the framework of a gel phantom study. Fur-
thermore, the MRI visibility of BioXmark® was tested for the first time in ex vivo tumorous
pancreas tissue. An MR-Linac motion phantom was commissioned at a diagnostic 3.0 T
MR scanner and a tool was developed for automatic assessment of the 3D geometrical
fidelity and motion tracking accuracy of the used scanner. The material properties of three
different corsets were tested regarding their applicability in PT. Furthermore, their effect on
pancreas motion reduction was tested on a healthy volunteer by use of orthogonal 2D-cine
and 4D-MRI on a 1.5 T MRI scanner. Subsequently, a clinical study was conducted, includ-
ing 13 patients with abdominal cancer. Within the study, the effect on respiratory induced
pancreas motion through the used 3DPE corset was analyzed by use of orthogonal 2D-
cine and 4D-MRI on a 3.0 T MRI scanner. Furthermore, the patient’s tolerance towards the
corset was assessed.
Results
BioXmark® did not show a correlation between magnitude of visibility and artefact (RS = 0.0)
and only a weak correlation between size of visibility and artefact (RS = 0.4). Contrary, for
the solid markers a linear dependency between size of visibility and artefact was observed
(RS = 0.99) and a non-linear correlation between the magnitude of visibility and artefact
(RS = 0.964).
Injected in three ex vivo pancreas resection specimen, BioXmark® was detectable as
hypointensity on both T1-w and T2-w MRI. Markers of all three size categories (20/25µL,
50/60µL, 100µL), injected with three differently sized needles (18 G, 22 G, 25 G), could
be detected with the clinically used sequences. However, a diffuse gelation or an injection
too close to the surface hampered detectability, leading to 4 out of 17 markers being non-
detectable on MRI.
The MR-Linac motion phantom was successfully commissioned on a diagnostic 3.0 T
MRI scanner. A fixation and positioning aid was designed and constructed to allow a safe
and reproducible positioning of the actuator and the phantom (< 0.4 mm). A tool for auto-
matic distortion analysis was developed based on a reference CT scan. The analysis of
a clinically used 3D GRE sequence revealed a maximum 3D distortion of 1.3 mm over an
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elliptic cylindrical volume of 15 × 23 × 6 cm³. The reference CT scan also showed an intrin-
sic error of the target motion in AP/LR direction. High-contrast and geometrically reliable
2D-cine MR images of the phantom’s moving target could be obtained. A tool for auto-
matic target tracking was developed which revealed high accuracy of the motion depicting
sequences (< 0.2 mm in 2D-cine acquisitions, < 0.3 mm in 4D-MRI).
A comparable reduction of respiratory induced pancreas motion of 46 % – 56 % (7.7 mm –
9.4 mm) was found for all three corsets. The material analysis, however, excluded the PU
corset from use in PT due to its heterogeneities and showed that the 3DPE corset can be
integrated in PT planning with the clinically used Hounsfield look-up table. The 3DPE corset
was implemented into the PT workflow within a clinical study for 13 patients with abdominal
cancer, where the corset was well tolerated. The MRI-based assessment of respiratory
induced pancreas motion in 9 patients with and without the corset yielded a pancreas 3D
motion reduction of in average 37 % (∼ 3.3 mm).
Conclusions
BioXmark® and the developed 3DPE corset have been considered suitable for use in MR
guided PT. BioXmark® was visible as signal void in MRI independently of the used pulse
sequence when exceeding the voxel size. BioXmark® , however, has to be investigated in
vivo to confirm its MRI visibility in a realistic environment, which could potentially lead to
a different gelation behavior affecting visibility. The developed corset reduced respiratory
pancreas motion in patients with abdominal tumors and can be used in future for patients
in MR guided PT. The study also revealed that a distinct amount of patients does not sig-
nificantly benefit from a corset due to their already small (< 6 mm) pancreas motion in free
breathing. Hence, a prior estimation of the patient’s individual free breathing motion should
be included before an abdominal corset is implemented in their PT workflow. The MR-Linac
motion phantom showed a high accuracy in motion depiction and can be used in future for
QA of the diagnostic MRI scanner for motion depicting sequences. This is strongly advised
when new pulse sequences are implemented.
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8 Zusammenfassung
Hintergrund
Patienten mit Bauchspeicheldrüsenkrebs könnten von der Protonentherapie (PT) profi-
tieren, aufgrund ihres Potentials der Schonung von Risikoorganen. Jedoch führen die inter-
und intrafraktionelle Beweglichkeit der Bauchspeicheldrüse zu hohen Unsicherheiten bei
der Dosisapplikation und erfordern daher große Sicherheitssäume. Aufgrund des hohen
Weichgewebskontrastes in der MRT und der Möglichkeit der Echtzeitbildgebung gewinnt
die Unterstützung der Strahlentherapie durch die MRT stetig höheres Interesse. In der
Translation von konventioneller Röntgen-geführter XT zur MR-geführten PT müssen Meth-
oden zur Kontrolle der inter- und intrafraktionellen Organbeweglichkeit re-evaluiert, adap-
tiert oder neu entwickelt werden.
Fragestellung/Hypothese
Für die interfraktionelle Bewegungskontrolle wurde die Hypothese aufgestellt, dass der neu
entwickelte Flüssigmarker BioXmark®, injiziert in Pankreasgewebe, sichtbar in der MR-
Bildgebung ist und verglichen zu üblich verwendeten soliden Markern die Bildartefakte re-
duziert. Für die intrafraktionelle Bewegungskontrolle wurde erwartet, dass ein Patienten-
individuelles MR-kompatibles Korsett die atmungs-induzierte Pankreasbeweglichkeit re-
duziert, von Patienten mit Tumoren im Oberbauch gut vertragen wird und in die PT im-
plementiert werden kann. Ein 4D MR-Linac Bewegungsphantom wurde für die Evaluierung
der Geometrietreue und der Genauigkeit der Bewegungswiedergabe des genutzten diag-
nostischen 3.0 T MR Scanners verwendet. Es wurde erwartet, dass dieses Phantom für
die Verwendung am diagnostischen MR Scanner implementiert werden kann und für die
Qualitätssicherung von bewegungscharakterisierenden MR Pulssequenzen genutzt wer-
den kann.
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Material und Methode
Die MR Eigenschaften von BioXmark® wurden in einer Phantomstudie durch MR Re-
laxometrie quantitativ analysiert und verglichen mit zwei Arten von soliden Marker. Des
weiteren wurde die MR-Sichtbarkeit von BioXmark® das erste mal in ex vivo tumorösem
Pankreasgewebe getestet für Markern dreier Größenkategorien (20/25µL, 50/60µL, 100µL),
injeziert mit jeweils drei verschiedenen Nadelgrößen (18 G, 22 G, 25 G). Ein 4D MR-Linac
Bewegungsphantom wurde für den diagnostischen 3.0 T MR Scanner unserer Klinik kom-
missioniert und Programme für die automatische Evaluierung der 3D Geometrietreue und
Genauigkeit der Bewegungscharakterisierung entwickelt. Drei Korsetts aus verschiedenen
Materialien (PU, PE, 3DPE) wurden in Bezug auf die Verwendbarkeit in der PT untersucht.
Des weiteren wurde der Effekt der Korsetts auf die Reduzierung der Pankreasbeweglichkeit
bei einem gesunden Freiwilligen analysiert, mittels zeitaufgelöster 2D-cine MRT und res-
pirationskorrelierter 4D-MRT in einem 1.5 T MR Scanner. Daraufhin wurde eine klinische
Studie durchgeführt, die 13 Patienten mit Tumor im Oberbauch einschloss. Im Rahmen der
Studie wurde der Effekt des verwendeten 3DPE Korsetts auf die Reduktion der Pankreas-
beweglichkeit analysiert, mittels 2D-cine MRT und 4D-MRT in einem 3.0 T MR Scanner.
Abschließend wurde die Patienten-Verträglichkeit bei Anwendung des Korsetts analysiert.
Ergebnisse
Für BioXmark® wurde keine Korrelation zwischen der Intensität der Sichtbarkeit und Arte-
fakte gefunden (RS = 0.0) und nur eine schwache Korrelation zwischen der Größe der
Sichtbarkeit und Artefakte (RS = 0.4). Im Gegensatz dazu wurde für die soliden Marker
eine lineare Abhängigkeit der Größe der Sichtbarkeit und Artefakte (RS = 0.99) und eine
nicht-lineare Abhängigkeit zwischen der Intensität der Sichtbarkeit und Artefakte gefunden
(RS = 0.964). Nach Injektion in drei ex vivo Pankreas-Resektionspräparate war BioXmark®
als Hypointensität in sowohl T1- als auch T2- gewichteten MR Bildgebung sichtbar. Marker
aller drei getesteten Größenkategorien waren in klinisch verwendeten MR Sequenzen de-
tektierbar. Jedoch führte eine diffuse Gelierung oder Injektion zu nah am Geweberand zur
Minderung der Detektierbarkeit. Dies hatte zur Folge hatte, dass 4 von in Summe 17 Mark-
ern in der MR-Bildgebung nicht erkennbar waren.
Das MR-Linac Bewegungsphantom wurde erfolgreich am diagnostischen 3.0 T MR Scan-
ner kommissioniert. Eine Fixierungs- und Positionierungshilfe wurde entwickelt und kon-
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struiert, die eine sichere und reproduzierbare Positionierung des Aktuators und des Phan-
toms (< 0.4 mm) ermöglichte. Ein Programm zur automatischen Verzerrungsanalyse wurde
entwickelt, basierend auf einer Referenz-CT Aufnahme. Die Auswertung einer klinisch ver-
wendeten 3D GRE Sequenz offenbarte eine maximale Verzerrung von 1.3 mm in einem
elliptischen Zylindervolumen von 15 × 23 × 6 cm³. Das Referenz-CT offenbarte zusätzlich
einen Abweichung der eingestellten Targetbeweglichkeit in AP/LR Richtung. Kontrastreiche
und geometrisch korrekte 2D-cine MR Bilder des sich bewegenden Phantom-Targets kon-
nten aufgenommen werden. Ein Programm für ein automatisiertes Target-Tracking wurde
entwickelt, welches eine hohe Genauigkeit der bewegungscharakterisierenden Sequenzen
bestätigte (< 0.2 mm in 2D-cine MRT, < 0.3 mm in 4D-MRT).
Eine vergleichbare Reduzierung der respirationsbedingten Pankreas-Bewegung von 46 % –
56 % (7.7 mm – 9.4 mm) wurde für die drei getesteten Korsetts gefunden. Die Materialanal-
yse führte jedoch zum Ausschluss des PU Korsetts für die Verwendung in der PT, aufgrund
der gravierenden Heterogenität des Korsettmaterials. Das 3DPE Korsett wurde als für die
PT implementierbar bewertet, wobei eine direkte Integration in der PT Planung mit der
klinisch verwendeten Hounsfield-SPR Übersetzungstabelle möglich war. Das 3DPE Ko-
rsett wurde für 13 Patienten mit Tumor im Oberbauch in den PT Arbeitsablauf integriert, in
welchem das Korsett von den Patienten gut toleriert wurde. Die MR-basierte Analyse der
respirationsbedingten Pankreasbewegung in 9 Patienten mit und ohne Korsett ergab eine
Reduzierung der Beweglichkeit um 37 % (∼ 3.3 mm).
Schlussfolgerungen
BioXmark® und das entwickelte 3DPE Korsett wurden als verwendbar für die MR geführte
PT bewertet. BioXmark® war in der MR-Bildgebung als Hypointensität sichtbar, unab-
hängig von der verwendeten MR Pulssequenz, solange die Markergröße die Voxelauflö-
sung überschritt. Die MR-Sichtbarkeit von BioXmark® sollte jedoch in vivo getestet werden,
da sich dort die Gelierung unterscheiden könnte und dementsprechend die Sichtbarkeit
beeinflussen könnte.
Das MR-Linac Bewegungsphantom kann in Zukunft für QA von bewegungscharakter-
isierenden Pulssequenzen des diagnostischen MR Scanners verwendet werden. Dies ist
empfohlen, wann immer neue Pulssequenzen implementiert werden.
Das entwickelte Korsett reduziert die respirationsbedingte Pankreas-Beweglichkeit in Pa-
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tienten mit Tumor im Oberbauch um ∼37 % und kann in Zukunft für die MR geführte PT
verwendet werden. Die Studie offenbarte jedoch auch, dass eine erhebliche Anzahl an Pa-
tienten nicht von der Verwendung eines Korsetts profitiert, aufgrund ihrer initial geringen
Beweglichkeit bei freier Atmung (< 6 mm). Schlussfolgernd ist eine vorherige Einschätzung
der Beweglichkeit jedes individuellen Patienten bei freier Atmung zu empfehlen, bevor eine
Entscheidung über die Implementierung des Korsetts in der PT getroffen wird.
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A Gel phantom for assessment of MR properties of fiducial
markers
A.1 Sequence parameter
Relaxometry of gel samples
In Table A.1 the pulse sequence parameters are listed that were used for relaxometry of
the initial gel samples. This was performed as an optimization procedure to determine the
optimal aggarose concentration of the gel in order to mimic the T1 and T2 relaxation times
of in vivo pancreas tissue. Besides T1 mapping by a dual flip angle (FA) method and T2
mapping by a multi-echo (8 echos) spin echo (SE) method, a B1 map was determined
based on a dual repetition-time (TR) gradient-echo (GRE) method for correction of the
spatial inhomogeneities in the radio-frequency (RF) transmit field.
Table A.1: MRI sequence parameters for T1 and T2 mapping of prepared gel samples. B1 mapping
was additionally performed for correction of B1 inhomogeneities for accurate calculation of the T1
map.
Sequence Dual TR GRE Dual FA GRE 8-echo SE
(B1 mapping) (T1 mapping) (T2 mapping)
Field-Of-View FOV / mm³ 120×120×20 120×120×20 120×120×20
Resolution / mm³ 0.94×0.94×3 0.94×0.94×2 0.94×0.94×2
Echo Time TE / ms 1.0 2.3 20 + 7×20
Repetition Time TR / ms 312 / 412 20 2000
Flip Angle FA / ° 12 5 / 17 90
Pixel Bandwith BW / Hz 2463 2205 2367
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Quantitative evaluation of markers in phantom
For quantification of MRI visibility of the tested solid fiducial markers, a T ∗2 map was created
based on a multi-echo spoiled gradient-echo (SPGR) sequence and for the liquid markers a
ρ(H) map was created based on a multi-echo gradient-and-spin echo (GRaSE) sequence.
For the evaluation of induced artefacts a ∆B0 map was created based on the phase infor-
mation of the multi-echo SPGR sequence. For correction of T1 decay within the GRaSE
sequence, a T1 map was created based on the golden standard inversion recovery spin-
echo (IRSE) technique. For correction of spatial inhomogeneities in the RF transmit field, a
B1 map was created based on a dual TR GRE sequence. All relevant sequence parameters
can be seen in Table A.2.
Table A.2: MRI sequence parameters for quantitative evaluation of fiducial marker visibility and
artefacts by T∗
2
-, ∆B0- and ρ(H)-mapping.
Sequence multi-echo SPGR multi-echo GRaSE IRSE dual TR GRE
FOV / mm³ 224×224 224×224 224×224 224×224
×45 ×45 ×45 ×45
Res / mm³ 1.0×1.0 1.0×1.0 1.0×1.0 1.0×1.0
×1.5 ×1.5 ×1.5 ×5
TE / ms 2.3 + 7×4.6 16 +7×16 28.3 2.7
TR / ms 38 1500 5000 30/150
TI / ms - - 50/150/500/ -
900/1500/3400
FA / ° 12 90 90 60
BW / Hz 1236 1316 1296 355
NSA 2 1 1 1
SENSE 2 2 2 2
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Qualitative evaluation of marker visibility in phantom
For validation of the determined source of visibility for liquid and solid markers, a qualitative
evaluation was performed based on sequences used clinically for patients with PDAC (T1
weighted 3D GRE (THRIVE), T2 weighted Turbo SE, Diffusion weighted imaging and the
reconstructed appearent diffusion coefficient map (ADC)) and a SE and GRE with two
different echo times respectively. The sequence parameters can be seen in Table A.3. The
liquid marker was visible in all contrasts created and visible with identical size in GRE at
different echo times, whereas solid markers are poorly visible in SE sequences and appear
substantially larger in GRE sequences with late echo times.
Table A.3: MRI sequence parameters for qualitative evaluation of fiducial marker visibility. Sequence
(a)-(d) are clinically performed for patients with pancreatic carcinoma. Sequence (e)-(h) are two
gradient echo and spin echo sequences with two different echo times respectively, to visualize the
different visibility characteristics of the three marker types.
Sequence (a) THRIVE (b) TSE (c,d) DWI/ADC (e, f) GRE (g,h) SE
FOV 302×302 375×299 375×303 200×200 200×200
/ mm³ ×110 ×109 ×111 ×30 ×30
Res 1.5×1.5 1.0×1.1 2.0×2.0 1.0×1.0 1.0×1.0
/ mm³ ×1.5 ×3.0 ×3.0 ×1.5 ×1.5
TE / ms 1.3 120 89 2.3 / 29.9 18 / 109
TR / ms 3.2 1127 2391 38 1500
FA / ° 10 90 90 12 90
BW / Hz 723 291 23 858 1216
NSA 1 2 2 1 1
SENSE 2 2 2 1 1
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The spherical gel phantom was scanned with a coronal T1-weighted 3D gradient echo
sequence with six different isotropic resolutions (0.125 mm³ – 64 mm³) for evaluation of visi-
bility in dependence of resolution. The resulting six exemplary slices taken from each of the
sequence are shown in Figure A.1. In accordance to our study, marker size was computed
by segmentation of voxels which show a lower signal than the 3σ deviation of the mean
signal of the phantom material. The apparent size of the four BioXmark® marker is shown
in Figure A.2. The segmented volume was additionally analyzed regarding its minimal sig-
nal, from which the visible magnitude was evaluated as the maximum signal reduction in
percent units [pu], where 1 represents a perfect signal void. The evaluation of the induced
visible magnitude is shown in Figure A.3. It was observed that at the highest resolution the
apparent marker size corresponded well with the injected marker volume. At lower resolu-
tion marker size is overestimated while visible magnitude decreases. Marker ≥ 25µL were
visible at all 6 resolutions.
Figure A.1: Marker plane of the spherical phantom acquired with a coronal T1-weighted 3D gradient
echo sequence with six different resolutions
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Figure A.2: Visible size of liquid markers of different size as a function of resolution.
Figure A.3: Maximum signal reduction in liquid marker of different size as a function of resolution.
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CT and MRI sequences for qualitative evaluation of liquid fiducial marker visibility
in ex vivo pancreas tissue
The pancreas resection specimens injected with different sizes of liquid markers were
scanned within two hours after resection with CT and MRI. The sequence parameters used
can be seen in Table A.4. The scan parameter for both CT and MRI were oriented on clin-
ically used protocols for patients with PDAC. In Figure A.4 all injected marker sides in all
three resection specimen are presented for CT, T1 weighted and T2 weighted MRI. The
markers are marked with a yellow circle. It is obivous that several markers can not be prop-
erly visualized in MRI but all marker sizes could be detected. Markers not visible in MRI
showed a strong non-spherical gelation in CT.
Table A.4: CT and MRI sequence parameters for evaluation of fiducial marker visibility in freshly
resected ex vivo tumorous pancreas tissue.
Imaging modality MRI – T1w MRI – T2w CT
FOV / mm³ 258×258×120 254×254×79 500×500×242
Res / mm³ 1.51×1.51×3 0.76×0.76×3 0.98×0.98×2
TE / ms 1.4 80 -
TR / ms 3.2 800 -
FA / ° 10 90 -
BW / Hz 721 290 -
NSA 1 1 -
SENSE 2 2 -
X-ray exposure / mAs - - 12
X-ray voltage / kVp - - 120
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Figure A.4: Exemplary slices of all 17 marker injection sites in three resection specimens showing
the markers circled in yellow in (from top to bottom) T1 weighted gradient recalled echo (T1-w GRE),
T2 weighted turbo spin echo (T2-w TSE) and computed tomography (CT) for patient 1-3. Marker
injections were ordered form smallest too largest with marker volumes between 20µL – 100µL.
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B Motion phantom for QA
B.1 Geometric distortion analysis
In Table B.5 the sequence parameters are listed that were used for 3D distortion analysis
with a reference CT and a T1 weighted 3D GRE MRI sequence for evaluation.
Table B.5: Scan parameters used for MR and CT image acquisition of the 3D distortion grid and
evaluation of the setup reproducibility.
Modality MRI - 3D GRE CT
Resolution / mm² 1.47×1.47 0.68×0.68
Slice thickness / mm 1.5 0.6
FOV / mm³ 352×240×200 350×350×315
BW / Hz 721 -
TE/TR / ms 1.4/3 -
Tube voltage / kVp - 80
Tube current time product / mAs - 420
B.2 Target relaxometry
Table B.6 lists the pulse sequence parameters for relaxometry of the moving cylinder of the
MR-Linac phantom for evaluation of T1 and T2 relaxation times in order to facilitate con-
trast optimization in balanced steady-state free-procession sequences, as used for motion
depicting sequences.
B.3 Target tracking analysis
Table B.7 lists all sequence parameters used for motion assessment with the MR-Linac
phantom. Single-slice 2D cine, orthogonal 2D cine and retrospectively resorted 4D MRI
sequences were used for motion assessment and evaluated regarding their tracking accu-
racy.
138
B Motion phantom for QA
Table B.6: MR sequence parameters used for relaxometry of the moving target and background gel
for sequence optimization.
Sequence IR SE GraSE
[for T1 mapping] [for T2 mapping]
Resolution / mm² 1.56×1.56 1.0×1.0
Slice thickness / mm 5 6
FOV / mm³ 150×150×50 150×150×6
BW / Hz 2378 2331
TE/TR / ms 26/5000 8.6/5000
TI / ms 50/150/500/ -
900/1500/3400
∆TE / ms - 8.6
Table B.8 lists all motion amplitudes and target velocities of the MR-Linac motion phan-
tom used for assessment of tracking accuracy of the 3.0 T MR scanner.
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